




Investigating the Effects of Host Factors (proteins 
and non-proteins) on Mycobacteria 
 
 
A thesis submitted in partial fulfilment of the requirements for the degree of 
Doctor of Philosophy 
 
By 
Muhammad Suleman Riaz 
 
 
Division of Biosciences 
Department of Life Sciences 
College of Health and Life Sciences 









I hereby declare that the research presented in this thesis is my own work, except where 









Mycobacterium tuberculosis (M.tb), the causative agent of tuberculosis, is one of the leading 
causes of death due to a single infectious agent and results in more than 1 million human deaths 
every year. M.tb infection of the host initiates a local inflammatory response, resulting in the 
migration of a number of host plasma protein and non-protein factors to the site of infection. 
In addition, some of these factors are also produced locally at the site of infection. It is 
envisaged that these host factors are likely to come in direct contact with M.tb and immune 
cells and may modulate the outcome of the infection. 
In this study, a number of host factors including transferrin, lactoferrin, fibrinogen, C-reactive 
protein, alpha-2-macroglobulin (α2M), vitronectin, plasminogen, low-density lipoprotein 
(LDL), high-density lipoprotein (HDL), serotonin, L-alpha dipalmitoyl phosphatidylcholine 
(DPPC) and platelet activating factor C-16 (PAF C-16) were screened in vitro for their direct 
effect on the growth of mycobacteria using M.smegmatis as a model. As a result of this 
screening, PAF C-16, a phospholipid compound was identified that directly inhibited the 
growth of M.smegmatis and M.bovis BCG in a dose and time-dependent manner.  
Use of a range of PAF C-16 structural analogues, including Lyso-PAF, PAF C-18, 
Hexanolamino PAF, 2-O-methyl PAF & Pyrrolidino PAF, revealed that small modifications in 
structure did not alter the direct growth inhibition property of PAF C-16 and similar levels of 
M.smegmatis and M.bovis BCG growth inhibition were observed as compared to PAF C-16. 
Structural dissection of PAF C-16 suggested that the attachment of carbon tail to the glycerol 
backbone via ether bond at sn-1 position was important for its direct growth inhibition activity 
against mycobacteria. Microscopy and flow cytometry with PAF C-16 treated M.smegmatis 
and M.bovis BCG showed damage to the bacterial cell membrane. The addition of membrane-
stabilizing agents, α-tocopherol, tween-80 and tween-20, partially mitigated the growth 
inhibitory effect of PAF C-16. These results suggested that the growth inhibition activity of 
PAF C-16 against mycobacteria is most likely due to its detergent-like effect, resulting in 
damage to the bacterial cell membrane. 
PAF C-16 and its structural analogues were also investigated for their effect on the growth of 
intracellular M.smegmatis inside THP1 cells. In vitro, PAF C-16, PAF C-18 and Hexanolamino 
PAF inhibited the growth of intracellular M.smegmatis, whereas, analogues such as Lyso-PAF 
and 2-O-methyl PAF failed to show any growth inhibitory effect, suggesting that the presence 
of acetyl group at sn-2 position was important for growth inhibition of intracellular 
iv 
 
M.smegmatis. Use of PAF receptor antagonists partially mitigated the inhibitory effect of PAF 
C-16 on the growth of intracellular M.smegmatis, suggesting this inhibition was through 
receptor-mediated signalling pathways. Blocking of PAF C-16 signalling pathway components 
such as phospholipase C and phospholipase A2, resulted in the increased survival of 
intracellular M.smegmatis. Arachidonic acid, a product of PAF C-16 signalling pathway 
directly inhibited the growth of M.smegmatis. Furthermore, inhibition of iNOS enzyme and 
antibody-mediated neutralization of TNF-α partially mitigated the inhibitory effect of PAF C-
16 on intracellular M.smegmatis growth, suggesting that the production of NO and TNF-α were 
also involved in PAF C-16 induced intracellular growth inhibition.  
Overall, this study has identified PAF C-16, its structural analogues such as Lyso-PAF, PAF 
C-18, Hexanolamino PAF and other compounds including 1-O-hexadecyl-sn-glycerol, 
miltefosine and hexadecyl lactate with novel anti-mycobacterial activity. Further investigations 
are needed to demonstrate their effectiveness against M.tb both in vitro and in animal models 
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Tuberculosis (TB) is an infectious airborne disease in humans, caused by acid-fast bacillus 
known as Mycobacterium tuberculosis (M.tb). TB is one of the leading causes of human 
mortality worldwide, resulting in more than 1 million human deaths every year (WHO, Global 
TB report 2016). In humans, the most common type of TB is pulmonary TB, about 60-80% of 
the total M.tb cases comprises of pulmonary TB. However, M.tb infections are not limited to 
lungs and M.tb can spread to other organs such as lymph nodes, meninges, pleura, kidneys and 
gastrointestinal tract, bones and joints etc., a condition known as extra-pulmonary TB (Julceus 
et al., 2017; Gomes et al., 2014; Wang et al., 2014; Sandgren et al., 2013). 
 
1.2 Epidemiology of Tuberculosis 
There is an estimate that about one-third of the world’s population (1.7 billion people) is 
latently infected with M.tb, a condition with no active disease symptoms due to the containment 
of pathogen by the host immune system. This latent infection with M.tb provides a huge 
reservoir for reactivation of active TB and its spread across the globe (Houben and Dodd, 
2016).  
According to World Health Organization (WHO), approximately 10.4 million new cases of TB 
were reported worldwide during 2015. Out of these new M.tb cases, 90% (9.4 million) were 
detected in the adult human population with a male to female ratio of 1.6:1. The remaining 
10% (1.0 million) M.tb infections were detected in children, out of which 170,000 proved to 
be fatal (WHO, Global TB report 2016). 
TB is more prevalent in developing world such as Asia and the Sub-Saharan African regions 
(Lönnroth et al., 2010). During 2015, 61% of new TB incidences were reported from Asian 
countries and 26% from Africa. About 87% of new TB cases reported were from 30 high TB 
burden countries including India, Indonesia, China, Nigeria, Pakistan, South Africa, 
Bangladesh and Philippines (WHO, Global TB report 2016). Different predisposing factors 
including low socioeconomic status, closed living conditions, overcrowding, malnutrition and 
poor health conditions contribute to the spread of TB in these countries (Lönnroth et al., 2009). 
The number of TB cases per 100,000 individuals in different countries of the world reported 
during 2015 is shown in Figure 1.1. 




Figure1.1: Worldwide distribution of TB cases reported during 2015. Estimated TB incidences 
per 100,000 individuals are represented with different colours. The figure shows that TB is 
more common in Africa and Asia and the highest number of TB cases per 100,000 inhabitants 
was mostly found in African countries (WHO, Global TB report 2016). 
The global menace of TB has become more severe due to Human Immunodeficiency Virus 
(HIV) infections (Daley et al., 1992). There is an increased risk of TB in HIV patients due to 
the killing of CD4+ T cells by HIV virus, the main fighting force against M.tb. This co-infection 
of HIV and M.tb is a lethal combination and most patients succumb to death much earlier than 
individual infections on their own (Jones et al., 1993). HIV positive individuals are 20-30% 
more likely to reactivate TB as compared to HIV negative individuals (Girardi et al., 2000). 
According to WHO, the rate of TB in regions with high prevalence of HIV is more than twice 
(400 cases in 100,000 population per year) as compared to regions with low HIV prevalence. 
The incidences of TB in HIV patients are more common in Africa and account for one-fourth 
of the total number of TB cases in the region. An estimated 1.2 million new TB cases were 
reported in HIV patients worldwide in the year 2015 (WHO, Global TB report 2016). 
Multidrug-resistant tuberculosis (MDR-TB) is another obstacle that threatens the control TB 
worldwide. In MDR-TB, M.tb become resistant to antibiotics and the patient fails to respond 
to first line anti-TB drugs (isoniazid and rifampicin). MDR-TB can develop as a result of the 
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inappropriate use of anti-TB drugs, inadequate treatment regimens, poor quality of anti-TB 
drugs and premature treatment stoppage (Gandhi et al., 2010; Espinal et al., 2003). The drug-
resistant M.tb strains can transmit directly from person to person, contributing to the spread of 
the drug-resistant bacteria in a population. According to WHO Global TB report 2016, new 
cases of MDR/RR-TB have virtually been detected across the globe (Figure 1.2). About 
480,000 new cases of MDR-TB were reported to the WHO during 2015. India, China and 
Russia have the highest number of patients with MDR-TB where one in eight TB patients fails 
to respond to the standard anti-TB drug therapy (WHO, Global TB report 2016).  
 
Figure1.2: Worldwide distribution of MDR/RR-TB cases reported during 2015. The size of the 
coloured circle represents the number of MDR/RR-TB cases reported in a particular country. 
The figure shows that countries like India, China and Russia have the highest number of 
MDR/RR-TB with 50,000 or more cases reported in the year 2015 (WHO, Global TB report 
2016). 
 
1.3 Mycobacterium tuberculosis (M.tb) 
Mycobacterium tuberculosis (M.tb) belongs to the family Mycobacteriacae of phylum 
Actinobacteria. There are more than 190 different species included in the genus Mycobacterium 
(Tsukamura, 1967). Some of these species are highly pathogenic such as Mycobacterium 
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tuberculosis, Mycobacterium africanum, Mycobacterium leprae, Mycobacterium bovis, 
Mycobacterium caprae and Mycobacterium microti and cause disease in different organisms 
including humans. 
M.tb are non-motile, rod-shaped bacteria that are about 2-4µm in length and 0.2-0.5µm in 
width. M.tb are slow growing aerobic bacteria, with a doubling time of 15-20 hours. M.tb have 
a unique cell wall with high lipid content and are poorly stained during gram staining.   
However, these bacteria can be identified by staining with Ziehl–Neelsen stain (acid-fast stain) 
and are, therefore, classified into a separate group known as the acid-fast group of bacteria 
(Todar, 2008). 
Cole et al reported the complete genome sequence of M.tb (H37Rv strain) for the first time in 
1998. M.tb have a circular genome that comprises of 4.4x106 nucleotides and contains around 
4,000 genes. The M.tb genome has a high GC content of 65.6% (Cole et al., 1998). The M.tb 
genome was later updated with functions assigned to 2,058 bacterial proteins (Camus et al., 
2002). 
 
1.4 M.tb cell wall structure  
M.tb have a thick and hydrophobic cell wall with a high content of lipids and waxes. This 
unique composition of the cell wall makes M.tb resistant to environmental stresses such as 
changes in pH, drought and antibiotics. The cell wall also provides protection to M.tb from the 
host organism’s immune system and contributes to the virulence of M.tb in different ways (Hett 
and Rubin, 2008).  
The M.tb cell wall has a two-layered architecture (Figure 1.3). The layer next to the cell 
membrane is made up of a network of peptidoglycan chains. The peptidoglycan chains in acid-
fast cell wall consist of repeating units of N-acetylmuramic acid (NAM) and N-
acetylglucosamines (NAG) cross-linked by short peptide chains consisting of L-alanyl-D-iso-
glutaminyl-meso-diaminopimelic acid (DAP). These cell wall peptidoglycan chains are 
covalently attached to arabinogalactan via phosphodiester bonds. The arabinogalactan, in turn, 
binds to mycolic acids with varying carbon chain lengths (C70-C90). This 
mycolylarabinogalactan-peptidoglycan (mAGP) arrangement forms a complex, known as the 
“cell wall core”. The mAGP core constitutes the main skeleton of the bacterial cell wall and is 
vital to the cell integrity. The outer surface of cell wall core in M.tb is infused with various 
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structural components including glycolipids such as lipomannan (LM), lipoarabinomannan 
(LAM), which are anchored by phosphatidyl-myo-inositol mannosides (PIMs) (Brennan, 2003; 
Lee et al., 1996). 
Each LAM in M.tb cell wall consists of a basal PIM unit that attaches non-covalently to the 
cell membrane at one end. The inositol ring of PIM at the other end binds to a D-mannan 
polymer followed by D-arabinose chains with capping motifs at the terminal ends. A major 
difference in the structural composition of slow growing and fast growing mycobacteria is the 
capping of the terminal-β-Ara. In slow-growing species capping at LAM consist of mannose 
residues (ManLAMs), whereas, in fast-growing mycobacteria, LAMs are capped with 
phosphoinositol (PILAMs) (Alderwick et al., 2007). LAMs are important M.tb cell wall 
components that can bind to different receptors such as mannose receptors and TLR4 etc. on 
the surface of immune cells and modulate immune responses. LAMs help in inhibiting 
phagosomal maturation and shift the cytokine response of phagocytic cells to M.tb from pro-
inflammatory to anti-inflammatory (Briken et al., 2004; Strohmeier and Fenton, 1999). M.tb 
mutants without LAMs are more sensitive to antibiotics, macrophage killing and in some cases 
failed to establish an effective infection in mice (Fukuda et al., 2013; Stoop et al., 2013; Kaur 
et al., 2008). Fukuda et al, have shown that changes in LM/LAM have a significant effect on 
the cell wall integrity of mycobacteria and structural defects in LM/LAM lead to loss of acid-
fast staining, increase susceptibility to antibiotics and decrease in virulence (Fukuda et al., 
2013). 
Phosphatidyl-myo-inositol mannosides (PIMs) family in mycobacteria consists of different 
members with a varied number of mannose units (1-5 units) (Guerin et al., 2010). The PIMs 
have been shown to be important in the immunopathogenesis of tuberculosis. PIM2 was shown 
to be important in granuloma formation in mice model by causing the recruitment of T cells 
during the early stages (Apostolou et al., 1999). PIM2 was also shown to cause the production 
of pro-inflammatory cytokines such as TNF-α from mice macrophages (Rhoades et al., 2003).  
The M.tb cell wall also contains other important components such as the 19kDa lipoprotein. 
The 19kDa lipoprotein binds to Toll-like receptor 2 (TLR2) on human monocyte-derived 
macrophages in vitro and has been shown to be involved in inducing apoptosis in these 
macrophages (Sánchez et al., 2012). However, the 19kDa lipoprotein from M.tb can also 
contribute to the virulence of the bacteria by inhibiting the processing and expression of M.tb 
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antigens via MHC class II molecules on macrophages resulting in decreased recognition by T 
cells (Noss et al., 2001).  
 
Figure 1.3: M.tb cell wall structure. The figure shows the arrangement of different layers of the 
M.tb cell wall. The cell wall core consists of a complex of peptidoglycan chains, 
arabinogalactan and mycolic acid. Structures such as Lipomannans (LMs) and 
lipoarabinomannans (LAMs) and different proteins are infused on the outer surface of the cell 
wall core, whereas the phosphatidyl-myo-inositol mannosides (PIMs) serve as anchors for both 
LMs and LAMs (Adapted from Kleinnijenhuis et al., 2011). 
 
1.5 Pathogenesis of M.tb 
M.tb spreads via aerosol droplets produced by a TB patient during coughing. When a healthy 
individual inhales these aerosol droplets, M.tb enters the respiratory tract and is carried to the 
lungs of the new host (Zumla et al., 2011). Inhalation of an aerosol droplet containing 1-10 
bacilli is enough to initiate infection (Sundaramurthy and Pieters, 2007). Resident phagocytic 
cells known as alveolar macrophages along with a small number of dendritic cells serve as the 
first line of host defence and engulf the pathogenic M.tb by receptor-mediated phagocytosis in 
an attempt to control the infection (Details in section 1.7). Upon phagocytosis, the M.tb are 
trapped in membrane-bound vacuoles known as phagosomes. The alveolar macrophages try to 
eliminate the intracellular M.tb through various mechanisms including the formation of 
phagolysosome, production of reactive nitrogen species and apoptosis (Details in section 1.9). 
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However, there are escape mechanisms through which M.tb can evade intracellular killing by 
macrophages while residing inside the phagosomes (Details in section 1.10). 
M.tb inside the alveolar macrophages cause the release different cytokines and chemokines 
from these cells. This results in the recruitment of different immune cells including blood-
derived monocytes and neutrophils at the site of infection. The monocytes differentiate into 
effector macrophages and produce cytokines such as TNF-α, IL-6, IL,1 etc. which help in the 
elimination of intracellular M.tb (Giacomini et al., 2001; Cooper and Flynn, 1995). During 
initial stages of infection, a few dendritic cells with the phagocytosed M.tb migrate to the 
regional lymph nodes where they can activate the adaptive immune system by displaying M.tb 
antigens on their surfaces in association with major histocompatibility complexes (MHC) 
resulting in the subsequent production of antigen-specific T lymphocytes. Antigen-specific T 
cells from the lymph nodes then migrate to the site of infection and produce different pro-
inflammatory cytokines such as IFN-γ that activates macrophages to eliminate the intracellular 
M.tb (Harding and Boom, 2010). However, the strength of host T cell response in M.tb 
infection determines whether the infection is arrested at this point or advances to the subsequent 
phases. 
 
1.6 M.tb granuloma structure and function 
Granulomas are important features associated with M.tb infection. Granulomas are of central 
importance to M.tb pathogenesis and determine the outcome of M.tb infection (Guirado and 
Schlesinger, 2013). A granuloma is a compact structure that consists of an organized 
aggregation of various immune cells at different stages of differentiation (Figure 1.4). The core 
region of granuloma consists of M.tb infected and uninfected macrophages, foamy 
macrophages, multinucleated giant cells (Langhans giant cells), epithelioid cells (a special form 
of differentiated macrophages), necrotic tissue and free M.tb. The outer ring surrounding the 
core of granuloma consist of lymphocytes, having a majority of T cells (CD4+ T cells and CD8+ 
T cells) and a small number of B cells (Gonzalez-Juarrero et al., 2001).  
The main purpose of the granuloma is to restrict M.tb from spreading by creating an immune 
microenvironment. However, it also provides M.tb with a niche to survive over long periods as 
the bacteria can modulate the immune response. A balance between the pro-inflammatory and 
anti-inflammatory immune response is vital for the survival of M.tb inside granuloma. Pro-
inflammatory cytokines such as TNF-α and IFN-γ play key roles in the development and 
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functioning of granulomas (Ly et al., 2008). TNF-α helps in maintaining the structure of 
granuloma by keeping sustained levels of chemokines and cellular recruitment and retention. 
It has been shown that in TNF-α deficient (TNF−/−) mice there was an initial delay in CC and 
CXC chemokines induction due to their deregulated transcription levels. This prevented the 
recruitment of immune cells like macrophages and CD4+ T cells in the TNF−/− mice when 
challenged with M.tb and caused a loose aggregation of immune cells that failed to contain the 
infection in the TNF−/− mice (Roach et al., 2002). TNF-α blocking therapies in humans have 
been shown to be associated with an increased risk of TB reactivation (Gómez‐Reino et al., 
2003). Neutralizing TNF-α by a monoclonal antibody MP6-XT22 in chronic murine 
tuberculosis model resulted in the reactivation of TB with a 10-fold increase in the number of 
M.tb bacilli in the lungs as compared to isotype control mice. Furthermore, histopathology of 
lungs tissue showed that the TNF-α neutralized mice had a loose aggregation of macrophages 
and the lymphoid aggregates were also less apparent as compared to the isotype control mice 
(Mohan et al., 2001). IFN-γ is also important for the stable persistence of granulomas as it 
causes the activation of macrophages. Challenging IFN-γ gene knockout mice (IFN-γ−/−) with 
M.tb showed early mortality and 10-100 folds more M.tb in different organs as compared to 
the wild-type control. Furthermore, granulomas were formed in the absence of IFN-γ, the 
histopathological examination revealed that granulomas from IFN-γ−/− mice were necrotic and 
had a large number of extracellular M.tb as compared to the wild-type control (Flynn et al., 
1993).  
ICAM-1, also known as CD54 is an intercellular adhesion molecule that has been shown to be 
important for granuloma formation. ICAM-1 knockout mice, when challenged with M.tb 
showed higher bacterial load and lack of organized granulomas in the lungs as compared to the 
wild-type control. Furthermore, ICAM-1 knockout mice infected with M.tb died earlier as 
compared to wild-type control mice (Saunders et al., 1999).  
The role of CD4+ T cells in control of M.tb and granuloma formation is evident from the 
reactivation of latent TB in patients with HIV co-infection (Girardi et al., 2000). HIV virus 
kills CD4+ T cells, the major fighting force against M.tb as they are the main producers of IFN-
γ. Using CD4 knockout mice it was shown that there was a marked decrease in the number of 
immune cells recruitment in the lungs when challenged with M.tb. These CD4 knockout mice 
were unable to develop a normal granulomatous response and died earlier as compared to wild-
type control (Saunders et al., 2002). 





Figure 1.4: Structure of M.tb granuloma. The figure shows the arrangement of different 
immune cells involved in granuloma formation during M.tb infection. The inner region of 
granuloma mostly consists of necrotic tissue along with free M.tb which is surrounded by 
aggregates of macrophages with different phenotypes. The outer ring consists multiple layers 
of T cells along with a small number of B cells (Ramakrishnan, 2012). 
 
1.7 Immune cells surface receptors involved in binding and phagocytosis of M.tb 
Immune cells have different receptors on their surfaces that are involved in the binding and 
uptake of M.tb bacilli during infection. Binding of M.tb to specific receptors on the immune 
cells determines the kind of response that is generated by these immune cells to the pathogenic 
M.tb upon phagocytosis. The roles of some of the receptors are discussed as under:  
1.7.1 Complement receptors  
Complement receptors present on the surface of macrophages are responsible for the 
phagocytosis of M.tb. The complement C3 receptors like CR1, CR3 and CR4 are the major 
macrophage complement receptors involved in the uptake of C3b and iC3b opsonized M.tb 
(Ferguson et al., 2004). However, these receptors can also phagocytose un-opsonized M.tb by 
interaction with bacterial polysaccharides (Cywes et al., 1997), phosphatidylinositol 
mannosides (PIMs) and glycolipids (Villeneuve et al, 2005). The exact host response to M.tb 
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phagocytosed through complement receptor is still unclear. In vitro, macrophages from CR3 
knockout mice showed reduced phagocytosis of M.tb as compared to macrophages from wild-
type control, however, similar levels of intracellular M.tb survival and replication was observed 
in the macrophages from both CR3 knockout mice and wild-type control (Melo et al., 2000). 
In vivo, CR3 knockout mice when injected intravenously with M.tb showed similar bacterial 
load in organs such as lungs, liver and spleen when compared with the wild-type control. These 
results suggest that M.tb can be effectively phagocytosed even in the absence of CR3 receptors 
(Hu et al., 2000). 
1.7.2 Mannose receptors 
Mannose receptors are transmembrane receptors expressed on the surface of immune cells such 
as immature dendritic cells and mature macrophages, which interact with bacterial structures 
containing sugars, specifically mannose (Cochand et al., 1999; Taylor and Drickamer, 1993). 
It has been shown that mannose receptor binds virulent M.tb strains such as Erdman and H37Rv 
but not the avirulent strains such as H37Ra (Schlesinger, 1993). In case of M.tb, the mannose 
receptor chiefly binds to the mannose cap of LAM (Schlesinger et al., 1994). Entry of M.tb 
into the macrophage by binding to mannose receptor can result in the inhibition or delay of 
phagosome-lysosome fusion and hence facilitate the intracellular survival of M.tb (Kang et al., 
2005). Binding of M.tb ManLAM to the mannose receptor is considered beneficial for the 
bacteria as it can inhibit the production of pro-inflammatory cytokine IL-12, important for the 
development of T helper type1 cells (Nigou et al., 2001). 
1.7.3 Scavenger receptors 
Cell surface scavenger receptors belong to a family of transmembrane glycoproteins and can 
bind to a variety of ligands. Scavenger receptors like MARCO and Class A receptors have been 
shown to bind to M.tb structures such as the cord factor and help in the phagocytosis of M.tb 
by macrophages (Bowdish et al., 2009).  
1.7.4 Fcγ receptors 
Fcγ receptors facilitate the phagocytosis of Ig-G opsonized M.tb. The entry of mycobacteria 
via Fcγ receptors enable the macrophages to eliminate the intracellular bacteria by causing the 
production of ROIs and promoting the phagosome-lysosome fusion (Schäfer et al., 2009; 
Armstrong and Hart, 1975). 
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1.7.5 DC specific ICAM-3 grabbing non-integrin (DC-SIGN) 
DC-SIGN is a carbohydrate binding receptor majorly associated with dendritic cells (Tailleux 
et al., 2003). However, DC-SIGN may also be present on macrophage surface (Tailleux et al., 
2005). Binding of DC-SIGN to M.tb cell wall structures such as ManLAMs and LMs results 
in the production of IL-10 and thus help in promoting anti-inflammatory response to the 
pathogen (Geijtenbeek et al., 2003). 
1.7.6 Toll-like Receptors (TLRs) 
Toll-like Receptors (TLRs) comprises a family of highly conserved transmembrane receptors. 
There are 12 different kinds of TLRs and each TLR recognizes a particular group of ligands. 
Each TLR consist of an extracellular amino leucine-rich repeat (LRR) domain for PAMPs 
recognition and intracellular carboxy-terminal tail similar to IL-1R, known as the Toll/IL-1 
receptor (TIR) domain. Binding of ligands to TLRs result in activation of the transcription 
factor NF-κB. This NF-κB can then upregulate the production of different cytokines (Sandor 
et al., 2003; Dunne and O'Neill, 2003). TLRs such as TLR1, TLR2, TLR4, TLR6, and TLR9 
can recognize a variety of structural components from M.tb including LAM, PIM, 19kDa 
lipoprotein and DNA etc. TLR2 and TLR4 are overexpressed during M.tb infection and have 
been shown to interact with 19kDa M.tb lipoprotein, LAM, LM and PIMs present on the 
surface of M.tb (Quesniaux et al., 2004; Means et al., 1999). Ligand binding to TLR2, 
TLR2/TLR1 heterodimer or TLR2/TLR6 heterodimer has been shown to be associated with a 
pro-inflammatory response resulting in the production of cytokines such as TNF-α and IL-1β 
(Kleinnijenhuis et al., 2009; Sandor et al., 2003; Takeuchi et al., 2002). TLR2 gene knockout 
(TLR2−/−) mice when challenged with M.tb (100CFU/mouse) were unable to control the 
infection and died earlier as compared to the wild-type mice infected with the same dose of 
M.tb (Drennan et al., 2004). 
 
1.8 Role of immune system during M.tb infection 
The host’s immune system is of prime importance in determining if the pathogenic M.tb will 
be eliminated, contained within granulomas or continue to spread and cause active disease. In 
humans, the response to pathogenic M.tb is multifactorial and involves immune cells from both 
the innate and adaptive immune system and small soluble proteins known as “cytokines” 
secreted by different immune cells. 
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1.8.1 Innate immune cells  
The innate immune system comprises of various immune cells including macrophages, 
dendritic cells, natural killer cells and neutrophils. The role of different innate immune cells 
during M.tb infection is discussed as under: 
1.8.1.1 Role of Macrophages 
Macrophages play a vital role during M.tb infection by acting as the first line of host defence. 
Macrophages are phagocytic cells that can bind to and engulf pathogenic M.tb. These cells 
have an array of receptors on their surfaces such as phagocytic receptors and pattern 
recognition receptors (PRRs) that are important for recognition and uptake of M.tb (Rajaram 
et al., 2014). The PRRs are able to recognize special structures on the pathogens known as the 
pathogen-associated molecular patterns (PAMPs) such as LAMs, LMs, mycolic acid etc. The 
entry of M.tb to phagocytic cells is facilitated by specific binding to different cells surface 
receptors which result in the stimulation of different signalling pathways. The route of M.tb 
entry determines the response of macrophage and the fate of intracellular M.tb (Kleinnijenhuis 
et al., 2011; Akira et al., 2006). The macrophage cell surface receptors include complement 
receptors, mannose receptors, scavenger receptors, Fcγ receptors, DC-specific ICAM-3 
grabbing non-integrin (DC-SIGN) and Toll-like receptors (TLRs) (Hossain and Norazmi, 
2013; Schäfer et al., 2009). Once the pathogenic M.tb is internalized by macrophages, the 
intracellular bacteria can be killed by different mechanisms such as formation of 
phagolysosomes, production of reactive nitrogen species and apoptosis (Details in section 1.9). 
However, M.tb has evolved certain mechanisms including inhibition of phagosome maturation, 
modulation of antigen maturation and resistance to reactive nitrogen intermediates through 
which it can escape killing by macrophages (Details in section 1.10).  
Macrophages also process and display different antigenic proteins on their surfaces via major 
histocompatibility complexes (MHC), that leads to the activation of the adaptive immune 
system resulting in a T cells response (Ladel et al., 1995). These T cells secrete important 
cytokines like IFN-γ and TNF-α which in turn activate the macrophages to eliminate the 
intracellular M.tb (Roach et al., 2001).  
1.8.1.2 Role of Dendritic Cells 
Mature dendritic cells are powerful antigen-presenting cells (APCs) due to the expression of 
high levels of MHC Class I and II molecules and other co-stimulatory molecules such as CD80 
and CD86 (Mellman and Steinman, 2001). These cells play a vital role in bridging the innate 
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and adaptive immune responses. Immature dendritic cells are specialized phagocytic cells and 
can engulf M.tb via binding to different cell surface receptors. After M.tb uptake, the dendritic 
cells migrate to the lymph nodes and mature. These mature dendritic cells in the lymph nodes 
can activate naïve T cell into antigen-specific CD4+ T cells and CD8+ T cells by presenting the 
processed bacterial antigen via MHC class II and MHC class I respectively (Marino et al., 
2004). Activated CD4+ T cells produce IFN-γ and TNF-α, which act on the macrophages and 
activates them, thus helping in eliminating the intracellular M.tb (Henderson et al., 1997). The 
importance of dendritic cells in M.tb control by activating CD4+ T cells was confirmed in mice 
models. Depletion of dendritic cells resulted in a decreased number of activated CD4+ T cells 
after M.tb challenge and higher number of M.tb were detected in the lungs and spleen of the 
test mice lacking dendritic cells as compared to the control during the early stages of infection 
(Tian et al., 2005). Dendritic cells also secrete pro-inflammatory cytokines such as IL-1β and 
IL-6, which help in the recruitment of other immune cells at the site of infection (Giacomini et 
al., 2001). Similarly, dendritic cells upon infection with M.tb produce high levels of 
chemokines such as CCL3, CCL4, CXCL8 and CXCL9 that play important role in the 
migration of NK cells and T cells to the site of infection (Slight and Khader, 2013).  
In humans, the IRF8 gene is essential for the normal development of dendritic cells and is 
suggested to be important in the anti-mycobacterial immunity. Mutations in IRF8 have been 
shown to be associated with disseminated BCG infections in human (Hambleton et al., 2011). 
1.8.1.3 Role of Natural Killer Cells 
Natural killer (NK) cells are important cells of the innate immune systems. NK cells can bind 
to different bacterial pathogens such as M.tb and possess direct cytotoxicity by releasing 
different bactericidal compounds including granulysin and perforin (Lu et al., 2014). NK cells 
from a healthy donor were able to lyse M.tb infected monocytes and reduce the growth of 
intracellular M.tb (Vankayalapati et al., 2002). The cytotoxic function of NK cells seems to be 
associated with Glutathione (GSH), which been shown to possess direct anti-microbial activity 
(Guerra et al., 2012; Millman et al., 2008). Similarly, NK cells can induce apoptosis in 
monocytes and other immune cells by FasL/Fas-mediated pathway (Brill et al., 2001). HIV 
virus can delay FasL/Fas-mediated apoptosis, which may lead to delayed apoptosis of M.tb 
infected cells resulting in prolonged infection (Cossarizza et al., 2000). NK also cells express 
different cell surface ligands such as CD40L. Binding of CD40 expressed on the surface of 
infected macrophages with the CD40L on NK cells leads to the upregulation of co-stimulatory 
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molecules like CD80 and CD86 as well as the production of NO by macrophages (Carbone et 
al., 1997).  
NK cells secrete IFN-γ during the early stages of M.tb infection, which activates macrophages 
and helps in the control of M.tb (Olsen et al., 2005; Flynn et al., 1993). NK cell can bind to 
M.tb cell wall components such as mycolic acid directly through natural cytotoxicity receptors 
known as NKp44 which causes the activation of NK cells and the production of pro-
inflammatory cytokines. Cytokines such as IL-2 and IL-12 upregulate the expression of cell 
surface receptors such as NKp30, NKp44 and NKp46 on NK cells. These receptors interact 
with various stress ligands such as UL16 binding protein 1 (ULBP1) on M.tb infected 
macrophages and cause the release of INF-γ and increase macrophage activation resulting in 
the elimination of intracellular M.tb (Esin et al., 2013; Portevin et al., 2012). The protective 
role for NK cells during mycobacterial infections was also established in mice models. 
Depleting NK cells in mice using anti-NK1.1 monoclonal antibody resulted in the increased 
multiplication of M.avium as compared to control mice (Harshan and Gangadharam, 1991).  
1.8.1.4 Role of Neutrophils 
During M.tb infection, neutrophils from the blood are rapidly recruited to the site of infection. 
Neutrophils are phagocytic cells and have been shown to engulf M.tb both in vivo and in vitro 
(Ganbat et al., 2016; Eruslanov et al., 2005). However, there exists conflicting data about the 
capacity of neutrophils to eliminate intracellular M.tb. Several studies reported that neutrophils 
were unable to kill intracellular M.tb and activating these cell with IFN-γ showed no effect on 
the anti-mycobacterial ability (Eruslanov et al., 2005; Pedrosa et al., 2000). There are reports 
which show that neutrophils present in the sputum and BAL fluids of TB patients contain 
replicating M.tb, indicating their inability to control the bacteria (Eum et al., 2010). However, 
other groups showed that in vitro neutrophils and neutrophils derived products can kill M.tb. 
Kisich et al showed that neutrophils from a healthy individual stimulated by TNF-α possessed 
anti-mycobacterial activity and suggested that the poor anti-mycobacterial activity of 
neutrophils might be associated with improper stimulation (Kisich et al., 2002). Similarly, 
challenging rats with M.tb after LPS induced neutrophilia showed a significantly lower number 
of M.tb in the lungs and after 24 hours of LPS treatment and neutrophils from the 
bronchoalveolar lavage of these animals were able to kill M.tb (Sugawara et al., 2004). 
Neutrophil extracellular traps (NETs) are extracellular networks composed of DNA from 
neutrophils bound to special cytoplasmic proteins and are considered to play an important role 
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in the bactericidal activity of neutrophils. M.tb infected neutrophils were shown to release 
NETs in vitro however they were ineffective in killing M.tb (Ramos-Kichik et al., 2009). 
An important role for neutrophils has been suggested during M.tb granuloma formation. 
Neutrophil-depleted mice showed reduction in the number, size and density of granulomas 
(Seiler et al., 2003). Early M.tb infection foci contain a mixture of macrophages, neutrophils 
and lymphocytes. Neutrophils at the site of infection secrete various chemokines such as CCL3, 
CCL4 CXCL2, CXCL9 and CXCL10 that attract monocytes and T lymphocytes and help in 
granuloma formation (Seiler et al., 2003).  
1.8.2 Adaptive immune cells 
The adaptive immune system comprises T lymphocytes/T cells and antibodies producing B 
cells. 
The adaptive immune response in case of M.tb is predominantly cell-mediated involving 
antigen-specific T cells and plays a key role in determining the outcome of infection (Wolf et 
al., 2008). The adaptive immune response to M.tb is of the delayed type that becomes 
detectable in mice models after a minimum of 12 days post aerosol M.tb infection (Chackerian 
et al., 2002). T cells are produced in the thymus and are distinguished from other cell types due 
to the presence of T cell receptors (TCR) and CD3 molecule. T cells can be subdivided into 
various types including CD4+ T cells, CD8+ T cells and γδ T cells based on the expression of 
their cell surface molecules (Cooper, 2009).  
1.8.2.1 Role of CD4+ T Cells 
CD4+ T cells, also known as helper T cells are of central importance in M.tb infection. Based 
upon the cytokine secretion profile in response to antigens, CD4+ T cells are subcategorized 
into two major groups, T helper type 1 (Th-1 cells) and T helper type 2 (Th-2 cells) (Mosmann 
et al., 1986). Th-1 cells secrete IFN-γ and IL-2 and TNF-α and provide resistance to M.tb 
infections whereas, Th-2 cells secrete IL-4, IL-5, IL-9, IL-13 and IL-10 and are associated with 
M.tb susceptibility and pathology (Al-Attiyah et al., 2006). 
During M.tb infection antigen presenting cells such as dendritic cells with phagocytosed M.tb 
migrate to the mediastinal lymph nodes and present processed bacterial antigen using MHC 
class II molecules expressed on their cell surface to naïve T cells. This results in the activation 
of naïve T cells and the proliferation of M.tb antigen-specific CD4+ T cells in the lymph nodes. 
These antigen-specific CD4+ T cells then relocate from the lymph node to the site of M.tb 
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infection to control the infection (Boom et al., 2003). A Th-1 type T cell response to M.tb 
infection results in the production of cytokines such as IFN-γ at the site of infection. IFN-γ is 
considered to be vital for protective immunity against M.tb as it can activate macrophages to 
kill the intracellular M.tb (Caccamo et al., 2010). Furthermore, Th-1 cells also produce 
important cytokines such as IL-2 and TNF-β (lymphotoxin-alpha) that activates CD8+ T cells 
(Serbina et al., 2001) and macrophages (Roach et al., 2001). Th-1 cells secreted lymphotoxin-
alpha is also crucial in the control of pulmonary TB as it helps in granuloma organization 
(Roach et al., 2001). 
A Th-2 T cell response to M.tb infection, on the other hand, results in a lack of protection 
mainly due to the production of anti-inflammatory cytokines like IL-10 which deactivates 
macrophages and causes the down-regulation of Th-1 cytokines. This cause the M.tb to survive 
inside the macrophages and leads to chronic progressive TB (Turner et al., 2002). 
The importance of CD4+ T cell-mediated immunity during M.tb infection was shown in mice. 
MHC class II-deficient (MHC II−/−) mice due to a lack of functional CD4+ T cells showed a 
higher number of M.tb in their lungs and succumbed to the infection earlier as compared to the 
control mice (Mogues et al., 2001). Similarly, mice models deficient in the CD4 molecule 
(CD4−/−) were also shown to be highly susceptible to M.tb infection and died earlier as 
compared to the control (Caruso et al., 1999). Both MHC II−/− and CD4−/− mice showed lower 
levels of INF-γ in the lungs as compared to wild-type mice after infection with M.tb.  
The loss of CD4+ T cells in humans during HIV infection can trigger the reactivation of latent 
TB to an active form and also increase the susceptibility of HIV patients to new M.tb infection 
as well (Alimonti et al., 2003). The protective role of CD4+ T cells was also confirmed in latent 
TB macaque models. It was shown that SIV infection in these animals led to a loss in the 
number of CD4+ T cells in the lungs as compared to the SIV negative control animals that 
resulted in the reactivation of latent TB (Diedrich et al., 2010). 
1.8.2.2 Role of CD8+ T cells 
CD8+ T cells also play an important role during M.tb infection as these cells are able to 
recognize a number of M.tb antigens. Naïve T cells develop into antigen-specific CD8+ T cells 
in response to bacterial antigen presented via MHC class 1 molecule expressed on the surface 
of antigen-presenting cells (Weerdenburg et al., 2010). M.tb specific CD8+ T cells have been 
detected in the lungs of mice infected with M.tb (Lewinsohn et al., 2003). The protective role 
of CD8+ T cells during M.tb infections can be attributed to their ability to produce cytokines 
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such as INF-γ and TNF-α along with cytotoxic molecules (granzymes) that causes apoptosis 
(Jeong et al., 2014; Serbina and Flynn, 1999). Another important characteristic of CD8+ T cells 
is their cytolytic activity. CD8+ T cells have been shown to kill intracellular M.tb via perforin 
and granulysin. Stenger et al showed in vitro that granulysin produced by CD8+ T cells possess 
direct M.tb growth inhibition ability in cultures and proposed that CD8+ T were able to inhibit 
intracellular M.tb growth in granule-mediated fashion (Stenger et al., 1998). CD8+ T cells 
recognize M.tb antigen on infected macrophage surface via MHC class I molecules. Proteins 
such as β2-microglobulin and TAP-1 play important roles in the packaging and trafficking of 
MHC class I heavy chain. Mice models with a disruption in β2-microglobulin gene or TAP-1 
gene upon infection with M.tb showed a higher number of M.tb bacilli in lungs and succumbed 
to infection earlier as compared to control mice due to lack of functional CD8+ T cells (Behar 
et al., 1999). CD8+ T cells are particularly important during latent M.tb infection and cytokine-
producing CD8+ T cells are present in M.tb granulomas. Depletion of CD8+ T cells in mice 
model with chronic M.tb infection caused an increase in M.tb burden indicating their protective 
role (van Pinxteren et al., 2000). The importance of CD8+ T cells in controlling M.tb infection 
was also shown by depleting CD8+ T cells in BCG vaccinated rhesus macaques using Anti-
CD8 antibody. CD8+ T cells depletion resulted in a significant decrease in vaccine-induced 
immunity to pulmonary M.tb infection as compared to isotype antibody treated control animals 
(Chen et al., 2009).  
1.8.2.3 Role of γδ T cells 
γδ T cells are a special type of T cells, having a T cell receptor (TCR) that can be distinguished 
from αβ T cells due to its physical properties and ligand binding sites. These cells are generally 
present in a low percentage (5%) in humans (Carding and Egan, 2002). Janis et al first reported 
the detection of γδ T cells in M.tb infected mice and showed that these cells do not require 
antigen presentation through MHC and can interact directly with soluble M.tb antigens in vitro 
(Janis et al., 1989). In vitro, human monocytes/macrophages infected with live M.tb were 
shown to be potent inducers of human γδ T cells expansion. γδ T cells from healthy donors 
were shown to produce high levels of IFN-γ in response to M.tb infected monocytes suggesting 
their protective role during M.tb infections (Gioia et al., 2003). A special subset of γδ T cells 
known as Vγ9Vδ2 T cells was shown to recognize and directly bind mycobacterial antigens 
such as phosphoantigens (Tanaka et al., 1994; Havlir et al., 1991). Furthermore, Vγ9Vδ2 T 
cells were shown to kill macrophage phagocytosed M.tb by producing cytolytic enzymes 
granulysin and perforin indicating their direct role in host protection against M.tb (Dieli et al., 
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2001). γδ T cells are considered to be involved in connecting the innate and adaptive immune 
responses during M.tb infection. Vγ9Vδ2 T cells were shown to induce maturation in M.tb 
infected immature dendritic cells by upregulating the expression of CD80 and CD40 in these 
cells (Meraviglia et al., 2010), which are powerful antigen-presenting cells and can strengthen 
the cellular immune response against M.tb infection. 
1.8.2.4 Role of B cells and antibodies 
Until early 20th century the protective role of B cells and antibody-mediated immunity during 
M.tb infections was generally considered to be insignificant. A number of serum transfer 
studies using antibodies as protective agents failed to show consistent results (Glatman-
Freedman and Casadevall, 1998). However, several recent studies suggest that B cells and 
antibodies can help in protection against M.tb by participating in the formation of granuloma, 
T cells activation through antigen presentation and the production of cytokine (Kozakiewic et 
al., 2013; Almeida et al., 2011; Tsai et al., 2006).  
The importance of B cells during M.tb infection was established using mice models. Maglione 
et al showed that B cells deficient (B cell−/−) mice were more susceptible to M.tb infection and 
showed a higher number of M.tb in lungs as compared to wild-type control. Furthermore, 
increased recruitment of neutrophils and higher levels of IL-10 were detected in lungs of these 
B cell−/− mice as compared to wild-type mice (Maglione et al., 2007). Another study by 
Vordermeier et al showed that 3-6 weeks after M.tb infection, B cell-deficient mice showed up 
to 8 times higher bacterial load in different organs such as lung, liver, spleen etc. as compared 
to wild-type control (Vordermeier et al., 1996).  
Serum analysis from children with tuberculosis suggested that reduction in serum IgG is 
associated with disseminated M.tb infections, as the levels of serum IgG to M.tb antigens such 
as LAM were significantly lower in children with disseminated M.tb infections as compared to 
those having localised M.tb infections (Costello et al., 1992). The protective role of antibodies 
against M.tb was shown in mice models where administration of specific monoclonal 
antibodies (mAb) against M.tb surface antigens such as arabinomannan, LAM etc. increased 
the survival of M.tb infected mice by inhibiting the growth of M.tb, reducing M.tb 
dissemination and helping in granuloma formation. (Hamasur et al., 2004; Williams et al., 
2004; Pethe et al., 2001; Teitelbaum et al., 1998). Antibody opsonisation of M.tb helps in the 
uptake of the bacteria by macrophages through FcγR and has been shown to promote 
phagosome maturation and enhance the killing of intracellular M.tb (Kumar et al., 2015). 
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1.8.3 Role of cytokines during M.tb infection 
Cytokines are small soluble proteins produced by a variety of cells in the immune system and 
can affect the activity of other cells by acting as messengers, regulating their functions. The 
role of different cytokines during M.tb infection is discussed as under: 
1.8.3.1 Interferon- γ (IFN-γ) 
During M.tb infections IFN-γ is mainly produced by T cells (CD4+ T cells, CD8+ T cells) 
(Jeong et al., 2014) and NK cells (Olsen et al., 2005). IFN-γ has been shown to perform 
multiple roles during M.tb infection and is important for host protection. IFN-γ activates 
macrophages by upregulating the transcription of different genes including genes coding for 
antimicrobial molecules such as reactive nitrogen species and helps them in eliminating the 
intracellular M.tb (Cavalcanti et al., 2012). Mutations in the IFN-γ receptor 1 encoding genes 
in humans have been shown to be associated with a loss of protective immunity against 
mycobacteria (M. fortuitum, M. chelonei, and two strains of M. avium) resulting in 
disseminated infections that were fatal (Newport et al., 1996). Individuals with IFN-γ receptor 
mutations are vulnerable to M.bovis BCG infections which are otherwise poorly pathogenic in 
normal humans (Dorman et al., 2004; Jouanguy et al., 1996). Cooper et al and Flynn et al have 
shown the importance of IFN-γ during M.tb infection using mice model. They showed that 
mice with a disruption in IFN-γ gene upon infection with sublethal doses of M.tb showed a 
higher number of M.tb bacilli in the lungs (100-1000 folds increase) as compared to control 
which was reduced by administration of exogenous IFN-γ. The IFN-γ−/− mice were unable to 
contain the infection and large number of M.tb was detected in organs like kidneys and bone 
marrow indicating dissemination of M.tb infection (Cooper et al., 1993). Although granulomas 
were formed in the absence of IFN-γ, the granulomas in IFN-γ−/− mice were shown to be highly 
necrotic and contain a large number of M.tb (Flynn et al., 1993).  
1.8.3.2 Tumor necrosis factor- α (TNF-α) 
TNF-α is a pro-inflammatory cytokine, produced by monocytes, macrophages (Valone et al., 
1988), dendritic cells (Henderson et al., 1997) and T cells (Allie et al., 2013) in response to 
M.tb. During TB, TNF-α is produced at the site of infection and this increase production of 
TNF-α is associated with undesirable inflammatory effects and fever (Tramontana et al, 1995). 
TNF-α is one of the most important cytokines produced during M.tb infection and has vital 
roles in macrophage activation and granuloma formation (Flesch and Kaufmann, 1990). In 
humans, the use of the TNF-α neutralizing antibody for conditions such as Crohn's disease and 
rheumatoid arthritis has been shown to be associated with an increase in reactivation of latent 
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TB (Keane et al., 2001). In mice model, TNF-α has been shown to help in the containment of 
M.tb during latent infection. Neutralizing TNF-α in these organisms resulted in the reactivation 
of latent TB that proved to be fatal (Mohan et al., 2001, Flynn et al., 1995). Mice with 
disruption in TNF gene (TNF−/−), when challenged with M.tb, succumbed to infection much 
earlier as compared to control and had a greater number of M.tb in their lungs and poorly 
formed granulomas (Bean et al., 1999).  
1.8.3.3 Interleukin-12 (IL-12) 
IL-12 is another important host defence cytokine produced during M.tb infection. IL-12 acts as 
a bridge between the innate and adaptive immune responses and enhances the production of 
IFN-γ (Zhang et al., 1994). IL-12 is produced upon the phagocytosis of M.tb by immune cells 
such as monocytes, macrophages and dendritic cells (Ladel et al., 1997; Fulton et al., 1996). 
Administration of exogenous IL-12 in BALB/c mice at the time of infection with virulent M.tb 
was shown to be associated with a protective effect as indicated by lower bacterial counts in 
lungs and increased survival time when compared with the untreated control mice (Flynn et 
al., 1995). Similarly, mice model with a disruption in IL-12 gene (IL-12p40−/−) when 
challenged with M.tb were unable to control M.tb infection and died earlier as compared to 
wild-type control mice. Cytokine analysis from these IL-12p40−/− mice showed reduced 
expression of IFN-γ mRNA while the expression of TNF-α was delayed (Cooper et al., 1997). 
In humans, deletion mutations in IL-12p40 and IL-12R genes have been shown to be associated 
with a reduction in IFN-γ production and recurrent mycobacterial infection (Altare et al., 2001; 
de Jong et al., 1998). 
1.8.3.4 Interleukin-1 (IL-1) 
Pro-inflammatory cytokine IL-1α and IL-1β (collectively referred as IL-1 here) are produced 
by host immune cells such as monocytes, macrophages and dendritic cells in response to M.tb 
(Giacomini et al., 2001). IL-1α and IL-1β double knockout mice when challenged with M.tb 
showed larger granulomatous lesions without Langhans like giant cells and higher number of 
M.tb in lungs as compared to the control mice 3 weeks post infection (Yamada et al., 2000). 
Furthermore, cultured alveolar macrophages from the IL-1 knockout mice showed low level of 
NO production as compared to those from control mice (Yamada et al., 2000). In addition, IL-
1R deficient (IL-1R−/−) mice were more susceptible to M.tb infection, had a high mortality rate, 
showed greater dissemination of bacteria to different organs and defective granuloma 
formation (Juffermans et al., 2000). 
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1.8.3.5 Interleukin-6 (IL-6) 
IL-6 is also produced at the site of infection during TB (Hoheisel et al., 1998). IL-6 deficient 
mice showed increased susceptibility to M.tb (Saunders et al., 2000) and succumbed to M.tb 
doses that were otherwise non-lethal in control mice (Ladel et al., 1997) indicating a protective 
role for this cytokine in M.tb infection. However, other studies have shown that in vitro IL-6 
promotes the growth of M.avium (Shiratsuchi et al., 1991) and also inhibits the production of 
IL-1 and TNF-α (Schindler et al., 1990) suggesting a negative role for this cytokine in 
controlling TB.  
1.8.3.6 Interleukin-18 (IL-18) 
IL-18 is a pro-inflammatory cytokine produced mainly by macrophages. IL-18 has been shown 
to activate Th-1 cells and induce the production of IFN-γ from these cells and thus has a 
protective role during M.tb infection (Giacomini et al., 2001). It was shown in vitro that 
neutralizing IL-18 in human PBMC infected with M.tb resulted in a marked decrease in IFN-γ 
production (Vankayalapati et al., 2000). IL-18 gene knockout mice were shown to be highly 
susceptible to M.tb. In these knockout mice greater number of M.tb was detected in the lungs 
and had larger granulomas as compared to wild-type control (Sugawara et al., 1999). 
Administration of exogenous IL-18 lowered the number of M.tb in the lungs of IL-18 knockout 
mice and reduced the sizes of granulomatous lesions. Furthermore, decreased expression of 
IFN-γ was observed in the IL-18 knockout mice as compared to the wild-type control 
(Sugawara et al., 1999). 
1.8.3.7 Interleukin-17 (IL-17)  
IL-17 is produced by specific CD4+ T cells and γδ T cells in the lungs during the early phase 
of mycobacterial infections in mice models (Lockhart et al., 2006; Aggarwal et al., 2003). IL-
17 gene knockout mice (IL-17−/−) showed delayed-type hypersensitivity responses with a lower 
number of IFN-γ secreting T cells during BCG infection and developed impaired granulomas 
(Yoshida et al., 2010; Umemura et al., 2007). IL-17 has been suggested to play a protective 
role during chronic M.tb infection in mice. IL-17−/− mice when challenged with virulent M.tb 
died earlier as compared to control mice and the histological examination of lungs from these 
IL-17−/− mice showed impaired granulomas (Umemura et al., 2016) 
1.8.3.8 Interleukin-23 (IL-23) 
IL-23 is a pro-inflammatory cytokine produced by monocytes, macrophages and dendritic cells 
(McKenzie et al., 2006). During early pulmonary M.tb infection, IL-23 is required for the 
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production of IL-17 (Khader et al., 2011). IL-23 knockout mice showed effective control of 
M.tb suggesting IL-23 has no direct role during early M.tb infection (Khader et al., 2005). 
However, IL-23 has been shown to be involved in the long-term protection against M.tb in 
mice model. IL-23a deficient (IL-23a−/−) mice, lacking the p19 component of IL-23 showed 
significantly higher number of M.tb in the lungs during late stages of infection (150-250 days 
post infection) as compared to wild type control. IL-23 causes the expression of important 
chemokine CXCL13 in the lungs of M.tb infected mice. This CXCL13 has an important role 
in T cell accumulation and granuloma formation during M.tb (Khader et al., 2011). 
1.8.3.9 Interleukin-4 (IL-4) 
IL-4 is an anti-inflammatory cytokine that has a negative impact on INF-γ production and 
macrophage activation (Lucey et al., 1996) and is mainly associated with a Th-2 type CD4+ T 
cell response (Killar et al., 1987). Increased production of IL-4 by circulating T lymphocytes 
has been detected in human TB patients (van Crevel et al., 2000). Similarly, mice infected with 
M.tb showed increased production of IL-4 which was associated with disease progression and 
reactivation of latent infection (Hernandez-Pando et al., 1996). Buccheri et al showed that 
neutralizing IL-4 in BALB/c mice by anti-IL-4 antibody treatment significantly reduced the 
number of M.tb in the lungs during the early stage of infection as compared to untreated control 
(Buccheri et al., 2007). Similar results were obtained using IL-4 gene knockout (IL-4−/−) 
BALB/c mice that showed a lower number of M.tb in the lung and spleen tissue as compared 
to wild-type control. Administration of exogenous IL-4 in these IL-4−/− mice resulted in an 
increase in the number of M.tb, suggesting a protective effect of IL-4 for the pathogenic M.tb 
(Buccheri et al., 2007). Overexpression of IL-4 in mice model was shown to affect M.tb 
induced granulomas by increasing the overall size of the granuloma and greater accumulation 
of eosinophils (Lukacs et al., 1997).  
1.8.3.10 Interleukin-10 (IL-10) 
IL-10 is an anti-inflammatory cytokine that can be found in the serum and alveolar lavage of 
TB patients (Olobo et al., 2001; Verbon et al., 1999). IL-10 is produced as a result of 
phagocytosis of M.tb by macrophages (Shaw et al., 2000) and binding of bacterial structures 
such as LAM play an important role in the production of IL-10 from these cells (Dahl et al., 
1996). IL-10 is also produced by other types of cells such as T- lymphocytes (Barnes et al., 
1993). IL-10 production during M.tb infection interferes with the host defence and helps in the 
bacterial survival by downregulating the production of different pro-inflammatory cytokines 
like TNF-α, IL-12 and INF-γ. The role of IL-10 in TB progression was investigated in vivo 
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using CBA/J mouse model and it was observed that blocking the IL-10 receptor with anti-IL-
10R1 improved the control of M.tb inside the lungs due to an increase in the number of CD4+ 
and CD8+ T cells capable of producing INF-γ and increased the survival duration as compared 
to the mice treated with control antibody (Beamer et al., 2008). Similarly, IL-10 deficient (IL-
10−/−) mice models when challenged with virulent M.tb were able to control the infection and 
showed a significant decrease in the number of M.tb in the lungs and spleen as compared to 
control. Furthermore, in IL-10−/− mice increased percentage of IFN-γ producing CD4+ T cells 
were present in the lungs indicating the early control of M.tb (Redford et al., 2010). 
1.8.3.11 Transforming growth factor- β (TGF-β) 
TGF-β is an anti-inflammatory cytokine produced by monocytes, macrophages and dendritic 
cells in response to M.tb (Toossi et al., 1995). TGF-β is produced in excess at the site of 
infection during TB (Toossi et al., 1995) and M.tb virulence factors such as LAM can induce 
the selective production of TGF-β (Dahl et al., 1996). TGF-β protects the pathogenic M.tb from 
the host’s immune system by suppressing the immune response. TGF-β has a negative impact 
on cell-mediated immunity as it inhibits T cell proliferation and the production of INF-γ, 
whereas in macrophages TGF-β affects cellular activation by downregulating the production 
of pro-inflammatory cytokines such as IL-1, IL-6 and TNF-α (Toossi and Ellner, 1998). In 
vitro, exogenous TGF-β was shown to increase the intracellular growth of M.tb in human 
monocytes while neutralizing TGF-β by a monoclonal antibody resulted in decreased 
replication of intracellular M.tb as compared to control treated with isotype antibody (Hirsch 
et al., 1994). Naturally occurring TGF-β inhibitors, Decorin and LAP in vitro restored T cells 
blastogenesis and improved the production of INF-γ in PBMCs isolated from TB patients 
(Hirsch et al., 1997). 
 
1.9 Mechanism involved in killing of intracellular M.tb 
The phagocytosis of M.tb can result in the activation of macrophages. Activated macrophages 
eliminate the intracellular M.tb through various mechanisms that are discussed as under: 
1.9.1 Acidification of phagosome 
Macrophages can eliminate intracellular M.tb contained within membrane-bound phagosomes 
by making the environment inside the phagosomes highly acidic. This acidification is vital for 
the fusion of phagosomes with lysosomes and helps in the activation of hydrolytic enzymes 
involved in the degradation of pathogens. In addition, the acidic environment inside the 
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phagosome provides a hostile environment to the bacteria where metabolism is difficult and 
can lead to the elimination of intracellular M.tb (Flannagan et al., 2009). Macrophages achieve 
this acidification of phagosome through a large number of vacuolar H+-ATPases or proton 
pumps present on the phagosomal membrane. The H+-ATPase consists of a cytoplasmic V1 
domain, responsible for ATP hydrolysis resulting in energy production and a membrane-
embedded V0 domain that uses the energy from ATP hydrolysis to translocate protons across 
the membrane (Kissing et al., 2015).  
1.9.2 Reactive oxygen intermediates (ROIs) and reactive nitrogen intermediates (RNIs) 
An effective host defence mechanism against intracellular pathogens involves the production 
of toxic compounds such as reactive oxygen intermediates (ROIs) and reactive nitrogen 
intermediates (RNIs) by phagocytic immune cells such as macrophages (Nathan and Shiloh, 
2000). Macrophages can produce ROIs through the activity of nicotinamide adenine 
dinucleotide phosphate (NADPH)-oxidase complex assembled on the phagosomal membrane. 
Activated NADPH-oxidase transfer cytosolic electron to oxygen (O2) inside the phagosome 
resulting in the production of superoxide (O2
−), hydrogen peroxide (H2O2), hydroxyl radical 
(OH•) and other ROIs for killing the phagosome bound pathogen (Slauch, 2011). However, 
ROIs have been suggested to play a non-significant role in the elimination of intracellular M.tb 
(Howell Wescott et al., 2017). It was suggested that different M.tb products such as sulfatides 
and LAM are able to scavenge ROIs (Chan et al., 1991), hence limiting the role of ROIs in the 
control of M.tb infection. In vitro both ROI deficient and normal mice macrophages with 
intracellular M.tb showed a comparable level of anti-mycobacterial activity. In addition, the 
use of oxygen radical scavengers such as catalase and superoxide dismutase showed no effect 
on the anti-mycobacterial activity of macrophages (Chan et al., 1992). However, there are other 
studies that show the involvement of ROIs in the control of M.tb infection in model organisms. 
The gene knockout mice lacking p47(phox) gene required for NADPH-oxidase activity showed 
significantly increased numbers of M.tb during the early stages of infection, indicating a 
protective role of ROIs during M.tb infection (Cooper et al., 2000). 
In addition to ROIs, macrophages are also able to produce increased quantities of nitric oxide 
(NO) upon stimulation with cytokines such as IFN-γ TNF-α and IL-1 and different pathogen 
products such as LPS (Mastroeni et al., 2000; Flynn et al., 1993). NO is produced as a result 
of oxidation of L-arginine by an enzyme known as inducible NO synthases (iNOS). This NO 
can be further converted into reactive nitrogen intermediates (RNIs) such as peroxynitrite 
(ONOO−) upon reaction with oxygen radicals (Fang, 2004). In vitro, NO has been shown to be 
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highly toxic to M.tb even at low concentrations. M.tb exposure to <100 parts per million (ppm) 
NO resulted in more than 99% M.tb killing in cultures (Long et al., 1999). There are different 
mechanisms through which NO and other RNI can kill M.tb. These include damage to the 
bacterial DNA by causing strand breaks as well as modification of bacterial cell surface and 
intracellular proteins and lipids (Bogdan, 2001). The importance of NO in control of 
intracellular M.tb was shown using mice models. It was shown that iNOS gene knockout mice 
failed to produce NO and other RNI and were more susceptible to M.tb infection with a higher 
mortality rate as compared to the wild type control (Adams et al., 1997). Similarly, iNOS 
inhibitors treatment in mice model with latent TB caused the reactivation of disease and 
resulted in early mortality as compared to the untreated control (Flynn et al., 1998). In vitro, 
NO and RNIs were shown to be involved in the intracellular killing of M.tb (Bose et al., 1999) 
and M.bovis BCG (Nozaki et al., 1997) in human macrophages suggesting their important role 
in the host defence. 
1.9.3 Apoptosis 
Apoptosis is the host cell defence response to intracellular pathogens such as viruses and 
bacteria. Apoptosis of M.tb infected macrophages involves programmed cell death that results 
in the killing of intracellular M.tb (Behar et al., 2011).  
A family of serine proteases known as caspases is vital for the initiation and execution of 
apoptosis. Apoptotic pathways can be divided into three distinct types depending on the type 
of caspase initially activated. The extrinsic apoptotic pathway involves the initial activation of 
procaspase 8 or procaspase 10 by TNF-α or FasL binding to the cell surface receptors such as 
TNFR1 and Fas (Brunner et al., 2003). The intrinsic apoptotic pathway involves the initial 
activation of procaspase 9 by cytochrome c released from the mitochondria in response to 
intracellular stress signals such as DNA damage, nutrient deficiency or oxidative stress 
(Saelens et al., 2004). The third apoptotic pathway involves caspase activation through 
granzymes B released by CD8+ T cells or NK cells along with perforin (Trapani and Smyth, 
2002). All the three apoptotic pathways ultimately converge at the same target and activate 
effector caspases including caspase 3, caspase 6 and caspase 7 that can induce different 
processes such as condensation of nuclear chromatin, DNA breakage and the formation of 
apoptotic vesicles leading to cell death. 
The extrinsic apoptotic pathway was shown to be involved in the killing of intracellular M.tb. 
Keane et al showed for the first time that M.tb was able to induce apoptosis in human alveolar 
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macrophages through TNF-α production (Keane et al., 1997). They also showed that attenuated 
M.tb strain such as H37Ra were more potent inducers of apoptosis as compared to virulent 
strain H37Rv, although both induced similar level of TNF-α production by macrophages 
(Keane et al., 1997). This reduced apoptotic potential of virulent M.tb strains was later shown 
to be associated with the increased expression of the anti-apoptotic Mcl-1 gene of macrophages 
by virulent M.tb (Riendeau and Kornfeld, 2003; Oddo et al., 1998). 
Apoptotic cell death leads to the production of membrane-bound vesicles containing the 
cytoplasmic content of dying cells along with bacterial components called apoptotic bodies. 
These apoptotic bodies are eliminated as they attract phagocytic cells predominantly 
macrophages by releasing signal such as ATP and expressing phosphatidylserine (Martin et 
al., 2012). 
 
1.10 M.tb survival strategies inside host cells 
M.tb has evolved several unique strategies through which it can evade the hostile environment 
inside phagocytic macrophages. Some of these survival mechanisms are discussed as under: 
1.10.1 Inhibition of Phagosome maturation 
In order to eliminate the pathogenic M.tb, macrophages engulf the bacteria in membrane-bound 
structures called phagosomes. These phagosomes then undergo a maturation process involving 
sequential fusion with early endosomes, late endosomes and finally lysosomes (Aderem and 
Underhill, 1999). However, in case of M.tb, the phagosome maturation process is blocked 
beyond the fusion with early endosome. This early fusion provides the phagocytosed M.tb to 
access nutrient and protection. There are several mechanisms through which M.tb halt 
phagosome maturation.  
First, M.tb produced enzymes such as urease resulting in the production of ammonia. This 
causes an increase in the pH of the phagosome making it more alkaline which hampers the 
transport of material from early to late endosome leading to disruption in phagosome 
maturation (Harth and Horwitz, 1999; Clemens et al., 1995). In addition, intracellular M.tb are 
able to exclude the vacuolar H+-ATPase from the phagosome membranes, resulting in lack of 
acidification and higher pH in the phagosomal lumen (Wong et al., 2011). 
The phagosome membrane contains various proteins that are involved in the interaction of 
phagosome with early and late endosome as well as the lysosome. One such protein is a small 
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GTPase protein known as Rab7 that controls the maturation of early endosome to late 
endosome. M.tb avoids phagosome maturation by blocking the acquisition of Rab7 (Fratti et 
al., 2003; Via et al., 1997). Rab14 is another protein that M.tb utilizes to avoid phagosome 
maturation. Rab14 is not needed during the later stages of phagosome maturation and is 
disassociated during phagosome maturation. However, M.tb blocks the disassociation of Rab14 
and hence halts the phagosome maturation (Kyei et al., 2006). M.tb also produce an acid 
phosphatase called SapM, which causes the release of Phosphatidylinositol-3-phosphate (PI3P) 
from the phagosome. This PI3P is essential for phagosome maturation as it provides a site for 
docking several proteins involved in the maturation of phagosome into phagolysosome 
(Vergne et al., 2005; Saleh and Belisle, 2000; Wurmser et al., 1999). 
Another possible mechanism used by M.tb for inhibiting phagosome maturation is through the 
accumulation of host cell coronin I protein around the phagosome (Ferrari et al., 1999). It is 
suggested that this envelope of coronin I around phagosome prevent phagosome-lysosome 
fusion by regulating calcium-dependent signalling processes (Jayachandran et al., 2007). 
1.10.2 Modulation of antigen presentation 
Macrophages can initiate adaptive immune response by processing the M.tb antigens and 
presenting them to T cells via MHC molecules expressed on their cell surfaces. However, M.tb 
has evolved strategies through which it can interfere with antigen processing and its 
presentation by macrophages. M.tb cell surface molecule such as ManLAM can inhibit the 
production of IFN-γ resulting in reduced expression of MHC class II molecules (Baena and 
Porcelli, 2009). Although the exact mechanism is not clear it has been suggested that 
attenuation of MHC class II molecules could be due to the inhibition of IFN-γ gene expression 
and/or downregulation of different molecules such as MHC Class II trans-activator (CIITA). 
CIITA is a major transcriptional regulator of MHC class II expression (Chang et al., 1994). 
The interaction of 19kDa lipoprotein molecule from M.tb has also been shown to cause 
inhibition of antigen processing and downregulation of MHC class II molecules in vitro in 
mouse macrophages as compared to untreated control (Noss et al., 2001). TLR 2 receptors on 
macrophages were shown to play an important role in this downregulation of MHC Class II 
molecules. It was shown that macrophages isolated from TLR2 knockout (TLR2−/−) mice when 
treated with 19kDa lipoprotein showed greater expression of MHC class II molecules as 
compared control (Noss et al., 2001). 
                                                                                                                                      Chapter 1 
29 
 
1.10.3 Resistance to reactive oxygen and nitrogen intermediates 
Activated macrophages can eliminate intracellular mycobacteria by producing highly toxic 
compounds such as reactive nitrogen intermediates (RNIs) and reactive oxygen intermediates 
(ROIs) (Fang, 2004). M.tb, however, as a part of its resistance mechanism produces different 
enzymes that can inactivate some of these toxic compounds. For example, the production of 
KatG, a catalase-peroxidase can inactivate reactive oxygen inside the phagosomes and help in 
the growth of M.tb in animal models such as mice and guinea pigs (Li et al., 1998). Similarly, 
another protective mechanism involves M.tb proteasome, which helps in the removal or 
refolding of proteins damaged by reactive nitrogen intermediates (Darwin et al., 2003). 
 
1.11 Diagnosis of TB 
Some of the diagnostic tests currently used for TB are discussed as under: 
1.11.1 Chest X-ray 
Chest X-rays are performed to detect pulmonary TB in patients with abnormal respiratory 
symptoms. Chest X-rays showing cavitation or calcified shadows in the upper and middle lobes 
of the lungs are positive indications for pulmonary TB (van Cleeff et al., 2005). However, a 
chest radiograph is not by itself diagnostic for TB and only provide clues for the diagnosis. 
1.11.2 Sputum Microscopy 
Sputum smear microscopy using a light microscope is the primary method for diagnosing 
pulmonary TB in most of the low income and middle income countries with a high number of 
TB cases. This method of diagnosis is advantageous because it is inexpensive, rapid and 
relatively simple (Dye et al., 2005). For M.tb detection via microscopy, sputum samples are 
collected from the patient on 3 consecutive days. The sputum is smeared on a glass side and 
acid-fast staining (Ziehl–Neelsen staining) is performed to detect red M.tb bacilli using a light 
microscope. This technique has been reported to have a sensitivity ranging from 50-80% in 
detecting pulmonary TB in the adult population (Levy et al., 1989; Aber et al., 1980). Sputum 
microscopy has a poor track record in detecting pulmonary TB in children (20%) and in HIV 
positive patients (Perkins et al., 2006; Shingadia and Novelli, 2003). Other limitation of this 
method including non-specificity for M.tb as the presence of other mycobacterial species may 
produce false positive results. 
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An important new innovation to this diagnostic technique in high income countries is the 
introduction of fluorescence microscopy using acid-fast fluorescence dyes such as auramine-
O or auramine-rhodamine. Comparison of fluorescence and conventional microscopy showed 
similar specificity and 10% higher sensitivity for fluorescence microscopy than that of 
conventional microscopy (Steingart et al., 2006).  
1.11.3 M.tb cultures 
For the definitive diagnosis of TB, cultures are grown from samples such as sputum, 
bronchoalveolar lavage etc. of suspected patients for the detection of M.tb. A culture test is 
considered to be the gold-standard for M.tb detection and has a higher sensitivity of around 
82%. M.tb number as low as 10 bacilli per ml of the specimen can be detected using this method 
(Yeager, Jr. et al., 1967). Conventionally 3 sputum samples are used for culture diagnosis 
however, the use of 2 specimens has been shown to be equally sensitive (Leonard et al., 2005). 
One of the major drawback associated with this technique is the longer duration of diagnosis 
since M.tb are slow growing bacteria and may require 3-6 weeks for detectable growth. 
Automated culture detection systems such as BACTEC MGIT 960 and MB/BacT system have 
been introduced for diagnosis of TB. These systems utilize modified Middlebrook 7H9 broth 
and have improved sensitivity combined with a shorter M.tb detection duration of 8-10 days as 
compared to conventional culturing methods. These systems have the additional advantage of 
performing drug susceptibility test (DST) simultaneous to the detection of M.tb in the 
diagnostic samples (Muyoyeta et al., 2009; Palomino et al., 2008). Hasan et al showed that 
BACTEC MGIT-960 was 100% sensitive and 93.3% specific in detecting mycobacteria when 
compared to Löwenstein–Jensen (LJ) culture method in a study conducted in Bangladeshi 
population (Hasan et al., 2013). Whereas, in case of detecting M.tb susceptibility to first-line 
TB drugs, MB/BacT system showed 95-100% sensitivity and 100% specificity when compared 
to LJ culture method (Barreto et al., 2002). 
1.11.4 Tuberculin skin test 
Tuberculin skin test is one of the oldest diagnostic test mostly used for the detection of latent 
TB due to its lower cost. This test is also known as intradermal Mantoux test. During tuberculin 
skin test, intermediate strength purified protein derivatives (PPD) from M.tb are injected 
intradermally. An indurate develops in the skin at the site of injection due to cell-mediated 
immunity against the injected PPD. The size of this indurate is measured after 48-72 hours and 
conclusion is drawn about latent M.tb infection based on the size (Huebner et al., 1993). The 
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sensitivity of Tuberculin skin test in detecting pulmonary M.tb infections in the first time TB 
patients is approximately 80% (Nash and Douglass, 1980). However, there are limitations to 
this diagnostic method. The PPD which is a culture filtrate of tubercle bacilli shares almost 200 
antigens with M.bovis BCG and other non-pathogenic mycobacteria. Therefore, previous BCG 
vaccination or exposure to environmental mycobacteria can hamper the results from this test 
(Wang et al., 2002).  
1.11.5 Interferon-γ release assay (IGRA) 
Interferon-γ (IFN-γ) release assay (IGRA) is a blood-based diagnostic test for TB. It relies on 
the release of IFN-γ by T-lymphocytes upon exposure to specific M.tb antigens, ESAT-6 and 
CFP-10 which are encoded by the genes in the region of difference 1 (RD1) of M.tb genome.  
Two commercially available immunological tests, QuantiFERON-TB Gold and T-SPOT.TB 
tests are used ex vivo for diagnosing M.tb infections. QuantiFERON-TB Gold test uses enzyme-
linked immunosorbent assay (ELISA) to measures IFN-γ released by sensitized T lymphocytes 
after incubation M.tb specific antigens (Mazurek et al., 2005). The second IGRA test known 
as T-SPOT.TB test. This test identifies M.tb specific T lymphocytes from the blood sample 
secreting INF-γ using enzyme-linked immunospot (ELISpot) assay technique (Lalvani et al., 
2001). 
The main advantage of these tests over Tuberculin skin test is that the ESAT-6 and CFP-10 are 
specific to M.tb, hence excluding false positive results from BCG vaccinated individuals or 
people exposed to environmental mycobacteria. A comparative study conducted for detection 
of active pulmonary tuberculosis in patients with clinical and radiological symptoms in 
Rawalpindi, Pakistan showed QuantiFERON-TB Gold test to be 80% sensitive while the 
sensitivity for Tuberculin skin test was 28% (Khalil et al., 2013). Similarly, the T-SPOT.TB 
test was shown to have a higher sensitivity of 83% in the diagnosis of active pulmonary TB as 
compared to Tuberculin skin test with a sensitivity of 38.3% (Simsek et al., 2010). The T-
SPOT.TB test was shown to be 10% more sensitive that QuantiFERON-TB Gold test in 
detecting latent TB infections in health care workers in South Africa (van Zyl-Smit et al., 
2016). 
The major limitation of both QuantiFERON-TB Gold test and T-SPOT.TB test is that these 
tests are unable to distinguish between active and latent tuberculosis. 
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1.11.6 Nucleic acid amplification tests (NAATs) 
Amplification of specific M.tb DNA sequences from the patient specimen can be used for the 
diagnosis of TB. These tests are fast and can give results in 3-6 hours (Catanzaro et al., 1997). 
Cobas TaqMan MTB assay is a commercially available NAAT that consists of a real-time PCR 
(qPCR) kit for rapid detection of M.tb from clinical specimens. Using Culture test as a reference 
Cobas TaqMan MTB assay has shown a sensitivity of 83% and a specificity of 97% in patients 
with clinical symptoms of TB (Lee et al., 2013). Similarly, another commercially available 
NAAT known as Gene Xpert MTB/RIF assay not only allows rapid M.tb detection through 
DNA amplification but can simultaneously detect rifampicin resistance causing mutations by 
using rpoB gene as a target (Zeka et al., 2011). GeneXpert MTB/RIF assay has shown a 
sensitivity of around 87-93% and a specificity of 98% when compared to culture test as a gold 
standard during different studies (Moussa et al., 2016; Bunsow et al., 2014). The Gene Xpert 
MTB/RIF assay has a sensitivity of 100% and a specificity of 96% in detecting RIF resistance 
strains of M.tb (Bunsow et al., 2014). 
1.12 Treatment of TB 
Currently, there are more than 20 drugs used in different combinations for treatment of TB. 
The use of particular combinations of drugs depends upon the circumstances during which it 
is used. The anti-TB drug can be divided into 2 major groups known as first-line drugs and 
second-line drugs. 
1.12.1 First Line Drugs  
The first line drugs consist of four anti-TB drugs including isoniazid, rifampicin, pyrazinamide 
and ethambutol. First line drugs are used for the treatment of TB in new patients as these 
patients have the least chances of showing resistance to any of these drugs. During standardized 
short-course therapy for TB, all the four antibiotics are administered to the patient once every 
day for the first 2 months. The purpose of taking all 4 drugs simultaneously is to eliminate M.tb 
mutants and avoid drug resistance. Isoniazid and rifampicin are continued for another 4 months 
while pyrazinamide and ethambutol are discontinued (van Deun et al., 2010). There is a 5% 
relapse chance for TB in patients who have undergone the standardized short-course therapy 
with first line drugs (Gegia et al., 2017).  
The first line anti-TB drug are discussed as under: 




Isoniazid is an important anti-TB drug that has been used since 1952. Isoniazid inhibits the 
production of mycolic acid in mycobacteria and hence prevents the synthesis of bacterial cell 
wall. It also causes the production of oxygen derived free radicals (superoxide, peroxide and 
hydroxyl radicals) and organic free radicals (carbon-containing compounds with a free electron 
such as •CH3) that damage DNA (Timmins and Deretic, 2006). The minimum inhibitory 
concentration (MIC) of isoniazid ranges from 0.02-0.20 µg/mL for M.tb (Arbex et al., 2010). 
However, isoniazid is a prodrug and requires M.tb catalase-peroxidase enzyme KatG for its 
conversion to active form isonicotinic acid (Zhang et al., 1992). Resistance to isoniazid can 
arise due to missense mutations causing amino acid substitutions, or small deletions or 
insertions in the KatG genes. This results in the lower efficacy of isoniazid and inhibits the 
prodrug from being converted into its functional metabolite (Slayden and Barry, 2000). 
Furthermore, isoniazid can efficiently kill actively growing M.tb however, it has limited effect 
against slow-growing intracellular M.tb (Zhang, 2005). 
1.12.1.2 Rifampicin 
Rifampicin is the most important drug included in the first line drugs for TB treatment and has 
been in use since 1966. Rifampicin can kill metabolically active M.tb as well as bacteria in 
stationary phase. Rifampicin blocks the transcription of mycobacterial genes by binding to the 
β-subunit of DNA-dependent RNA polymerase. This stops the synthesis of mRNA resulting in 
a lack of important protein for M.tb and finally cell death (Blanchard, 1996). The MIC of 
rifampicin is 0.05-0.50 µg/mL for M.tb (Arbex et al., 2010). Point mutations or deletions in the 
RNA polymerase B gene (rpoB) result in resistance to rifampicin (Telenti et al., 1993). About 
95% of this resistance causing mutations in bacteria are restricted to an 81bp region of rpoB 
called RRDR (rifampicin resistance determining region) (Caws et al., 2006). 
1.12.1.3 Pyrazinamide 
Pyrazinamide has been used as an anti-TB drug since 1952. Chemically pyrazinamide is a 
nicotinic acid derivative and is similar to isoniazid in structure. The antibacterial activity of 
pyrazinamide is pH dependent and the minimum inhibitory concentration (MIC) of 
pyrazinamide is 6.25-50.0 µg/mL for M.tb at pH 5.5 (Arbex et al., 2010). Pyrazinamide is a 
prodrug and requires M.tb enzyme nicotinamidase/pyrazinamidase for its conversion to active 
form pyrazinoic acid (Konno et al., 1967). The mechanism of action for pyrazinamide is still 
not fully clear. It is suggested that pyrazinamide kills M.tb by passively entering the bacteria 
and converting into pyrazinoic acid. The bacteria lack an efficient system efflux system causing 
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accumulation of pyrazinoic acid in the cytoplasm leading to a decrease in intracellular pH 
(Zhang et al., 2003). It is also suggested that this change in pH leads to the inactivation of 
important bacterial enzymes such as fatty acid synthase I, which plays important role in 
mycolic acid synthesis (Zimhony et al., 2007). Pyrazinamide has sterilizing effect by 
eliminating non-replicating persistent M.tb present in acidic environments such as 
phagolysosome that is responsible for bacteriological relapse (Mitchison, 1985). Pyrazinamide 
is used along with other first-line TB drugs due to its sterilizing effect and can shorten the 
treatment time to 6 months. Resistance to pyrazinamide can arise due to missense mutations, 
or small deletions or insertions in the pncA gene leading to the production of non-functional 
nicotinamidase/pyrazinamidase enzyme (Scorpio and Zhang, 1996). 
1.12.1.4 Ethambutol 
Ethambutol is a bacteriostatic drug that has been used for treating TB since 1966. Ethambutol 
can inhibit the growth of M.tb and is effective against intracellular as well as extracellular M.tb. 
The minimum inhibitory concentration (MIC) of ethambutol is 1-5 µg/mL for M.tb (Arbex et 
al., 2010). Ethambutol inhibits the formation of M.tb cell wall by interfering with the 
biosynthesis of an important polysaccharide arabinogalactan. Ethambutol inactivates the 
enzyme arabinosyl transferase, which mediates polymerization arabinose into arabinan and 
then arabinogalactan (Mikusova et al., 1995). Resistance to ethambutol develops due to 
missense mutations in the embB gene cluster coding for arabinosyl transferase (Telenti et al., 
1997). 
1.12.2 Second Line Drugs 
Multidrug-resistant TB (MDR-TB) is defined as a condition in which patient does not respond 
to both isoniazid and rifampicin. The second line drugs are only used during MDR-TB when 
M.tb is resistant to the first line drugs. Treatment of MDR-TB with second-line drugs requires 
longer durations and the treatment is continued for 24 months. MDR-TB patients are treated 
by giving them different anti-TB drugs in combination with fluoroquinolones (Gegia et al., 
2017). Proper treatment is of utmost importance in case of MDR-TB for recovery of patients 
and to stop further acquisition of resistance mutation by the pathogenic M.tb. If MDR-TB is 
not treated properly it can develop into extensively drug-resistant TB (XDR-TB). During XDR-
TB the patients become resistant to a fluoroquinolone and one drug from aminoglycosides or 
cyclic peptides groups (CDC, 2006). 
Some of the second line drugs used for treating MDR-TB are described as under: 




Fluoroquinolones including fluorine-containing nalidixic acid derivatives are used for treating 
pulmonary, extrapulmonary and disseminated TB (Rustomjee et al., 2008). Fluoroquinolones 
include a number of drugs such as sparfloxacin, gatifloxacin, moxifloxacin, levofloxacin, 
ciprofloxacin, and ofloxacin. Among all fluoroquinolones, gatifloxacin and moxifloxacin were 
shown to be the most effective in treating rifampicin-tolerant persistent M.tb in vitro and had 
MIC of 0.20-0.25µg/mL (Arbex et al., 2010). Fluoroquinolones are also bactericidal against 
intracellular M.tb. In mice, moxifloxacin was the most effective in killing M.tb followed by 
sparfloxacin, levofloxacin, and ofloxacin respectively (Shandil et al., 2007). In humans, 
fluoroquinolone such as ciprofloxacin or ofloxacin is commonly used for treating MDR-TB 
(Bass et al., 1994).  
Fluoroquinolones kill M.tb by targeting the bacterial topoisomerases II (DNA gyrase) that are 
essential for DNA replication, repair and recombination. Fluoroquinolones directly inhibit 
bacterial DNA synthesis by binding to the enzyme-DNA complex and cause a blockade of 
DNA replication and strand breakage (Aubry et al., 2004). Resistance to fluoroquinolones 
develops due to mutations in the gyrA and gyrB genes of M.tb coding for A and B subunits of 
topoisomerase II. Majority cases of M.tb with fluoroquinolones resistance have missense 
mutations in a small portion of gyrA gene called quinolone resistance-determining region 
(QRDR) (Sun et al., 2008; Cheng et al., 2004).  
 1.12.2.2 Streptomycin 
Streptomycin was the first antibiotic used for treating TB, however, M.tb became resistant to 
this antibiotic due to its use as monotherapy. Streptomycin binds to the 16S rRNA and inhibits 
the translation of bacterial proteins (Moazed and Noller, 1987). Resistance to streptomycin is 
due to mutations in the rrs or rpsL gene that alter the streptomycin binding site on 16S rRNA 
(Ramón-García et al., 2006; Finken et al., 1993). 
1.12.2.3 Aminoglycosides and Cyclic peptides 
Aminoglycosides and cyclic peptides used for TB treatment share the same mechanism of 
action for killing M.tb. These drugs kill M.tb by binding irreversibly to the ribosomal subunits 
and prevent the initiation of translation during protein synthesis (Maus et al., 2005; Kotra et 
al., 2000).  
Kanamycin and amikacin are aminoglycosides used for treating TB. These drugs inhibit protein 
synthesis by binding to the 16S rRNA specifically in regions that interact with tRNA and lead 
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to misreading of tRNA (Alangaden et al., 1998). Resistance to these drugs is due to mutations 
at position 400 and 1401 of the rrs gene coding for 16S rRNA result in mutants with high-level 
resistance to kanamycin and amikacin (Suzuki et al., 1998). 
Capreomycin and viomycin are structurally related cyclic peptides used for TB treatment. 
These drugs share the same mechanism and inhibit protein synthesis in M.tb by binding at the 
interface of the 30S small and 50S large ribosomal subunits (Stanley et al., 2010). Resistance 
to these drugs is due to mutations in tlyA gene that codes for rRNA methyltransferase (Johansen 
et al., 2006) 
1.12.2.4 Ethionamide 
Ethionamide is a pro-drug, structurally similar to isoniazid and is used for treating TB. The 
pro-drug is activated by ethA-encoded enzyme mono-oxygenase, resulting in the formation of 
the functionally active ethionamide-NAD adduct. This active ethionamide-NAD adduct 
interferes with mycolic acid synthesis by inhibiting the enoyl-ACP reductase enzyme (Wang 
et al., 2007; Baulard et al., 2000). Resistance to ethionamide occurs due to mutations in ethA 
gene encoding mono-oxygenase (Brossier et al., 2011) or the transcriptional repressor ethR 
gene (Carette et al., 2011). 
 1.12.2.5 Para-Aminosalicylic Acid 
Para-Aminosalicylic Acid (PAS) is bacteriostatic in nature and was the second drug found 
effective for treating TB (Dooneief et al., 1950). Earlier PAS was used in combination with 
isoniazid and streptomycin for treating TB, however, PAS is now used as a second line drug 
for treating MDR-TB. The mechanism of action for PAS is not completely understood. It is 
suggested that PAS interferes with folic acid synthesis by limiting the supply of 
dihydropteroate synthase enzyme needed by para-aminobenzoic acid (Rengarajan et al., 2004). 
Mutations in the thyA gene encoding thymidylate synthase A enzyme which is important for 
activation of PAS and folC gene have been shown to be associated with resistance to PAS 
(Mathys et al., 2009; Rengarajan et al., 2004). 
1.12.2.6 D-Cycloserine 
D-cycloserines are bacteriostatic drugs that are used for treating MDR-TB. D-cycloserines are 
analogues of D-alanine and interfere with peptidoglycan synthesis by blocking the activity of 
D-alanine : D-alanine ligase (Feng and Barletta, 2003). This drug also prevents the conversion 
of L-alanine to D-alanine by inhibiting the enzyme D-alanine racemase (Strych et al., 2001). 
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The actual target for this antibiotic is unknown in M.tb however, recombinant M.smegmatis 
with mutations in alrA were shown to be resistant to cycloserine (Caceres et al., 1997). 
1.12.2.7 Linezolid 
Linezolid used for treating MDR-TB belongs to the oxazolidinones family of drugs. Linezolid 
binds to the 50S ribosomal units and inhibit the early steps in protein synthesis (Thompson et 
al., 2002). Resistance to linezolid is rare in M.tb and only 1.9% of the MDR strains don’t 
respond to linezolid (Richter et al., 2007). In vitro analysis of resistant strains showed 
mutations in 23S rRNA and rplC gene encoding 50S ribosomal subunit (Beckert et al., 2012). 
There are also reports showing the involvement of M.tb efflux pumps in resistance to linezolid 
(Escribano et al., 2007).  
1.12.3 New Anti-TB Drugs 
Because of the emergence of resistant M.tb strains to the currently available anti-TB drugs, a 
number of new anti-TB drugs are being developed with the aim of improved efficacy and 
shorter treatment duration. Some of these new drugs are discussed as under: 
1.12.3.1 Bedaquiline 
Bedaquiline is a new antibiotic used specifically for treating MDR-TB (Diacon et al., 2009). 
This drug inhibits the ATP-synthase of M.tb by blocking the proton pumps (Hards et al., 2015). 
Bedaquiline is currently in phase III clinical trials.  
1.12.3.2 Delamanid 
Delamanid is a nitro-dihydro-imidazooxazole derivative that inhibits the synthesis of mycolic 
acid and is highly effective against both drug-susceptible and drug-resistant M.tb (Diacon et 
al., 2011; Matsumoto et al., 2006). Delamanid is currently in phase III clinical trials.  
1.12.3.3 Pretomanid (PA-824) 
Pretomanid (PA-824) is a nitroimidazole derivative that kills M.tb by inhibiting the synthesis 
of cell wall lipids (Manjunatha et al., 2009). PA-824 is effective against both actively dividing 
and non-replicating persistent M.tb (Diacon et al., 2012; Lenaerts et al., 2005). PA-824 is 
currently in phase III clinical trials. 
1.12.3.4 SQ-109 
SQ-109 is a synthetic ethambutol analogue that is effective against extensively drug-resistant 
M.tb strains in addition to actively dividing and persistent non-replicating M.tb. The minimum 
inhibitory concentration of SQ-109 is 0.16-0.63 mg/L for M.tb (Protopopova et al., 2005). This 
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drug inhibits M.tb growth by interfering with the assembly of mycolic acid into the 
mycobacterial cell wall core (Tahlan et al., 2012). It is currently in phase II clinical trials. When 
used in combination with isoniazid and rifampicin in mice models, SQ-109 enhanced the anti-
M.tb activity and reduced the time required to cure TB (Nikonenko et al., 2007).  
1.12.3.5 Benzothiazinone 
Benzothiazinone derivatives such as BTZ043 are a new class of anti-TB drug that interferes 
with the bacterial cell wall synthesis by blocking the synthesis of arabinans. BTZ043 targets 
the bacterial enzyme decaprenylphosphoryl-beta-d-ribose 2'-epimerase (Makarov et al., 2009). 
This enzyme is essential for the synthesis of decaprenylphosphoryl arabinose, which serves as 
a precursor for cell wall arabinans (Mikusová et al., 2005). These drugs have been shown to be 
effective in against drug-susceptible and MDR M.tb strains (Pasca et al., 2010). 
 
1.13 Anti-TB vaccines 
1.13.1 M.bovis Bacillus Calmette–Guérin (BCG) vaccine 
BCG is the only licenced vaccine currently available against TB and is used worldwide for TB 
prevention. This vaccine consists of an attenuated M.bovis strain that was derived from a 
virulent strain after passaging it in vitro for over a decade (Calmette et al, 1927; Calmette and 
Plotz, 1929). M.bovis BCG is closely related to M.tb and its genome has almost 99.95% 
similarity with M.tb. Genome analysis showed that the M.bovis BCG genome has undergone a 
large number of mutations during it's in vitro propagation including a number of deletions in 
the RD1 region (Behr et al., 1999). These deletions resulted in the loss of several important T 
cell stimulating antigens such as the ESAT-6 (early secretory antigenic target of 6kDa) and 
CFP10 (culture filtrate protein 10) (Pym et al., 2002). 
The BCG vaccine was first introduced in France and Belgium from 1921-1927 and showed 
high efficacy in protecting children against TB. Initial use of BCG vaccine was limited to 
tuberculin negative children as this vaccine was not expected to have a positive effect in M.tb 
infected individuals. Later studies indicated that it was safe to use BCG vaccine in tuberculin 
positive people which led to the mass vaccination programs in TB-endemic areas. Currently, 
BCG vaccine is administered to infants soon after birth in the form of a single intradermal dose 
in countries with high TB risk. It is estimated that >3 billion people have been vaccinated 
against TB using BCG vaccines. 
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There have been a number of efficacy trials and epidemiological studies that have established 
the protective role of BCG vaccines in children against different forms of TB. These studies 
showed that BCG vaccines have 60-80% protective efficacy in children against various forms 
of TB such as meningitis and miliary TB, while the protection against pulmonary TB varies 
from 20-80% geographically (Michelsen et al., 2014; Trunz et al., 2006; Wünsch Filho et al., 
1990; Romanus, 1987; Padungchan et al., 1986). In the adult population, BCG vaccine has 
shown limited protection against pulmonary TB. The largest community-based trail for BCG 
vaccine efficacy was conducted in Madras, South India from 1968-1971. Individuals who were 
vaccinated as adults during this trail on re-evaluation after 5 and 15 years respectively showed 
no protective effect against the development of active TB. This trial also showed much lower 
levels of protection by BCG vaccine against pulmonary TB in children (17%) as compared to 
other studies (Tripathy, 1987). Other controlled-field trials performed showed variable efficacy 
(0-80%) for BCG vaccine in controlling pulmonary TB in adults, with the lowest levels of 
protection in countries of high burden (Aronson et al., 2004; Colditz et al., 1994; Palmer and 
Long, 1966).  
This variability in BCG vaccine efficacy can be attributed to a number of factors including 
strain variation in BCG vaccine preparations. The original attenuated M.bovis culture produced 
in France was distributed to different laboratories without cloning. These laboratories then 
propagated the vaccine M.bovis BCG culture under different conditions using different 
protocols, which led to variations in the bacteria. Other factors such as genetic differences 
between population, nutritional condition of individuals and environmental factors may also 
lead to variability in vaccine efficacy (Behr, 2002). 
Pre-exposure to environmental mycobacteria can have a deleterious effect on BCG 
vaccination. Two hypothesis are put forward in this regard. The first hypothesis suggests that 
some level of protective immunity is generated in individuals exposed to environmental 
mycobacteria which mask the protective effect from a subsequent BCG vaccine (Fine and 
Vynnycky, 1998). The second hypothesis suggests that pre-exposure to environmental 
mycobacteria results in the generation of an immune response to antigens shared by different 
mycobacterial species. Subsequent BCG vaccination of pre-exposed individual prevents BCG 
from replication and affect the efficacy of the vaccine (Brandt et al., 2002). 
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1.13.2 New candidate anti-TB vaccines 
Due to the variability in efficacy of BCG vaccine and its limited effectiveness in regions with 
higher TB burden, novel anti-TB vaccines are required. Research is being done to develop new 
TB vaccines that can either be used to boost the immune response produced by prior BCG 
vaccination or to develop novel vaccines that can replace BCG altogether. Some of these new 
candidate anti-TB vaccines are discussed as under: 
1.13.2.1 MVA85A 
MVA85A was a subunit vaccine used in BCG vaccinated individual to boost the number of 
antigen-specific T cells. MVA85A consists of a recombinant modified vaccinia virus Ankara 
expressing M.tb antigen 85A (McShane et al., 2004). In BCG vaccinated mice models 
MVA85A was shown to be effective in further enhancing the protective immunity against M.tb. 
MVA85A was shown to increase the number of IFN-γ secreting CD4+ T cells (Goonetilleke et 
al., 2003). Phase I clinical trial for MVA85A showed the vaccine to be safe in humans and 
capable of inducing high levels of antigen-specific IFN- γ secreting T cells (McShane et al., 
2004). However, unfortunately, the phase IIb clinical trial conducted in infants in South Africa 
showed no significant enhancement in protection against TB in BCG prime MVA85A boosted 
individuals (Tameris et al., 2013). Further analysis revealed that MVA85A vaccine was unable 
to elicit the same levels of T cell response as the phase I clinical trials conducted in the UK. 
The T cell response generated by MVA85A in African population during phase IIb trials was 
10-fold less than the UK population observed in phase I trials (Wilkie and McShane, 2015). 
1.13.2.2 M72/AS01E 
M72/AS01E is another subunit vaccine that is currently in phase IIb clinical trials. This vaccine 
consists of a recombination fusion antigenic protein, M72, derived from two mycobacterial 
proteins Mtb32a and Mtb39a. The fusion protein M72 is delivered in the adjuvant AS01. The 
M72/AS01E exerts its protective effect by causing the production of high levels polyfunctional 
M72 specific CD4+ T cells and CD8+ T cells (Leroux-Roels et al., 2013). This vaccine has 
shown good safety profile in multiple phase I and phase IIa clinical trials carried out in adults 
(Montoya et al., 2013) and BCG vaccinated infants (Idoko et al., 2014).  
1.13.2.3 H1/IC31 and H56/IC31 
H1/IC31 and H56/IC31 are fusion protein vaccines currently in phase IIa clinical trials.  
H1/IC31 consist of M.tb secreted Ag85B protein fused with another antigenic M.tb protein 
ESAT-6. This fusion protein is combined with adjuvant IC31 composed of the antibacterial 
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peptide (KLK) and a synthetic oligodeoxynucleotide (ODN1a), for the vaccine delivery (Olsen 
et al., 2001). This vaccine can elicit a potent T cell response and has shown good results during 
phase I and some phase II clinical trials in naïve (van Dissel et al., 2010), BCG vaccinated (van 
Dissel et al.., 2011) and HIV+ individuals (Reither et al., 2014). 
H56/IC31 is a modified version of the H1/C31 vaccine. This vaccine consists of an additional 
protein Rv2660c fused with the Ag85B and ESAT-6. The advantage of H56/IC31is its ability 
to provide protection against latent TB by eliciting a strong cellular and humoral immune 
response as was shown during phase I trial conducted in South Africa (Luabeya et al., 2015). 
1.13.2.4 VPM1002 
The VPM1002 vaccine consists of recombinant BCG that produces enzyme listeriolysin O 
(LLO) due to the incorporation of genes from Listeria monocytogenes. The recombinant BCG 
also has a deletion of the ureC gene in order to improve the activity of LLO enzyme as it 
requires a pH of 5.5 (Farinacci et al., 2012). The LLO enzyme makes the phagosome membrane 
porous resulting in the leakage different enzymes and bacterial antigens into the cytoplasm 
leading to increased apoptosis and enhanced CD4+T cells and CD8+T cells responses (Grode 
et al., 2013). This vaccine is currently in phase IIa clinical trials. 
1.13.2.5 MTBVAC 
MTBVAC vaccines contain live attenuated M.tb. The M.tb used in these vaccines have two 
independent stable deletion mutations in the virulence genes fadD26 and phoP (Arbues et al., 
2013). This vaccine has shown a greater level of protective immunity as compared to BCG 
vaccines in pre-clinical models such as mice by enhancing T cell-based immunity (Nambiar et 
al., 2012). Similarly, these vaccines have shown good results in phase I clinical trials in humans 
and resulted in the production of high levels polyfunctional CD4+ T cells without any adverse 
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Table1.1: Candidate anti-TB vaccines.  











Phase IIb Fusion protein (Mtb39a, 
Mtb32a) in AS01 adjuvant 
H1/IC31 Statens Serum 
Institut (SSI), TBVI, 
EDCTP, Valneva 
Phase IIa Fusion protein (Ag85B, 
ESAT-6) in IC31 adjuvant 
H4/IC31 SSI, Sanofi, Institut 
Pasteur, Aeras 
Phase II Fusion protein 
(Ag85B,TB10.4) in IC31 
adjuvant 
H56/IC31 SSI, Valneva, Aeras Phase IIa Fusion protein (Ag85B, 
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Aeras, EDCTP 
Phase IIb Replication deficient 




Phase I Replication-deficient 
adenovirus-5 expressing 
Ag85A 
AD35.TB-S Aeras Phase I Replication deficient 
adeno virus-35 expressing 




rBCG30 Aeras Phase I  Recombinant BCG 
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VPM1002 Vakzine Projekt 
Management 
GmbH, Max Planck 
Institute, TBVI, 
Serum Institute of 
India 
Phase IIa Recombinant BCG with 





MTBVAC University of 
Zaragoza, Biofabri, 
TBVI 
Phase IIa Live attenuated M.tb with 










1.14 Mycobacterium smegmatis and Mycobacterium bovis BCG as models for M.tb  
Studying pathogenic bacteria of the genus mycobacteria such as M.tb is challenging due to a 
number of reasons. These bacteria are highly virulent due to which working with them require 
special protective measures including a biosafety level-3 laboratory and there is a persistent 
risk of accidental exposure to these pathogens which can result in serious diseases. In addition, 
the pathogenic M.tb are slow growing with a generation time of almost 22-24 hours in broth 
media. It takes about 3-4 weeks for the colonies to appear on agar plates and the colonies 
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generation requires special media. Therefore, other similar mycobacteria are used as models 
instead of using M.tb where feasible (Shiloh and Champion, 2010). Two non-pathogenic 
mycobacterial species, used as models for M.tb in the current study are discussed as under: 
1.14.1 Mycobacterium smegmatis (M.smegmatis) 
M.smegmatis are saprophytic bacteria mostly found in soil, water and plants. The genome size 
of M.smegmatis is 6.98 x 106 nucleotides, with high GC content of 67%. The genome mostly 
consists of the coding region (90% genome) and a total of 6716 proteins are encoded by 
M.smegmatis genome. M.smegmatis shares 95% gene homology with M.tb (Mohan et al., 
2015).  
M.smegmatis is used as a model organism for M.tb due similarities in basic structures, 
metabolism and cellular processes. M.smegmatis and M.tb have the same mechanism for cell 
wall synthesis (Takayama and Kilburn, 1989). This feature of M.smegmatis can be translated 
into treatments for M.tb by using M.smegmatis as a model to find ways to inhibit the synthesis 
of different cell wall components. Different previous studies have used M.smegmatis as a 
model during the screening process to select potentially active compounds against M.tb 
(Andries et al., 2005; Lu and Drlica, 2003; Murdock et al., 1978). 
In addition, M.smegmatis are non-pathogenic, fast-growing bacteria with a generation time of 
2-3 hours and the colonies appear after 72 hours. These bacteria do not have any special media 
requirements and can grow in commonly available synthetic or complex laboratory media 
which makes it much easier to work with them. 
1.14.2 Mycobacterium bovis BCG (M.bovis BCG) 
M.bovis BCG is an attenuated strain of Mycobacterium bovis that bears a very high level of 
similarity to M.tb showing 99.95% identity at the genomic level (Garnier et al., 2003). Because 
of this high level of genomic similarity, M.bovis BCG is used as a model to understand and 
investigate different aspects of M.tb such as physiology, pathogenesis and immunity (Altaf et 
al., 2010; Alli et al., 2009). However, the disadvantage of using M.bovis BCG is that it is slow 
growing bacteria and M.bovis BCG cultures require about 2-3 weeks for growth. In addition, 
M.bovis BCG cannot be grown in the commonly available culture media and requires a 
specially formulated growth medium to support its growth. 
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1.15 Host protein and non-protein factors used during screening 
Different host protein and non-protein factors used in the current study during the screening 
are briefly described as under: 
1.15.1 Transferrin 
Transferrin is an important plasma protein that consists of 679 amino acids and has a molecular 
weight of ~70kDa (Parkkinen et al., 2002). Transferrin is mainly produced by hepatocytes in 
the liver with two high affinity iron-binding domains at N-terminal and C-terminal (Beutler et 
al., 2000). Other cells such as sertoli (Lecureuil et al., 2004), oligodendroglial cells (Bloch et 
al., 1985), melanoma cells (Nicolson et al., 1990) and human breast cancer cells (Inoue et al., 
1993) can also synthesize transferrin. Transferrin is present in various body fluids such as blood 
plasma, lymph, bile, cerebrospinal, and breast milk. The plasma concentration of transferrin 
ranges from 2g-3g/L and the half-life is about 8 days (Cazzola et al., 1985). Transferrin 
facilitates the transport of iron in the body in a soluble form to different cells. Transferrin binds 
free iron with high affinity and hence prevents iron mediated free radical toxicity (Gomme et 
al., 2005). Lower levels of plasma transferrin (0.1g/L) are associated with anaemia, growth 
retardation and increased risk of infection (Hayashi et al., 1993). Transferrin also possess direct 
antimicrobial properties and can inhibit the growth of bacteria as well as fungi by causing 
damage to the cell membrane (Lin et al., 2014; Ellison et al., 1988). 
1.1.5.2 Lactoferrin 
Lactoferrin is an iron-binding glycoprotein that was first discovered in human milk and was 
named Lactoferrin due to its functional similarity to transferrin protein. Lactoferrin is produced 
by epithelial cells in apo-form and is present in most of the body fluids including plasma, milk, 
saliva, tears, bile and gastric fluids (Montreuil et al., 1960). Lactoferrin consists of 690 amino 
acids and bears almost 60% amino acid similarity with human transferrin (Lönnerdal and Iyer, 
1995). The normal plasma concentration of lactoferrin ranges from 0.4–2 mg/L, however, its 
concentration can increase up to 200 mg/L during inflammation and infections (Legrand et al., 
2008). The biological role of lactoferrin is not limited to its role in iron transportation. 
Lactoferrin also plays an important role in the innate immune system. Increased Lactoferrin 
levels at the site of infection due to pathogen induced inflammation results in binding more 
free iron, an important substrate for the growth bacterial pathogens and thus creates an 
environment difficult for bacterial survival. Lactoferrin can bind to the cell membrane of the 
pathogenic microorganisms such as bacteria, fungi and different parasites and can directly 
inhibit their growth (Rodriguez-Franco et al., 2005; Ellison et al., 1988). 




Fibrinogen is a precursor blood plasma protein that is converted enzymatically by thrombin 
into the active form fibrin (Mosesson, 2005). Fibrinogen is synthesized in the liver by hepatic 
cells and is secreted into the blood. Fibrinogen is present in the blood plasma at a concentration 
ranging from 150-400mg/dL with a half-life of about 4 days (Oswald et al., 1983). Fibrinogen 
has a molecular weight of 340kDa and structurally consists of two trimers held together by 
disulphide bonds. Each trimer is further composed of three polypeptide chains namely 
fibrinogen alpha, beta and gamma chains (Henschen et al., 1983). The major function of this 
protein is to help in blood clotting during tissue or vascular injury (Mosesson, 2005). 
Fibrinogen is a positive acute phase protein and its level increases during inflammation 
(Davalos and Akassoglou, 2012). High levels of fibrinogen can be dangerous as it cause 
damage to the blood vessels and facilitate in the formation of blood clots leading to stroke and 
heart attack (Wilhelmsen et al., 1984). Fibrinogen can bind to different bacteria and was shown 
to possess antibacterial properties against group A and group B streptococci, however, it was 
unable to inhibit the growth of gram negative bacteria such as E.coli (Påhlman et al., 2013). 
1.15.4 C-reactive protein 
C-reactive protein (CRP) is a ring shaped plasma protein that belongs to the ‘pentraxin’ family 
of proteins. Structurally CRP consists of five non-covalently associated protomers arranged 
around a central axis. Each protomer consists of 206 amino acid forming two anti-parallel β 
sheets and a single α helix (Thompson et al., 1999; Shrive et al., 1996). CRP an acute phase 
protein, synthesized by hepatic cells in the liver and is released in to the blood. The standard 
concentration of CRP in human plasma is between 5-10mg/L (Albert et al., 2003), however, it 
is increased by several folds during tissue injury, infection or other causes of inflammation 
(McIntyre et al., 1997). CRP hence serves as an important marker for inflammation and is 
useful in determining disease progression and effectiveness of treatment. CRP also plays an 
important role in the immune system by acting as a pattern recognition receptor (PRR). CRP 
binds phosphocholine moieties from the membranes of bacteria, fungi or dead cells in a Ca+2 
dependent manner. This CRP-phosphocholine complex leads to the activation of complement 
system through C1q protein and also promotes macrophage phagocytosis (Kaplan and 
Volanakis, 1974). 
1.1.5.5 Alpha-2-macroglobulin 
Alpha-2-macroglobulin (α2M) is a large blood plasma protein with a molecular size of 720kDa. 
Structurally α2M is a tetrameric protein having 4 identical subunits held together by disulphide 
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bonds (Feldman et al., 1985). α2M is mainly synthesized in the liver (Petersen et al., 1988) 
however, other cells such as macrophages (White et al., 1980) and fibroblasts (Mosher and 
Wing, 1976) can also make some α2M. The plasma levels of α2M in normal humans ranges 
from 200-300mg/dL (Housley, 1968). The major functions of α2M includes its ability to 
inactivate a variety of proteinases and act as a carrier protein for different cytokines (TGFβ, 
IL-1β) and growth factors (platelet-derived growth factor) (Broth, 1992). Administration of 
exogenous α2M was shown have a protective effect against Pseudomonas aeruginosa 
infections in guinea pigs (Khan et al., 1994).  
1.15.6 Vitronectin 
Vitronectin is a glycoprotein found in body fluids such as blood plasma, amniotic fluid and 
urine (Shaffer et al., 1984). The plasma concertation of vitronectin ranges from 0.25-
0.45mg/mL (Boyd et al., 1993). Majority of the vitronectin in human body is synthesized in 
the liver by hepatic cells and is secreted in to the blood. Vitronectin has also been detected in 
smooth and skeletal muscle, renal tissue, skin and vascular walls (Hayman et al, 1983). 
Structurally vitronectin is made up of 459 amino acids with a molecular weight of 75kDa. 
Vitronectin can exist as a single chain molecule or in the form of double chains held together 
by a disulfide bonds (Preissner, 1991). In humans, vitronectin is mainly involved in cellular 
adhesion, cell migration and angiogenesis (Leavesley et al., 1992). Vitronectin has also been 
shown to bind to bacteria and augment in the attachment of these bacteria to the host cells and 
possibly their uptake (Chhatwal et al., 1987). Vitronectin deposition on the surface of bacteria 
prevents the assembly of membrane attack complex (MAC) and protects the bacteria from 
MAC mediated lysis inside the host (Singh et al., 2010). 
1.15.7 Plasminogen 
Plasminogen is a precursor protein consisting of 810 amino acids that is produced in the liver 
and released in the blood circulation (Forsgren et al., 1987). Circulatory plasminogen upon 
binding clots or cell surfaces is converted into the active form by enzymes such as tissue 
plasminogen activator (tPA), urokinase plasminogen activator (uPA), kallikrein, and factor XII 
(Hageman factor). The active form of plasminogen is known as plasmin and consist 791 amino 
acids. The major function of plasminogen/plasmin system to dissolve fibrin clots (fibrinolysis) 
(Castellino and Ploplis, 2005) and also plays important roles in wound healing, embryogenesis 
and angiogenesis (Law et al., 2013). Host plasminogen form complexes by interacting with 
Streptokinase (SK) and Staphylokinase (SAK) enzymes from Streptococci and Staphylococci, 
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resulting in the formation of proteolytic surfaces that can help in the spread of bacteria 
(Bergmann et al., 2013). 
1.15.8 Plasma Lipoproteins 
Plasma lipoproteins are spherical particles that consist of a single layer of phospholipids, 
cholesterol and triglycerides with embedded apolipoproteins. Their main function is the 
transportation lipids to different parts of the body in a water soluble form. The plasma 
lipoproteins are categorized into high density lipoproteins (HDL), low density lipoproteins 
(HDL), intermediate density lipoproteins (IDL) and very low density lipoproteins (VLDL) 
based on their density and size (Morrisett et al., 1975).  
LDL particle ranges from 220-275Å in diameter and consists of 3000-6000 fat molecules 
(Fisher et al., 1972). Each LDL particle contains a 514 kDa apolipoprotein B-100 molecule 
along with other small proteins (Knott et al., 1986). The major function of LDL in the blood is 
to deliver cholesterol to different cells by binding to LDL receptors on their surfaces (Goldstein 
et al., 1983). Oxidatively modified forms of LDL (ox-LDL) play an important role the blood 
vessel biology and are involved in atherosclerosis. These ox-LDL causes injury to the 
endothelial cells of vascular vessels due to the increased recruitment of monocytes and 
activation of different pro-inflammatory signalling pathways (Steinberg and Witztum, 2010). 
High Density Lipoproteins (HDL) are small lipoprotein with a particle size of about 100 Å. 
HDL particles are rich in proteins and apoA-I is the most abundant protein present in the HDL 
(Brewer and Rader, 1991). The major function of HDL is to carry cholesterol from cells and 
tissue back to liver (Fisher et al., 2012).  
Bacterial infection accompanied by inflammation results in the production of different 
cytokines such as IL-6, TNF-α, and IL-1 etc, these cytokines cause profound changes in the 
concentration, composition and function of the plasma lipid  and lipoproteins such as LDL and 
HDL (Nassaji and Ghorbanni, 2012). 
1.15.9 Serotonin 
Serotonin, chemically known as 5-Hydroxytryptamine or 3-(β-Aminoethyl)-5-hydroxyindole 
is an important chemical with diverse functions found in humans and other animals (Erspamer, 
1986). Serotonin is mostly present in the gastrointestinal tract (GI) and the central nervous 
system (CNS) performing important function like regulating intestinal movements and working 
as a neurotransmitter  (Berger et al., 2009). It is also present in the serum and helps in the 
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constriction of smooth muscles in respiratory and cardiovascular systems (Saxena and Villaló, 
1990). During the process of inflammation serotonin is released by degranulation of mast cells 
and platelets leading to increased vascular permeability and vasodilation (Mössner and Lesch, 
1998). Serotonin has been shown to enhance phagocytosis in murine macrophages (Freire‐
Garaba et al., 2003) and was also able to directly inhibit the growth of fungi such as candida 
species (Lass-Flörl et al., 2003). 
 
1.16 Platelet Activating Factor (PAF) 
Platelet activating factor (PAF) or PAF-acether is a membrane-derived phospholipid with 
diverse physiological effects in mammals. Benveniste et al assigned the name “platelet 
activating factor” to a compound that was released from rabbit basophils upon stimulation with 
Ig-E and was able to activate platelets (Benveniste et al., 1972). Another group of researchers 
isolated a polar lipid similar to PAF in properties from the renal medulla and named it 
“antihypertensive polar renal lipid” due to its ability to reduce blood pressure in mice model 
(Muirhead et al., 1981). Other laboratories were able to synthesize a semisynthetic 
phospholipid compound, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine, and observed that 
this compound had identical physiochemical and biological properties to the naturally produced 
PAF and antihypertensive polar renal lipid (Benveniste et al., 1979; Blank et al., 1979; 
Demopoulos et al., 1979). Hanahan et al described the chemical structure for PAF produced 
by stimulated rabbit basophils by using techniques such as gas-liquid chromatography and 
mass spectral analysis and showed it as a 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine 
(Hanahan et al., 1980). Although the term PAF is still commonly used for this compound, it 
can be sometimes misleading suggesting that its activity is limited to platelets. On the contrary, 
this lipid mediator possesses a variety of physiological effects due to its role as intercellular 
and intracellular messenger. 
A variety of cell types including platelets (Alam et al., 1983), neutrophils (Biffl et al., 1996), 
monocytes/macrophages (Yagnik, 2014; Leaver et al., 1990), endothelial cells (Bussolino et 
al., 1986(a)) and mast cells (Schleimer et al., 1986) are able to produce PAF upon proper 
stimulation. Under normal physiological conditions, the concentration of PAF is very low in 
tissues and blood. PAF can be produced in higher amounts during inflammation and 
anaphylactic reactions by cells such as leukocytes (Vadas et al., 2013). 
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1.16.1 Structure of PAF 
Chemically PAF is 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (Hanahan et al., 1980). 
The glycerol backbone of PAF has an alkyl group attached to the sn-1 position via ether linkage 
that makes the tail of the compound. The most common form of naturally produced PAF in the 
body contains a 16-carbon alkyl chain and is known as PAF C-16 (Clay et al., 1984). The 
length of carbon tail can vary and there are naturally produced PAF analogues with 18-carbon 
chain (Oda et al., 1985). A short chain acyl group in the form of acetyl is attached at the sn-2 
position. This acetyl group increases the solubility of the molecule and helps PAF to function 
as a soluble signalling molecule. At the sn-3 position, a phosphocholine group is attached that 
constitutes the polar head region of the compound (Figure 1.5). All the structural elements of 
PAF can influence the biological potency of this phospholipid. Substitution of the acetyl group 
at the sn-2 position of PAF has been shown to affect the activity of the PAF significantly and 
even lead to the biological inactivation of the compound (McManus et al., 1993). 
 
 
Figure1.5: Chemical structure of Platelet Activating Factor C-16. At position sn-1, the aliphatic 
carbon tail consisting of 16 carbon atoms is attached. Acetyl group is present at position sn-2 
and phosphocholine at sn-3. 
1.16.2 PAF C-16 biosynthesis 
There are two distinct pathways for the production of PAF C-16 in vivo. These pathways 
include the remodelling pathway and the de novo pathway for synthesis of PAF C-16. These 
pathways are described in detail as under: 
1.16.2.1 The remodelling pathway for PAF C-16 synthesis 
The remodelling pathway was the first pathway described for the synthesis of PAF C-16 and 
involves structural modifications to pre-existing, membrane ether-linked phospholipids 
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(Wykle et al., 1980). The remodelling pathway of PAF C-16 synthesis is mostly used by a 
number of activated cells involved in inflammatory and allergic responses (Lee et al., 1984; 
Alonso et al., 1982).  
The synthesis of PAF C-16 is initiated by the enzyme phospholipase A2 (PLA2) (Ninio et al., 
1982) and carried out in two steps as shown in figure 1.6. The PLA2 enzyme first hydrolyzes 
arachidonate from the membrane ether-linked phospholipids such as 1-O-alkyl-2-
arachidonoyl-sn-glycero-3-phosphocholine. This enzymatic action results in the formation of 
1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine (Lyso-PAF), a precursor form of PAF C-16 
and the release of free arachidonic acid. In the next step, the enzyme acetyl coenzyme A (Lyso-
PAF acetyltransferase) adds an acetyl group at the position sn-2 of the 1-O-alkyl-2-lyso-sn-
glycero-3-phosphocholine (Lyso-PAF) resulting in the formation of PAF C-16 (Balestrieri et 
al., 1997; Uemura et al., 1991).  
 
Figure1.6: Remodelling pathway for PAFC-16 synthesis. During the first step, PLA2 enzyme 
hydrolyzes the membrane phospholipids and produces the inactive precursor from Lyso-PAF 
and arachidonic acid. In the second step, Lyso-PAF is converted to PAF by the enzyme acetyl 
transferase, which adds an acetyl group at position sn-2 replacing the hydroxyl group. 
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1.16.2.2 The de novo pathway for PAF C-16 synthesis 
PAF is synthesized continuously in small amounts in kidneys and central nervous system 
through the de novo pathway (Snyder, 1995; Bussolino et al., 1986(b)). This pathway consists 
of three steps including acetylation/acylation, dephosphorylation and transfer of 
phosphocholine from cytidine diphosphate-choline (CDP-choline) moiety to 1-O alky-sn-
glycero-3-phosphate inside the cells (Figure 1.7). 
During the first step, the enzyme acetyl coenzyme A acetyltransferase adds an acetyl group at 
the sn-2 position of 1-O alky-sn-glycero-3-phosphate resulting in the formation of 1-O alky-2-
acetyl-sn-glycero-3-phosphate. The phosphohydrolase enzyme then removes the phosphate 
group from position sn-3, forming 1-O alky-2-acetyl-sn-glycerol. Finally, the enzyme CDP-
choline phosphotransferase catalyses the transfer of a phosphocholine group resulting in the 
formation of PAF C-16 (Lee et al., 1988; Renooij and Snyder, 1981). 
 
Figure 1.7: De novo pathway for PAF C-16 synthesis. PAF is synthesized from 1-O-alkyl-sn-
glycero-3-phosphate in three steps including acetylation, dephosphorylation and transfer of 
phosphocholine during the last step. 
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1.16.3 PAF acetylhydrolase (PAF-AH) 
PAF C-16 concentration and activity is tightly regulated by specific calcium-independent 
subfamilies of acetylhydrolase enzymes known as PAF acetylhydrolase (PAF-AH). PAF-AH 
limit the availability of active PAF C-16 by removing the short chain acyl group from the sn-2 
position resulting in the formation of Lyso-PAF (Farr et al., 1980). PAF-AH is present both in 
the blood plasma (extracellular form) (Farr et al., 1980) and in different tissues (intracellular 
form) (Nijssen et al., 1986). The plasma form of PAF-AH is normally secreted by macrophages 
and circulates in the plasma, primarily in association with HDL and LDL particles (Elstad et 
al., 1989). The intracellular forms of PAF-AH can be exclusively cytosolic as in case of brain 
cells and erythrocytes or both cytosolic and membrane-bound as in case of liver and kidney 
cells (Stafforini et al., 1991).  
1.16.4 PAF receptor and signalling 
PAF C-16 can communicate signals to target cells by binding to specific receptors known as 
the platelet activating factor receptor (PAFR) on the surface of the target cells (Honda et al., 
1991; Nakamura et al., 1991). A wide variety of cells including platelets (Valone et al., 1982), 
monocytes/macrophages (Liu et al., 1992), neutrophils (O'Flaherty et al., 1986), eosinophils 
(Ukena et al., 1989), endothelial cells (Korth et al., 1989), cardiomyocytes (Sugimoto et al., 
1992), smooth muscle cells (Hwang et al., 1983) and cells of the central nervous system 
(Domingo et al., 1988) were shown to possess PAFR on their plasma membrane.  
PAFR belongs to “serpentine receptors” which are a family of transmembrane receptors. 
Structurally PAFR consist of seven α-helices that passes through the plasma membrane seven 
times (Figure 1.8). PAFR has a molecular weight of 39.2kDa and comprises of 342 amino 
acids. G proteins are attached to the third intracellular loop and to the carboxyl tail of the PAFR 
(Montrucchio et al., 2000; Shimizu et al., 1996). 
Binding of PAF C-16 to PAFR on target cells results in the activation of phosphatidylinositol-
specific phospholipase C (PLC) through the associated G proteins. This activated membrane-
bound PLC causes the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) from the 
plasma membrane causing the transient production of second messengers including inositol 
trisphosphate (IP3) and diacylglycerol (DG). The IP3 produced then causes the mobilization of 
intracellular Ca+2 along with the influx of extracellular Ca+2 via cell membrane-associated 
channels, leading to elevated levels of Ca+2 in the cytoplasm (Ishii and Shimizu, 2000). This 
Ca+2 together with DAG can activate protein kinase C (PKC) enzyme that results in the 
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phosphorylation of different intracellular proteins and leads to different cellular responses 
including leukocyte activation, platelet aggregation, chemotaxis, generation of reactive oxygen 
and nitrogen species and upregulation of different cytokines such as TNF-α, IL-6, IL-4 etc. 
(Chao and Olson, 1993). PAF C-16 binding to its receptor PAFR on target cells also causes the 
activation of cytosolic phospholipase A2 (cPLA2) mediated by intracellular Ca
+2 levels. The 
activation of cPLA2 leads to the hydrolysis of arachidonic acid from intracellular phospholipids 
resulting in the production of lysophosphatides. The arachidonic acid is further utilized in the 
synthesis of bioactive lipid mediator eicosanoid (Nakashima et al., 1989). 
 
 
Figure 1.8: PAF receptor (PAFR) and its signal transduction mechanisms. The figure shows 
the structure of trans-membrane PAFR with its associated G proteins. Binding of PAF C-16 to 
PAFR results in the activation of PLC, PKC and PLA2 along with the production of different 
intracellular second messengers including DAG, IP3 and Ca
+2  (Montrucchio et al., 2000). 
1.16.5 Physiological and pathophysiological roles of PAF C-16 
PAF C-16 is a phospholipid with diverse biological activities that works as a signalling 
molecule by binding to specific receptors known as PAF receptors (PAFR) on the target cells 
(Nakamura et al., 1991). The diverse effects of PAF C-16 can be attributed to the presence of 
PAFR on a variety of cells and the ability of PAF C-16 to activate different intracellular 
signalling pathways resulting in the production of downstream effector molecules specific for 
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cell type (Ishii and Shimizu, 2000). PAF C-16 can work as an autocrine molecule by acting on 
the cells producing it and can also mediate intercellular communication by acting over short 
distances as a paracrine signalling molecule or as an endocrine molecule where it is circulated 
in the blood (Prescott et al., 2000). Some of the important physiological and pathophysiological 
roles of PAF C-16 are discussed as under: 
1.16.5.1 Role of PAF C-16 in platelets aggregation  
One of the most well-known function of PAF C-16 is its ability to cause platelet aggregation. 
PAF C-16 is the most potent platelet aggregating agent and can cause complete aggregation of 
platelets at very low concentrations approaching nanomolar. PAFC-16 treatment causes the 
degranulation of platelets, resulting in the release of different molecules such as serotonin, 
ADP, ATP from their intracellular granules (Chesney et al., 1982; Vargaftig et al., 1981). 
1.16.5.2 Role of PAF C-16 in reproduction 
PAF C-16 has been suggested to plays an important role in the reproductive system in humans 
and other mammals. PAF C-16 improves sperm motility and enhances fertilization by acting 
as a capacitation factor (Ricker et al., 1989; Davis, 1981). PAF C-16 is produced by 
mammalian embryos from the 2-cell zygote till the blastocyst stage (Ripps et al., 1993). A 
number of studies indicated that PAF C-16 is involved in the implantation, development and 
parturition of mammalian embryos (Nishi et al., 1995; O'Neill et al., 1989). It was shown that 
preimplantation exposure of murine embryos to exogenous PAF C-16 resulted in improved 
birth rate and also improved size and weight at birth (Roudebush et al., 2004). 
1.16.5.3 Role of PAF C-16 in inflammation 
Inflammation is considered to have evolved as a protective mechanism contributing to the host 
innate immune system. However, it is also the key mediator mechanism that generates different 
complications in the body. These inflammation related complications can ultimately lead to 
different types of diseases (Medzhitov, 2008).  
Most of the current research focuses on the role of PAF C-16 as a mediator of inflammation. 
In vitro, acute inflammation models comprising of human endothelial cells stimulated with 
thrombin or histamine showed the production of PAF C-16 along with the expression of cell 
adhesion molecule P-selectin. This PAF C-16 form endothelial cells was able to bind to PAFR 
on the surface of polymorphonuclear leukocyte (PMNs) and activated these key effectors of 
acute inflammatory response, indicating an active role for PAF C-16 during inflammation 
(Lorant et al., 1999). 
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Nagase et al showed the association of PAF C-16 and inflammation in disease conditions by 
examining acute lung injury in mice models. It was observed that PAFR knockout mice showed 
reduced lung injury due to acid aspiration, whereas mice overexpressing PAFR showed more 
severe lung injury that proved to be fatal when compared with control mice (Nagase et al., 
1999). In humans, excess of PAF C-16 due to deficiency in PAF acetylhydrolase enzyme 
results in unregulated pro-inflammatory signalling that has been suggested to be associated 
with different disease conditions such as acute pancreatitis (Chen et al., 2008), Crohn's disease 
(Sobhani et al., 1992), ulcerative colitis (Ferraris et al., 1993) and neonatal necrotizing 
enterocolitis (Caplan et al., 1990). 
1.16.5.4 Role of PAF C-16 in asthma 
Another important pathological effect of PAF C-16 due to its pro-inflammatory nature is its 
role in asthma. Asthma is a respiratory system disorder characterized by activation of 
inflammatory cells, microvascular leakage, bronchoconstriction, and airway 
hyperresponsiveness. Asthma patients were shown to have increased level of PAF C-16 in their 
blood (Kurosawa et al., 1994) and higher expression of PAFR mRNA was detected in the lung 
tissue (Shirasaki et al., 1994) as compared to that of normal individuals. Treating antigen-
induced asthma in humans and guinea pigs with PAF antagonists that block PAFR, improved 
the disease symptoms (Kagoshima et al., 1997, Hozawa et al., 1995). Furthermore, mutations 
in the genes coding for PAF acetylhydrolase leading to loss of functional activity were found 
to be prevalent in asthma patients, suggesting the association of functional PAF acetylhydrolase 
deficiency and elevated PAF C-16 levels with increased risk of asthma (Stafforini et al., 1999). 
1.16.5.5 Role of PAF C-16 in type 1 diabetes 
PAF C-16 is also involved in the development of type 1 diabetes in humans due to its pro-
inflammatory nature. Type 1 diabetes results from the destruction of pancreatic β cells present 
in the islets of Langerhans (insulitis). About 50-fold more PAF C-16 was detected in the blood 
of type 1 diabetes individuals as compared to healthy controls (Nathan et al., 1992). A study in 
diabetes prone BB-rat models using PAF antagonist BN52021 showed that administration of 
PAF antagonist either protected these animals from diabetes or delayed the onset of diabetes 
as compared to the untreated control (Jobe et al., 1993). During another study in BB-rat models, 
it was shown that the use of recombinant PAF acetylhydrolase (rPAF-AH) reduced the 
frequency of diabetes by lowering the concentration of active PAF C-16 as compared to the 
untreated control. The immunohistochemistry of the islets showed decreased insulitis and 
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higher numbers of insulin-positive cells in rPAF-AH treated rats as compared to untreated 
control (Lee et al., 1999). 
1.16.5.6 Role of PAF C-16 in renal diseases 
PAF C-16 is produced in the kidneys (Schlondorff et al., 1986; Pirotzky et al., 1984) and 
elevated levels of PAF C-16 have been suggested to be involved in renal diseases such as acute 
renal failure (Lopez-Farré et al., 1988). It was shown that administration of exogenous PAF C-
16 in dogs and mice had negative effect on the kidney function and resulted in a dose-dependent 
decrease in glomerular filtration rate (Badr et al., 1989; Santos et al., 1988). This damaging 
effect of PAF C-16 at higher concentration was shown to be due to the vasoconstriction of the 
arterioles (Juncos et al., 1993). The damaging effect of exogenous PAF C-16 on the kidneys 
function was prevented by the use of PAF receptor antagonists (Yoo et al., 1990).  
1.16.5.7 Role of PAF C-16 in cancer 
There are reports which suggest a possible role for PAF C-16 in some cancers by promoting 
cells growth and tumours formation. PAF C-16 causes angiogenesis (Camussi et al., 1995), 
which contributes to the growth and metastasis of tumours. PAF C-16 was shown to trigger the 
formation of new blood vessels in breast cell-induced cancer in mice by stimulating the 
recruitment of endothelial cells along with the production of angiogenic factors such as FGF, 
placental growth factor, VEGF, HGF etc. (Bussolati et al., 2000). Human tumour-derived 
endothelial cells (TEC) were shown to produce greater quantities of PAF C-16 as compared to 
normal endothelial cells, which contributes to cell motility, adhesion and vessel formation. 
Overexpression of PAF-AH in these cells resulted in the inactivation of PAF C-16 resulting in 
reduced cell motility, cell adhesion and restored the sensitivity of these cells to apoptosis 
(Doublier et al., 2007). In mouse models, exogenous PAF C-16 was shown to have growth 
enhancing effects on tumour cells and augmented the metastasis of melanoma to lungs (Im et 
al., 1996). Disrupting PAF C-16 mediated signalling by using PAF receptor antagonists 
inhibited the cell proliferation and metastatic potential of different cancers such as human 
breast adenocarcinoma, colon adenocarcinoma, fibrosarcoma, hepatocarcinoma and 
neuroblastoma in vitro (Cellia et al., 2006).  
1.16.5.8 Role of PAF C-16 in infection 
The role of PAF C-16 during infection is not completely understood. Elevated levels of PAF 
C-16 have been detected in the blood during HCV and dengue virus infections (Jeewandara et 
al., 2015; Caini et al., 2007). In vitro intestinal epithelial cells were shown to produce increased 
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quantities of PAF C-16 when challenged Salmonella enteritidis (Egea et al., 2008). A 
protective role for endogenously produced PAF C-16 on the host organism was suggested 
during Candida albicans infection in mice. PAF C-16 was shown to cause the activation of 
NF-κB and upregulation of TNF-α in these infected mice (Choi et al., 2001). The protective 
role of endogenous PAF C-16 acting through its receptor was shown by using PAFR deficient 
mice during K. pneumoniae infection. The PAFR deficient mice showed higher bacterial load 
in the lungs and died earlier as compared to the wild-type control (Soares et al., 2002). A 
number of studies have shown that exogenous PAF C-16 while acting through PAFR can help 
in the elimination of intracellular pathogenic microorganisms such as Leishmania (Borges et 
al., 2017; Lonardoni et al., 2000), Trypanosoma (Aliberti et al., 1999) and Candida albicans 
(Kim et al., 2008) both in vivo and in vitro. These studies showed that PAF C-16 treatment 
resulted in enhanced production of ROIs, RNIs and cytokines such as TNF-α. Furthermore, 
exogenous PAF C-16 was also shown in vitro to have direct inhibitory effect on the growth 
gram-positive bacteria (Steel et al., 2002) and lower eukaryotes such as yeast (Nigam et al., 
2013).




M.tb infection elicits an inflammatory response in the host which causes leakage of a number 
of plasma proteins and non-protein factors at the site of infection. A number of such factors 
including PAF C-16 and serotonin are either present or produced locally at the site of infection, 
which we hypothesized are likely to have protective functions during microbial infections. We, 
therefore, investigated a number of such endogenously produced factors in vitro for their effect 
on the growth of mycobacteria. 
Aim and Objectives of the study 
Aim: To investigate the in vitro inhibitory effect of different endogenously produced host 
factors (proteins and non-proteins) on the growth of mycobacteria using non-pathogenic 
M.smegmatis and M.bovis BCG as models for M.tb. 
Objective 1: In vitro screening of different host factors  for their direct growth inhibitory effect 
against mycobacteria including proteins such as Transferrin, Lactoferrin, Fibrinogen, C-
Reactive Protein (CRP), Alpha-2-Macroglobulin (α2M), Vitronectin, Plasminogen, Low-
Density Lipoprotein (LDL), High-Density Lipoprotein (HDL) and non-protein factors such as 
Serotonin, L-Alpha Dipalmitoylphosphatidylcholine (DPPC) and Platelet Activating Factor C-
16 (PAF C-16). 
Objective 2: Characterization of the effect of small structural changes to PAF C-16 on 
mycobacterial growth inhibition by using PAF C-16 analogues, identification of the active 
portion of PAF C-16 and elucidation of the molecular mechanism of PAF C-16 induced 
mycobacterial growth inhibition. 
Objective 3: Investigation of the effect of PAF C-16 and its analogues on the growth of 
intracellular mycobacteria using phagocytic THP-1 cells and understanding the mechanism of 
PAF C-16 induced intracellular M.smegmatis growth inhibition.
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2.1 Growing and Storing mycobacteria 
Non-pathogenic mycobacterial species, M.smegmatis (mc2 155) and M. bovis BCG (Pasteur 
1173P2) were used in the current study. The bacteria were grown in broth cultures and stored 
at -80°C for use in future experiments.  
2.1.1 Growing M.smegmatis cultures in LB-broth 
Liquid cultures of M.smegmatis (mc2 155) were grown in Luria-Bertani (LB) broth. The culture 
media was prepared by dissolving 10grams of tryptone (Fisher Scientific, UK), 5grams of yeast 
extract (Fisher Scientific, UK) and 0.5gram of sodium chloride (Fisher Scientific, UK) in 1 
liter distilled water and autoclaved at 121°C for 15 minutes. Using a sterile inoculating loop 
three isolated M.smegmatis colonies streaked on LB-agar plate were transferred to 200ml LB 
broth supplemented with 0.1% (v/v) glycerol (Fisher Scientific, UK) and 0.05% (v/v) tween-
80 (Fisher Scientific, UK). A selective antibiotic, carbenicillin (Fisher Scientific, UK) was also 
added at a final concentration of 50µg/ml to the culture media. The bacterial culture was kept 
in a shaker at 37°C for the M.smegmatis to grow. Optical density (O.D600) for the bacterial 
culture was checked at regular intervals using a spectrophotometer (Ultrospec 10 Cell Density 
Meter, Amershem Biosciences). On reaching 0.70-0.90 O.D(600nm) M.smegmatis culture was 
removed from the shaker, checked for purity using acid-fast staining and stored at -80°C. 
2.1.2 Growing M.bovis BCG cultures in 7H9 media 
Liquid cultures of M. bovis BCG (Pasteur 1173P2) were grown in Middlebrook 7H9 broth 
(Sigma Aldrich, UK). The 7H9 broth media was prepared by dissolving 2.5grams of 7H9 
powder and 2.5ml of glycerol in 450ml distilled water (Fisher Scientific, UK). The media was 
sterilized by autoclaving at 121°C for 15 minutes. Using a sterile inoculating loop, three 
isolated M. bovis BCG colonies streaked on a 7H10 agar-plate (BD Biosciences, UK) were 
transferred to 200ml of 7H9 supplemented with 10% Albumin Dextrose Catalyse (ADC) and 
0.05% (v/v)  tween-80 (Fisher Scientific, UK). The bacterial culture was kept in a shaker at 
37°C to allow M.bovis BCG to grow and the optical density (O.D600) was checked at regular 
intervals after the first week using a spectrophotometer (Ultrospec 10 Cell Density Meter, 
Amershem Biosciences). On reaching 0.70-0.90 O.D(600nm) M.bovis BCG culture was removed 
from shaker, acid-fast staining was performed to ensure that there was no contamination and 
stored at -80°C for future experiments. 
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2.1.3 Acid-fast staining for M.smegmatis and M.bovis BCG 
Acid-fast staining, a special type of staining technique was performed for every batch of 
mycobacterial culture grown in order to identify M.smegmatis and M.bovis BCG and determine 
the purity of the culture.  
To perform acid-fast staining, 1ml aliquots of M.smegmatis or M. bovis BCG from their 
respective cultures were centrifuged at 5000rpm for 10 minutes (Eppendorf 5424 
Microcentrifuge). After centrifugation the supernatant was discarded and the bacterial pellet 
was resuspended in 50µl of culture media. About 10-15µl of the bacterial suspension was 
smeared on a clean glass slide and left to air dry for 10-15 minutes at room temperature. The 
bacterial smear was heat fixed by passing the glass slide 3-4 times through a Bunsen burner 
flame. The heat fixed smear was covered with an absorbent paper, flooded with carbol-fuschin 
stain (Pro Lab Diagnostics, UK) and heated for 5-10 minutes until it started steaming. During 
the entire heating process carbol-fuschin was continuously added to keep the smear flooded 
with the dye. After heating, excess carbol-fuschin was removed by gently washing the glass 
slide with tap water. A few drops of decolorizing solution (Pro Lab Diagnostics, UK) were 
added to the smear, followed by gentle washing with tap water. The smear was then flooded 
with methylene blue (Pro Lab Diagnostics, UK) for 45 seconds and washed with tap water. 
After air drying the glass slides with stained M.smegmatis or M. bovis BCG, they were observed 
under a light microscope (Brunel SP100) at 1000X magnification. A pure culture consisted of 
entirely red rods due to the retention of carbol-fuschin stain by the mycobacteria (Figure 2.1.3). 
Figure 2.1.3: Acid fast staining of mycobacteria. Microscopic images of M.smegmatis (Slide 
A) and M.bovis BCG (Slide B) grown in cultures at 1000X after performing acid fast staining. 
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2.1.4 Storing M.smegmatis and M.bovis BCG 
After establishing the purity of mycobacterial cultures by acid-fast staining, both M.smegmatis 
and M. bovis BCG were stored at -80°C for further use. M.smegmatis and M. Bovis BCG grown 
in broth cultures were transferred to 50ml falcon tubes and pelleted by centrifugation at 
5000rpm for 30 minutes. The supernatant was discarded and the bacterial pellet was 
resuspended in 3ml freezing solution. The freezing solution was prepared by mixing sterile LB 
broth or 7H9 and glycerol in equal volumes (1:1). About 200µl of M.smegmatis or M.bovis 
BCG suspension in freezing solution was transferred to sterile 1.2 ml cryotubes and stored at -
80°C. 
2.1.5 Preparation of agar plates for M.smegmatis and M.bovis BCG 
M.smegmatis colonies were grown on LB-agar plates. The LB-agar media was prepared by 
dissolving 10grams of tryptone (Fisher Scientific, UK), 5grams of yeast extract (Fisher 
Scientific, UK), 0.5grams of sodium chloride (Fisher Scientific, UK) and 15grams of nutrient 
agar (Fisher Scientific, UK) in 1 liter distilled water and autoclaved at 121°C for 15 minutes. 
About 15-20 ml of melted LB-agar was poured in petri plates under sterile conditions using 
laminar flow cabinets and petri plates were allowed to solidify and air dry for 90-120 minutes 
before plating M.smegmatis. 
M.bovis BCG colonies were grown on commercially available 7H10 plates purchased from BD 
Biosciences, UK. The plates were stored at 4°C and were air dried at room temperature in a 
laminar flow hood using sterile conditions for 30-45 minutes before using them for plating 
M.bovis BCG. 
2.1.6 Calculating the number of bacteria for stock M.smegmatis and M.bovis BCG 
In order to achieve consistency and uniformity in experiments, the number of bacteria per 
microliter for M.smegmatis and M.bovis BCG stocks was calculated. The bacterial stocks kept 
at -80oC were thawed at room temperature and sonicated using Transsonic T480, CAMLAB 
for 15 seconds to break bacterial clumps. The bacteria were mixed uniformly by vortexing for 
5-10 seconds and serial 10-fold dilutions of stock M.smegmatis and M.bovis BCG were 
prepared until 1x10-8 dilution in LB broth or 7H9 respectively. Finally, 200µl of bacterial 
suspension was plated from dilution 10-4, 10-5, 10-6, 10-7 and 10-8 on agar plates (LB-agar for 
M.smegmatis and 7H10 for M.bovis BCG) in triplicates. The plates were incubated at 37°C for 
72 hours for M.smegmatis and 2-3 weeks for M.bovis BCG. Dilution plates with countable 
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number of bacterial colony forming units (CFUs) were enumerated with naked eye and the 
number of bacteria per ml was calculated for the stock by using the following equation 
 
𝑨𝒗𝒆𝒓𝒂𝒈𝒆 𝒏𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝑪𝑭𝑼𝒔 𝒇𝒓𝒐𝒎 𝒕𝒓𝒊𝒑𝒍𝒊𝒄𝒂𝒕𝒆 𝒑𝒍𝒂𝒕𝒆𝒔




2.2 Direct mycobacterial growth inhibition assays using different test compounds 
To investigate in vitro the direct effect of different test compounds (proteins and non-proteins) 
on the growth of M.smegmatis and M.bovis BCG, direct growth inhibition assays were 
performed in vitro. Stock M.smegmatis or M.bovis BCG stored at -80°C with known number 
of bacteria per µl was thawed at room temperature, sonicated for 15 seconds to break any 
bacterial clumps and mixed uniformly by vortexing for 5 seconds. Stock bacteria were serially 
diluted, starting with an initial 1:100 (10-2) dilution prepared by adding 10µl of stock bacteria 
to 990µl broth media (LB or 7H9) in an eppendorf tube. After the initial 1:100 (10-2) dilution, 
10-fold serial dilution was performed by transferring 100µl of bacterial suspension from 10-2 
dilution to 900µl of broth media (LB or 7H9) for making10-3 dilution and so on. The process 
of 10-fold serial dilution was repeated until the dilution that gave countable number of CFUs 
on agar plates was achieved as shown in figure 2.2a 
 
Figure 2.2a: Serial dilution of stock bacteria (M.smegmatis and M.bovis BCG). Stock bacteria 
was serially diluted starting from an initial 1:100 (10-2) dilution followed 10-fold serial dilution 
afterwards till 10-6 dilution was achieved. 
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The bacteria at 10-6 dilution were used in the direct in vitro assays to find the effect of test 
compounds on mycobacterial growth. A set of properly labelled eppendorf tubes, each 
containing 1ml of bacterial suspension at dilution 10-6 were prepared. Different concentrations 
of test compound were added to the tubes. A suitable solvent control (solvent for test 
compound) was also included in the experiment as shown in figure 2.2b. The eppendorf tubes 
were then incubated at 37°C for 2 hours and the contents were mixed after every 15 minutes 
by inverting each tube 5 times. After incubation, the eppendorf tubes were vortexed for 5 
seconds and bacteria from each condition were plated on agar plates (LB-agar plates for 
M.smegmatis or 7H10 plates for M.bovis BCG) in triplicates by using 200µl of bacterial 
suspension. The agar plates were incubated at 37°C for 72 hours for M.smegmatis and 2-3 
weeks for M.bovis BCG after which the number of bacterial CFUs was counted with the naked 
eye. A comparison of CFUs number between different test conditions and the solvent control 
was done to determine the effect of the test compound on the growth of bacteria in vitro. 
Additional experiments to determine the effect of increase in incubation time on the growth 
inhibitory concentration of PAF C-16 against M.bovis BCG and M.smegmatis were performed 
in a similar manner as described above, however the treatment times were increased to 6, 12 
and 24 hours. 
 
 
Figure 2.2b: Diagrammatic representation of experimental setup for one of the direct growth 
inhibition assays. All the tubes contain 1ml of bacterial suspension in broth media (LB or 7H9) 
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at 10-6 dilution. 10µl ethanol (solvent for test compound) was added to tube A, whereas, test 
compound at concentrations of 10µg, 25µg, 50µg and 100µg was added to tube B, C, D and E 
respectively. 
 
2.3 Microscopy with PAF C-16 treated mycobacteria 
In order to investigate the effect of PAF C-16 treatment on M.smegmatis and M.bovis BCG 
microscopy was performed. The protocols are given as under: 
2.3.1 Light Microscopy with PAF C-16 treated M.smegmatis and M.bovis BCG 
The effect of PAF C-16 treatment on M.bovis BCG and M.smegmatis cell membrane was 
examined under a light microscope using cell viability dye, trypan blue. Approximately 1x108 
M.smegmatis or M.bovis BCG were transferred to appropriately labelled 1.5 ml eppendorf tubes 
and washed once with phosphate buffer saline (PBS) by centrifugation at 5000rpm for 10 
minutes. The bacteria were then resuspended in 1ml of broth media (LB or 7H9). 100µg/ml 
PAF C-16 was added to the bacterial suspension in “Test” eppendorf tube and 10µl/ml ethanol 
(solvent control) was added to the bacteria in the “Control” eppendorf tube. The tubes were 
incubated for 4 hours at 37°C with mixing after every 15 minutes. After incubation, the 
bacterial samples were washed twice with PBS at 5000rpm for 10 minutes. The supernatant 
was discarded and the pellets were resuspended in 20µl PBS and 20µl of 0.4% trypan blue 
(Gibco, UK). Slides were prepared by transferring 10µl of the mycobacterial suspension from 
each condition onto clean glass slides. The glass slides with stained bacteria were covered with 
glass coverslips, sealed and observed under a light microscope (Brunel SP100) at 400X 
magnification and images were taken for PAF C-16 treated and solvent control mycobacteria. 
2.3.2 Fluorescence Microscopy with PAF C-16 treated M.smegmatis and M.bovis BCG 
Propidium Iodide (PI), a nucleic acid binding fluorescent dye was used to detect damage to the 
mycobacterial cell membrane. Mid-logarithmic cultures for both M.bovis BCG and 
M.smegmatis at 0.90-1.00 O.D(600nm) were used for fluorescence microscopy. 1ml bacteria from 
fresh grown cultures was transferred to properly labelled eppendorf tubes. The bacteria were 
pelleted by centrifugation at 5000rpm for 10 minutes. The supernatant was removed and the 
bacterial pellets were washed by resuspending in PBS and centrifugation at 5000rpm for 10 
minutes. After washing the bacterial pellets were resuspended in 1ml broth media (LB or 7H9) 
and “Test” and “Solvent control” bacteria were treated with 100µg PAF C-16 and 10µl ethanol 
per ml bacterial suspension respectively for 2 hours at 37°C with mixing after every 15 minutes. 
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A positive control comprising of heat treated bacteria (100oC for 10 minutes) was also included 
in the experimental design. After incubation for 2 hours, the mycobacterial samples were 
washed twice with PBS at 5000rpm for 10 minutes to remove the residual PAF C-16 and 
ethanol. This was followed by staining with PI (BioLegend, USA) at a concentration of 1µg/ml 
for 20 minutes at room temperature in dark. Excess dye was removed by washing the bacterial 
samples twice with PBS by centrifugation at 5000rpm for 10 minutes. The bacterial pellet was 
finally resuspended in 100µl of PBS, and slides were prepared by smearing 5-10µl of the 
bacterial suspension onto a glass slide overlay with a coverslip and sealed. Images of the PAF 
C-16 treated and solvent control mycobacteria were acquired at 400X magnification with a 
Leica DM4000® fluorescence microscope using bright field channel to focus living and 
dead/injured bacteria and CY3 channel to detect the red fluorescence from the PI indicating 
bacteria with damaged cell membranes. 
 
2.4 Flow cytometry analysis of PAF C-16 treated M.smegmatis and M.bovis BCG 
For flow cytometry, 1ml bacteria was transferred from fresh grown cultures of M.bovis BCG 
and M.smegmatis at 0.90-1.00 O.D(600nm) into properly labelled eppendorf tubes. The bacteria 
was washed once with PBS by centrifugation at 5000rpm for 10 minutes and resuspended in 
1ml broth media (LB or 7H9). The test mycobacteria was treated with PAF C-16 at a 
concentration of 100µg/ml and to the solvent control 10µl ethanol per ml bacterial suspension 
(solvent for PAF C-16) was added. The eppendorf tubes were incubated for 2 hours at 37°C 
with mixing after every 15 minutes. A positive control comprising of heat treated mycobacteria 
at 100oC for 10 minutes was also included in the experimental design. After incubation, the 
mycobacterial samples were washed twice with PBS by centrifugation at 5000rpm for 10 
minutes to remove residual chemicals. Test and control bacteria were then stained with 1µg/ml 
PI (BioLegend, USA) for 20 minutes at room temperature and excess dye was removed by 
washing the bacteria twice with PBS at 5000rpm for 10 minutes.  The bacterial pellets were 
finally resuspended in 250µl of PBS. The damage to the bacterial cell membrane in test and 
control bacteria was quantified by performing flow cytometry using ACEA NovoCyte® Flow 
Cytometer. First, 20,000-25,000 untreated and unstained bacteria were acquired as a 
compensation. In the second step 20,000-25,000 bacteria were acquired for each solvent 
control, heat treated positive control and 100µg/ml PAF C-16 treated conditions. The data was 
plotted using NovoExpress® software and analyzed for membrane damage. 
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2.5 Assays to neutralize PAF C-16 induced direct growth inhibition of M.smegmatis 
Assays were performed to detect the neutralizing effect of  a number of compounds including 
PAF receptor antagonists (ABT0491 and WEB-2086), dexamethasone, benzenesulfonamide, 
alpha-tocopherol, ascorbic acid, tween-80 and tween-20 on PAF C-16 induced mycobacterial 
growth inhibition in vitro using a similar protocol. In this section, the protocol for experiments 
to determine the effect of PAF receptor antagonists (ABT0491) on PAF C-16 induced 
M.smegmatis growth inhibition is described. 
M.smegmatis stock at -80°C was thawed, sonicated for 15 seconds to break any clumps and 
mixed uniformly by vortexing for 5 seconds. Serial dilution of stock M.smegmatis was 
performed according to the protocol mentioned in section 2.2., 1ml of M.smegmatis 
suspensions at 10-6 dilution were transferred to properly labelled eppendorf tubes. M.smegmatis 
in eppendorf tubes labelled “E” and “F” was first incubated with 100µg/ml PAF receptor 
antagonist (ABT-491) for 1 hour at 37°C with mixing at 15 minutes intervals. After 1 hour 
PAF C-16 at a concentration of 50µg/ml and 100µg/ml was added to the eppendorf tubes E 
and F respectively, and the tubes were incubated at 37°C for another 2 hours with mixing after 
every 15 minutes. Individual controls comprising of M.smegmatis treated with 20µl/ml ethanol 
(solvent of test chemicals) (eppendorf tube A), 50µg/ml PAF C-16 (eppendorf tube B), 
100µg/ml PAF C-16 (eppendorf tube C) and 100µg/ml PAF receptor antagonist (ABT-491) 
(eppendorf tube D) were also included in the experiment (Figure 2.5). After incubation, 
200µl/ml of M.smegmatis suspension from all the tubes was plated on LB agar plates in 
triplicates. The plates were incubated for 72 hours at 37°C for the colonies to appear and the 
number of CFUs was counted by naked eye and test were compared to controls. 
 




Figure 2.5: Diagrammatic representation of experimental setup for effect of PAF receptor 
antagonist ABT-491 on PAF C-16 induced growth inhibition. All the tubes contain 1ml of 
M.smegmatis suspended in LB media. 20µl/ml ethanol (solvent for test compounds) was added 
to tube A, 50µg/ml PAF C-16 was added tube B, 100µg/ml PAF C-16 was added to tube C and 
100µg/ml PAF receptor antagonist (ABT-491) was added to tube D. The M.smegmatis in tube 
E and F were first treated with 100µg/ml PAF receptor antagonist (ABT-491) for 1 hour 
followed by treatment with 50µg/ml and 100µg/ml PAF C-16 respectively for another 2 hours. 
 
2.6 Growing and Storing human monocytes derived THP-1 cells 
Human monocytes derived THP-1 cells (ATCC® TIB-202™) were used as model phagocytic 
cells. THP-1 cells were grown in complete RPMI media at 37°C using an incubator with 5% 
CO2 supply. The complete RPMI was prepared by adding 10% fetal bovine serum (FBS) 
(HyClone, UK), 1% sodium pyruvate (Sigma Aldrich, UK), 1% L-glutamine (Sigma Aldrich, 
UK) and 1% penicillin/streptomycin (Sigma Aldrich, UK) to RPMI-1640 cell culture medium 
(Sigma Aldrich, UK). 
2.6.1 Thawing and culturing THP-1 cells 
THP-1 cells were grown from frozen stocks kept in liquid nitrogen. THP-1 cryotubes 
containing 5x106 cells/ml were thawed on ice. The defrosted THP-1 cells were quickly 
transferred to 10ml of RPMI media and washed twice by centrifugation at 1500rpm for 10 
minutes each to remove the DMSO from the freezing mixture. The cell pellet was finally 
resuspended in 10ml complete RPMI and the number of viable THP-1 cells was counted using 
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trypan blue staining. For trypan blue staining 20µl of THP-1 cell suspension was mixed with 
20µl of 0.4% trypan blue stain (Gibco, UK). From this mixture, 10µl was loaded on a 
haemocytometer and the viable THP-1 cells were counted by viewing them at 400X using an 
inverted microscope (Leica,DI ML). After determining the number of viable THP-1 cells, the 
cells were transferred to a cell culture flask and incubated at 37°C in a CO2 incubator (MCO-
18AC-PE IncuSafe, Panasonic) at 5% CO2 supply. 
The viability of cultured THP-1 cells was checked the following day by viewing them under a 
microscope. THP-1 cells that appeared to be round and shiny were considered alive. The THP-
1 cells were fed every 3 days by removing half of the culture media and replacing it with fresh 
complete RPMI. When necessary the THP-1 cells were split to keep the cell density at 
0.5x106/ml. 
2.6.2 Storing THP-1 cells 
To store THP-1 cells for future experiments, about 25ml of THP-1 cells were grown to a density 
of 1-1.5x106/ml. The THP-1 cell suspension was then centrifuged at 1500rpm for 10 minutes. 
After centrifugation, the supernatant was discarded and the cell pellet was resuspended in 5 ml 
freezing solution (10% DMSO in FBS) such that the final number of THP-1 cells per ml of 
freezing solution was 5x106. 1ml of THP-1 cell suspension in freezing solution was transferred 
to cryotubes and the cryotubes were quickly moved to -80oC freezer (New Brunswick, 
U41085). After 24 hours at -80°C, the frozen THP-1 cells cryotubes were transferred to liquid 
nitrogen for long-term storage. 
 
2.7 Intracellular growth inhibition assays for mycobacteria inside THP-1 cells using 
different test compounds 
Intracellular mycobacterial growth inhibition assays were performed to investigate the effect 
of test compounds such as PAF C-16 and different PAF C-16 structure analogues on the growth 
of phagocytosed mycobacteria (M.smegmatis and M.bovis BCG) inside THP-1 cells.  
2.7.1 Infecting THP-1 cells with mycobacteria 
About 20ml of THP-1 cells grown to a density of 0.5-0.75x106/ml in culture flasks were 
transferred to a 50ml falcon tube and centrifuged at 1500rpm for 10 minutes. The supernatant 
was discarded and the cell pellet was washed twice by resuspending in plain RPMI media and 
centrifugation at 1500rpm for 10 minutes. The cell pellet was finally resuspended in 15ml 
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complete RPMI without antibiotics and the number of cells per ml was counted using a 
haemocytometer. From the THP-1 cells suspension, 0.25x106 were transferred to properly 
labelled eppendorf tubes and the final volume in each tube was made 1ml by adding complete 
RPMI without antibiotics. 
Stock M.smegmatis or M.bovis BCG was sonicated for 15 seconds to break any clumps and 
mixed uniformly by vortexing. The stock bacteria was diluted by 10-fold in plain RPMI and 
1.25x106 bacteria were incubated with THP-1 cells in a ratio 5:1 (bacteria : THP-1 cell) at 37°C 
in a CO2 incubator for 2 hours to allow THP-1 cells to phagocytose the bacteria (Figure 2.7.1).  
 
Figure 2.7.1: Acid fast staining for phagocytosed mycobacteria inside THP-1. The microscopic 
images show M.smegmatis (red rods) inside the THP-1 cells after 2 hours incubation. The 
magnetic beads used for isolation of THP-1 cells can be seen attached to the THP-1 cells as 
well. 
2.7.2 Dyna beads™ preparation 
Dyna beads™ Pan Mouse IgG (Thermo Fisher Scientific, UK) attached to anti-human MHC 
Class I antibody were used to remove non-phagocytosed extracellular mycobacteria from THP-
1 cells after incubation. The beads were prepared by taking 12µl (5x106 beads) anti-mouse IgG 
coated magnetic beads from stock (4x108 beads/ml) and incubating with 6µl (1mg/ml stock 
concentration) mouse anti-human MHC Class I antibody (W6/32 against HLA A, B& C) 
(BioLegend, USA) for 90 minutes on ice to allow binding of W6/32 to the beads. Finally the 
beads were washed with plain RPMI twice by applying a Dynal® magnet (Thermo Fisher 
Scientific, UK), resuspended in 210µl plain RPMI and stored on ice.  
2.7.3 Binding of W6/32 coated Dyna beads with THP-1 cells 
After incubation of bacteria with THP-1 cells (section 2.7.1) for 2 hours to allow phagocytosis, 
50µl (1x106) of W6/32 coated Dyna beads were added to each eppendorf tube in a ratio of 4:1 
(Beads : THP-1 cells). The eppendorf tubes were then buried horizontally in ice and kept in a 
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shaker for 45 minutes to allow the attachment of Dyna beads to the THP-1 cells. After 
incubation, extracellular mycobacteria was removed by applying a Dynal® magnet. Dyna beads 
attached to THP-1 cells with intracellular mycobacteria migrated to a side and the supernatant 
along with extracellular bacteria was removed as illustrated in figure 2.7.2. The washing of 
extracellular mycobacteria was repeated three times with plain RPM by applying a Dynal® 
magnet and finally the THP-1 cell with intracellular mycobacteria were resuspended in 1ml 
complete RPMI without antibiotic. 
 
Figure 2.7.2: Separation of THP-1 cells by magnetic beads. W6/32 coated Dyna beads were 
used to isolated THP-1 cells having intracellular mycobacteria by binding to MHC class I on 
the THP-1 surface and applying a magnet. 
2.7.4 Treating mycobacteria infected THP-1 cells with test compound 
Test compounds such as PAF C-16 or PAF structure analogues were added to the eppendorf 
tubes containing THP-1 cells with intracellular mycobacteria in different concentrations. A 
solvent control for test compound was also included in the experiment and all the eppendorf 
tubes were incubated at 37°C in a CO2 incubator for 24 hours. 
2.7.5 Lysing THP-1 to release intracellular mycobacteria 
After 24 hours incubation, Dynal® magnet was applied eppendorf tubes containing THP-1 cells 
with intracellular mycobacteria. The Dyna beads attached to THP-1 cells migrated to the side 
of eppendorf tube. The supernatant was transferred to appropriately labelled 15ml falcon tubes 
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to collect any extracellular bacteria. The THP-1 cells attached Dyna bead in the eppendorf 
tubes were lysed by adding 1ml of 1% saponin solution (Fisher Scientific, UK) and vortexing 
the mixture for 10 minutes. After vortexing the cell lysate for each condition was transferred 
to the respective 15ml falcons already containing 1ml of bacterial supernatant previously 
collected for each condition. The contents of each falcon tube were mixed by vortexing for 5 
seconds and serial dilutions (10-1, 10-2 and 10-3) were prepared in sterile water. 
2.7.6 Plating bacteria from cell lysates 
Bacterial suspensions at dilutions of 10-2 and 10-3 were used for platting. 200µl of bacterial 
suspension was plated for each experimental condition in triplicates using LB-agar or 7H10 
plates. Plates were incubated at 37°C for 72 hours in case of M.smegmatis and 2-3 weeks for 
M.bovis BCG after which the number of bacterial CFUs were enumerated. A comparison of 
CFUs number between different test plates and the solvent control was done to determine the 
effect of the test compound on the growth of intracellular mycobacteria inside THP-1 cells. 
 
2.8 Flow cytometry to detect apoptosis in PAF C-16 treated THP-1 cells 
About 20ml of THP-1 cells grown to a density of 0.5-0.75x106/ml in culture flasks were 
transferred to a 50ml falcon tube and pelleted by centrifugation at 1500rpm for 10 minutes. 
The supernatant was discarded and the cells were washed twice by resuspending them in plain 
RPMI media and centrifugation at 1500rpm for 10 minutes. Finally the cells pellet was 
resuspended in complete RPMI media and the number of THP-1 cells per ml was counted using 
a haemocytometer. 
Approximately 0.5x106 THP-1 cells were transferred to properly labelled eppendorf tubes and 
the final volume in each tube was made 1ml by adding complete RPMI. PAF C-16 at a 
concentration of 1µg/ml was added to eppendorf tube labelled “Test”, 2µl/ml ethanol (solvent 
control for PAF C-16) was added to the THP-1 cells in the eppendorf tube labelled “Solvent 
control”  and incubated at 37°C for 24 hours in a CO2 incubator. THP-1 cells treated with 1µM 
staurosporine for 4 hours were included as positive control for apoptosis.  
FITC Annexin V Apoptosis Detection Kit with PI (BioLegend, USA) was used to detect 
apoptosis in 1µg/ml PAF C-16, 2µl/ml ethanol and 1µM staurosporine treated THP-1 cells 
according to the manufacturer’s protocol.  
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After incubation with test compounds, THP-1 cells were washed twice with PBS by 
centrifugation at 1500rpm for 10 minutes to remove any residual PAF C-16, ethanol or 
staurosporine. After washing the cells were resuspended in 1ml of Annexin V binding buffer.  
About 100µl of cell suspension was transferred to new eppendorf tubes and incubated with 5µl 
of Annexin V conjugated FITC and 2µl Propidium Iodide at room temperature for 15 minutes. 
Finally 400µl of Annexin V binding buffer was added to each tube and analyzed for apoptosis 
by performing flow cytometry. 20,000 THP-1 cell were acquired for test and control conditions 
using ACEA NovoCyte® Flow Cytometer. The data was plotted using NovoExpress® software 
and PAF C-16 treated THP-1 cells were compared with controls to detect PAF C-16 induced 
apoptosis. 
 
2.9 Flow cytometry to detect apoptosis in PAF C-16 treated THP-1 cells having 
intracellular M.smegmatis 
M.smegmatis infected THP-1 cells treated with PAF C-16 were analyzed for apoptosis using 
flow cytometry according to the following protocol: 
2.9.1 Infection of THP-1 cells with M.smegmatis 
About 20ml of THP-1 cells grown to a density of 0.5-0.75x106/ml in culture flasks were 
transferred to a 50ml falcon tube and pelleted by centrifugation at 1500rpm for 10 minutes.  
The supernatant was discarded and the cell pellet was washed twice by resuspending in plain 
RPMI media and centrifugation at 1500rpm for 10 minutes. Finally the THP-1 cells were 
resuspended in complete RPMI without antibiotics and the number of cells per ml was counted 
using a haemocytometer. About 0.5x106 THP-1 cells were transferred to properly labelled 
eppendorf tubes and the final volume in each tube was made 1ml by adding complete RPMI 
without antibiotics. 
Stock M.smegmatis with known number of bacteria per µl was used for infecting THP-1 cells. 
Approximately 2.5x106 M.smegmatis were added to THP-1 cells in a ratio 5:1 (bacteria : THP-
1 cell) and incubated at 37°C in a CO2 incubator for 2 hours to allow phagocytosis of  
M.smegmatis by THP-1 cells. After 2 hours the non-phagocytosed M.smegmatis were removed 
by washing the THP-1 cells three times with plain RPMI at 1000rpm for 5 minutes each. 
                                                                                                                                      Chapter 2 
74 
 
2.9.2 Treatment of M.smegmatis infected THP-1 cells with PAF C-16 
M.smegmatis infected THP-1 cells were then treated with 1µg/ml PAF C-16 for 24 hours in a 
CO2 incubator at 37°C. Different controls comprising of THP-1 cells only, M.smegmatis 
infected THP-1 cells treated with 2µl/ml (solvent control for PAF C-16) and THP-1 cells 
treated with 1µM staurosporine for 4 hours were also included in the experiment.  
2.9.3 Staining of THP-1 cells 
Apoptosis was detected in PAF C-16 treated test and control THP-1 cells by using FITC 
Annexin V Apoptosis Detection Kit with PI (BioLegend, USA). THP-1 cells were washed 
twice with PBS by centrifugation at 1500rpm for 10 minutes to remove any residual PAF C-
16, ethanol or staurosporine and resuspended in 1ml of Annexin V binding buffer. About 100µl 
of cell suspension was transferred to new eppendorf tubes and incubated with 5µl of Annexin 
V conjugated FITC and 2µl PI for 15 minutes at room temperature. 400µl of Annexin V binding 
buffer was added to each tube and analyzed for apoptosis by performing flow cytometry.  
2.9.4 Flow cytometry 
20,000 THP-1 cell were acquired for test and control conditions using ACEA NovoCyte® Flow 
Cytometer. The data was plotted using NovoExpress® software and PAF C-16 treated THP-1 
cells were compared with controls to detect PAF C-16 induced apoptosis. 
2.10 Investigating the effects of PAFR antagonists, iNOS inhibitors, phospholipases 
inhibitors and cytokine neutralizing antibodies on PAF C-16 induced intracellular 
M.smegmatis growth inhibition 
A number of compounds including PAF C-16 receptor antagonists (ABT-491 and WEB-2086), 
iNOS inhibitor (Aminoguanidine hemisulfate), phospholipase C inhibitor (U-73122), 
phospholipase A2 inhibitor (Benzenesulfonamide) and neutralizing antibodies for IL-6, IL-10 
and TNF-α were used to investigated their effect on PAF C-16 induced intracellular 
M.smegmatis growth inhibition. 
Assays with these compounds were carried out according to the protocol mentioned in section 
2.7 however, the only difference was in the treatment step. In the current assays M.smegmatis 
infected THP-1 cells were treated with test compounds mentioned above for 1 hour prior to 
treatment with PAF C-16. After one 1 hour, PAF C-16 (1µg/ml) was added to the cells and 
were incubated for 24 more hours at 37°C in a CO2 incubator. An additional control comprising 
of M.smegmatis infected THP-1 cells treated with test compound only was also included in the 
experimental design. 
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2.11 Studying the effect of PAF C-16 treatment on THP-1 cells phagocytosis 
Phagocytic assays were performed to check the effect of PAF C-16 on the uptake of 
M.smegmatis by THP-1 cells according to the following protocol: 
2.11.1 Treating THP-1 cells with PAF C-16 
About 20-25ml THP-1 cells grown in culture flasks to a cell density of 0.5-0.75x106/ml were 
transferred to a 50ml falcon tube and centrifuged at 1500rpm for 10 minutes. The supernatant 
was discarded and the cell pellet was washed twice by resuspending in plain RPMI and 
centrifugation at 1500rpm for 10 minutes. The cell pellet was finally resuspended in 15ml 
complete RPMI without antibiotics and the number of THP-1 cells per ml was counted using 
a haemocytometer. From the THP-1 cells suspension, 1x106 cells were transferred to properly 
labelled eppendorf tubes and the final volume in each tube was made 1ml by adding complete 
RPMI without antibiotics.  
PAF C-16 in different concentrations (0.01µg, 0.1µg, 1µg and 5µg/ml) was added to the 
eppendorf tubes containing 1x106 THP-1 cells. A solvent control (1µl ethanol/ml) was also 
included in the experimental design. All the eppendorf tubes were incubated at 37°C in a CO2 
incubator for 2 hours with gentle mixing after every 20 minutes. After incubation PAF C-16 
was removed by washing THP-1 cells with plain RPMI three times at 1500rpm for 10 minutes 
each. The THP-1 cells were then resuspended in complete RPMI without antibiotics and the 
number of THP-1 cells for all PAF C-16 treated conditions and solvent control was counted 
using a haemocytometer. Finally, 0.25x106 THP-1 cells were transferred into new labelled 
eppendorf tubes and the final volume in each tube was made 1ml by adding complete RPMI 
without antibiotics. 
2.11.2 Infecting THP-1 cells with M.smegmatis 
Stock M.smegmatis was sonicated for 15 seconds to break any clumps and mixed uniformly by 
vortexing. The bacteria was then diluted by 10-fold in plain RPMI and 1.25x106 M.smegmatis 
was added to THP-1 cells in each eppendorf tube in a ratio of 5:1 (M.smegmatis : THP-1 cell). 
The eppendorf tubes with THP-1 cell and M.smegmatis were incubated at 37°C in a CO2 
incubator for 2 hours to allow phagocytosis of M.smegmatis by THP-1 cells. 
2.11.3 Dyna beads™ preparation 
Dyna beads™ Pan Mouse IgG (Thermo Fisher Scientific, UK) attached to anti-human MHC 
Class I antibody were used to remove non-phagocytosed extracellular M.smegmatis from THP-
1 cells after incubation. The beads were prepared by taking 16µl (5x106 beads) anti-mouse IgG 
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coated magnetic beads from stock (4x108 beads/ml) and incubating with 8µl (1mg/ml stock 
concentration) mouse anti-human MHC Class I antibody (W6/32 against HLA A, B& C) 
(BioLegend, USA) for 90 minutes on ice to allow binding of W6/32 to the beads. Finally the 
beads were washed with plain RPMI twice by applying a Dynal® magnet (Thermo Fisher 
Scientific, UK), resuspended in 270µl plain RPMI and stored on ice.  
2.11.4 Binding of W6/32 coated Dyna beads with THP-1 cells 
After incubating M.smegmatis with THP-1 cells for 2 hours to allow phagocytosis (section 
2.11.2), 50µl (1x106) of W6/32 coated Dyna beads were added to each eppendorf tube in a ratio 
of 4:1 (Beads : THP-1 cells). The eppendorf tubes were then buried horizontally in ice and kept 
in a shaker for 45 minutes to allow the binding of Dyna beads to THP-1 cells. After incubation, 
extracellular bacteria was removed by applying a Dynal® magnet. Dyna beads attached to THP-
1 cells with intracellular M.smegmatis migrated to a side and the supernatant along with 
extracellular bacteria was removed. The washing of extracellular bacteria was repeated three 
times with plain RPM by applying a Dynal® magnet.  
2.11.5 Lysing THP-1 with phagocytosed M.smegmatis  
THP-1 cells with phagocytosed M.smegmatis were finally resuspended in 1% saponin solution 
(Fisher Scientific, UK) and lysed by vortexing for 10 minutes. After vortexing the cell lysate 
for different PAF C-16 treated and solvent control conditions were serially diluted (10-1 and 
10-2 dilutions) in sterile water. 
2.11.6 Plating M.smegmatis from cell lysates 
M.smegmatis suspensions at dilutions 10-1 and 10-2 were used for platting. 200µl of bacterial 
suspension PAF C-16 treated and solvent control conditions was plated in triplicates using LB-
agar plates. Plates were incubated at 37°C for 72 hours after which the number of M.smegmatis 
CFUs were enumerated. A comparison of CFUs number between different PAF C-16 treated 
and the solvent control plates was done to determine the effect of PAF C-16 treatment on the 
phagocytosis of M.smegmatis by THP-1 cells. 
 
2.12 Determining the Minimum Inhibitory Concentration (MIC) for Platelet Activating 
Factor (PAF C-16) against M.smegmatis 
The minimum inhibitory concentration is a qualitative experiment to determine lowest 
concentration of PAF C-16 required to inhibit the growth of M.smegmatis. 
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First sterile glass culture tubes were labelled properly. 4 ml of LB broth was added to the first 
tube labelled “100µg” and 2ml LB broth each was added to the rest of the tubes labelled “50µg, 
25µg, 12.5µg, 6.25µg, 3.12µg, 1.5µg and 0.78µg” respectively. To the first tube labelled 
“100µg”, PAF C-16 was added at a final concentration of 100µg/ml and mixed by vortexing. 
2-fold serial dilution was performed for PAF C-16 by transferring 2ml media from the 100µg 
tube to the next tube labelled “50µg”. This process was repeated until PAF C-16 concentration 
of 0.78µg/ml was achieved. From the last tube 2ml LB was discarded so that at the end each 
tube had a final volume of 2ml. A solvent control tube containing 2ml of LB and ethanol 
(10µg/ml solvent for PAF C-16) was also included in the experiment.  
Stock M.smegmatis was sonicated for 15 seconds to break any clumps and mixed uniformly by 
vortexing. About 1.0x106 M.smegmatis was added to each tube and the tubes were kept in a 
shaker incubator at 37°C for 48 hours. After 48 hours the culture tubes were taken out and 
examined with naked eye. Cloudiness of the growth media in the tubes indicated bacterial 
growth were as the clear tubes indicated effective bacterial control. The minimum inhibitory 
concentration was found to lie between last tube with clear media and the first tube with 
cloudiness. After visual inspection, optical density O.D(600) was also calculated for each tube. 
 
2.13 Statistical Analysis 
For bacterial growth inhibition assays, all the experiments were performed in triplicates and 
repeated 3-6 times. The data were expressed as mean ± SEM where “solvent control” was 
considered 100% bacterial survival and different test condition were compared to it. GraphPad 
Prism® software (Version 5.01) was used to determine the level of significance. Non-
parametric multiple comparison Kruskal-Wallis test was applied on ranks and individual 
datasets were compared by performing post hoc Dunn’s multiple comparison test. For 
comparison of two particular data sets non-parametric Mann Whitney test was used.  
p-value of less than or equal to 0.05 (p≤0.05) was considered to be significant. The p-values 




                                                                                                                                      Chapter 2 
78 
 
Table 1.2: Denotations used for p-value on graphs. 
p-value   Denotation 
0.01 to 0.05 * 
0.001 to 0.01 ** 
< 0.001 *** 
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Chapter 3: In vitro screening of different endogenous 
factors (proteins and non-proteins) for their inhibitory 




























M.tb infection of the host elicits localized inflammation in the lungs, resulting in the migration 
of different immune cells and leakage of plasma protein and non-protein factors at the site of 
infection (Sherwood and Toliver-Kinsky, 2004; Toossi, 2001). In addition, a number of host 
factors including phospholipids such as PAF C-16 (Camussi et al., 1987) and proteins such as 
C1q (Loos et al., 1989) can also be synthesized by immune cells such as macrophages, which 
are present at the site of infection. These host factors are likely to come in direct contact with 
the bacterial pathogen and immune cells and thus, may modulate the outcome of the infection. 
The direct effect of most these factors on M.tb growth is either poorly understood or completely 
unknown and therefore, needs further investigation. 
In this chapter, a number of endogenously produced host factors (proteins and non-proteins) 
were screened in vitro for their ability to directly inhibit the growth of mycobacteria using 
M.smegmatis (mc2 155) and M. Bovis BCG (Pasteur 1173P2) as model organisms for M.tb. All 
the compounds were first screened against the fast-growing M.smegmatis. Compounds that 
directly inhibited the growth of M.smegmatis were then tested against a slow-growing more 
similar M.tb model, M.bovis BCG during the second phase of screening. 
Different protein and non-protein factors investigated for their direct growth inhibitory effect 




d) C-Reactive Protein (CRP) 
e) Alpha-2-Macroglobulin (α2M) 
f) Vitronectin 
g) Plasminogen 
h) Low-Density Lipoprotein (LDL) 
i) High-Density Lipoprotein ( HDL) 
j) Serotonin 
k) L-Alpha Dipalmitoylphosphatidylcholine (DPPC) 
l) Platelet Activating Factor C-16 (PAF C-16) 
 
 




1) Screening a number of endogenously produced host protein and non-protein factors in 
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3.2 Direct effect of Transferrin on M .smegmatis growth in vitro 
Transferrin is a blood plasma glycoprotein that binds iron and transports it to different parts of 
the body via the bloodstream (Gkouvatsos et al., 2012). This iron binding capacity of 
transferrin plays an important role in body’s defence mechanism against invading 
microorganisms. Transferrin restricts the supply of free iron to different invading pathogens 
and discourages microbial infections (Cassat and Skaar, 2013), hence making it a good 
candidate to be screened in vitro for its direct effect on the growth of mycobacteria. 
Three individual experiments were performed using different concentrations (10µg, 25µg, 
50µg and 100µg/ml) of transferrin and a solvent control for transferrin (100µl water/ml 
bacterial suspension) according to the protocol mentioned in section 2.2. All the three 
experiment of transferrin with M.smegmatis showed the same trend (Figure 3.2b) and it was 
observed that transferrin protein in concentrations of up to 100µg/ml showed no inhibitory 
effect on the growth of M.smegmatis as indicated by the similar number of colony forming 
units (CFUs) for transferrin treated and solvent control M.smegmatis (Figure 3.2a, 3.2b and 
3.2c). Non-parametric Kruskal-Wallis test was applied on ranks to determine the p-value, 
which was found to be non-significant (p=0.77). 
 
 
Figure 3.2a: M.smegmatis CFUs on LB-Agar plates after treatment with different 
concentrations of transferrin. Plate (A) is the solvent control for transferrin (100µl water/ml 
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bacterial suspension). Plate (B) Plate (C), Plate (D) and Plate (E) show the number of CFUs 
after treatment with 10µg, 25µg, 50µg and 100µg/ml transferrin respectively. The picture 
shows one representative plate from the triplicate, for solvent control and different 




























































































































Figure 3.2b: Three individual experiments (A, B and C) for direct effect of transferrin on 
M.smegmatis growth. Each bar represents the average number of M.smegmatis CFUs from 
triplicate plates for solvent control and test conditions and error bar shows standard deviation 
(SD) of the triplicates.  



















































Figure 3.2c: Direct effect of transferrin protein on M.smegmatis growth. Each bar represents 
the average of three individual experiments and the error bars show standard error of means 
(SEM). The data is presented in percentage, where control is taken as 100% survival and 
different test conditions are compared to it. The graph shows that in vitro transferrin protein 
has no direct effect on the growth of M.smegmatis. Non-parametric Kruskal-Wallis test was 
applied on ranks to determine the p-value, which was found to be non-significant (p=0.77). 
 
3.3 Direct effect of Lactoferrin on M. smegmatis growth in vitro 
Lactoferrin is an iron-binding protein belonging to the transferrin family. The increased level 
of lactoferrin during inflammation (Legrand, 2011), its ability to bind free iron (García-
Montoya et al., 2012) and its growth inhibitory effect on a variety of pathogenic 
microorganisms including bacteria (Yamauchi et al., 1993; Arnold et al., 1977), viruses 
(Berlutti et al., 2011) and fungi (Nikawa et al., 1993) made it a good candidate to be screened 
for its direct effect on the growth of M.smegmatis. 
Three individual experiments were carried out to find the direct effect of lactoferrin on 
M.smegmatis growth using different concentrations (10µg, 25µg, 50µg and 100µg) of 
lactoferrin protein and a solvent control for lactoferrin (100µl water/ml bacterial suspension) 
according to the protocol mentioned in section 2.2. All these experiments of lactoferrin with 
M.smegmatis showed the same trend (Figure 3.3b) and it was observed that lactoferrin protein 
in concentrations of up to 100µg/ml had no direct inhibitory effect on the growth of 
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M.smegmatis as indicated by the number of CFUs for lactoferrin treated and solvent control 
M.smegmatis (Figure 3.3a, 3.3b and 3.3c). Non-parametric Kruskal-Wallis test was applied on 
ranks to determine the p-value, which was found to be non-significant (p=0.33). 
 
 
Figure 3.3a: M.smegmatis CFUs on LB-Agar plates after treatment with different 
concentrations of lactoferrin. Plate (A) is the solvent control for lactoferrin (100µl water/ml 
bacterial suspension), Plate (B), Plate (C), Plate (D) and Plate (E) shows the number of 
M.smegmatis CFUs after treatment with 10µg, 25µg, 50µg and 100µg/ml of lactoferrin 
respectively. The picture shows one representative plate from the triplicates for solvent control 
and different test concentrations of lactoferrin used during one of the experiment. 





























































































































Figure 3.3b: Three individual experiments (A, B and C) for the direct effect of lactoferrin 
protein on M.smegmatis growth. Each bar represents the average number of M.smegmatis 
CFUs from triplicate plates for solvent control and test conditions and error bar shows standard 
deviation (SD) of the triplicates. 


















































Figure 3.3c: Direct effect of lactoferrin on the growth of M.smegmatis. Each bar represents the 
average of three individual experiments and the error bars show standard error of means (SEM). 
The data is presented in percentage, where solvent control is taken as 100% survival and 
different test conditions are compared to it. The graph shows that in vitro lactoferrin protein 
has no direct effect on the growth of M.smegmatis. Non-parametric Kruskal-Wallis test was 
applied on ranks to determine the p-value, which was found to be non-significant (p=0.33). 
 
3.4 Direct effect of Fibrinogen on M. smegmatis growth in vitro 
Fibrinogen is a blood plasma glycoprotein that plays an important role in blood clotting. 
Increased levels of fibrinogen can be detected in the human body during infection and 
inflammation (Madden et al., 2008; Holm and Godal, 1984). This made fibrinogen a good 
candidate to be screened for its direct effect on mycobacterial growth. 
Three independent experiments using different concentrations (10µg, 25µg, 50µg and 
100µg/ml) of fibrinogen protein and solvent control for fibrinogen (100µl water/ml bacterial 
suspension) were carried out according to the protocol mentioned in section 2.2. All these three 
experiments showed the same trend (Figure 3.4b) and it was observed that in vitro fibrinogen 
protein in concentrations of up to 100µg/ml had no direct inhibitory effect on the growth of 
M.smegmatis as determined by counting the number of CFUs for fibrinogen treated and solvent 
control M.smegmatis (Figure 3.4a, 3.4b, and 3.4c). Non-parametric Kruskal-Wallis test was 
applied on ranks to determine the p-value, which was found to be non-significant (P=0.81). 





Figure 3.4a: M.smegmatis CFUs on LB-Agar plates after treatment with different 
concentrations of fibrinogen. Plate (A) is solvent control for fibrinogen protein (100µl water/ml 
bacterial suspension), Plate (B), Plate (C), Plate (D) and Plate (E) shows the number of 
M.smegmatis CFUs after treatment with 10µg, 25µg, 50µg and 100µg/ml of fibrinogen 
respectively. The picture shows one representative plate from the triplicates for solvent control 

































































































































Figure 3.4b: Three individual experiments (A, B and C) for the direct effect of fibrinogen 
protein on M.smegmatis growth. Each bar represents the average number of M.smegmatis 
CFUs from triplicate plates for solvent control and test conditions and error bar shows standard 
deviation (SD) of the triplicates. 
 


















































Figure 3.4c: Direct effect of fibrinogen on the growth of M.smegmatis. Each bar represents the 
average of three individual experiments and the error bars show standard error of means (SEM). 
The data is presented in percentage, where solvent control is taken as 100% survival and 
different test conditions are compared to it. The graph shows that in vitro fibrinogen protein 
has no direct growth inhibitory on M.smegmatis. Non-parametric Kruskal-Wallis test was 
applied on ranks to determine the p-value, which was found to be non-significant (P=0.81). 
 
3.5 Direct effect of C-reactive protein (CRP) on M.smegmatis growth in vitro 
C-reactive protein (CRP) is a blood plasma protein with standard concentration ranging from 
5-10mg/L of human serum, however, its concentration is increased several folds during 
pathogen infection, tissue injury and inflammation (Marnell et al., 2005). Therefore, CRP was 
investigated in vitro for its direct effect on the growth of M.smegmatis. All the experiments 
were carried out in the presence of calcium as CRP requires the presence of Ca+2 for its optimal 
functioning (Agarwal et al., 2002). 
Three individual experiments were carried out in the presence of 1mM CaCl2 to find the direct 
effect of CRP on M.smegmatis at different concentrations (10µg, 25µg and 50µg/ml) of CRP 
and a solvent control for CRP (10µl of 140mM NaCl+20mM Tris-HCl/ml of bacterial 
suspension) according to the protocol mentioned in section 2.2. All the experiments of CRP 
with M.smegmatis showed the same trend (Figure 3.5b) and it was observed that CRP in 
concentrations of up to 50µg/ml had no inhibitory effect on the growth of M.smegmatis as 
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indicated by the number of CFUs for CRP treated and solvent control M.smegmatis as shown 
in figures 3.5a, 3.5b and 3.5c. Non-parametric Kruskal-Wallis test was applied on ranks to 
determine the p-value, which was found to be non-significant (p=0.78) 
 
 
Figure 3.5a: M.smegmatis CFUs on LB-Agar plates after treatment with different 
concentrations of CRP. Plate (A) is solvent control for CRP (10µl of 140mM NaCl+20mM 
Tris-HCl/ml of bacterial suspension), Plate (B), Plate (C), and Plate (D) shows the number of 
M.smegmatis CFUs after treatment with 10µg, 25µg, and 50µg/ml of CRP respectively in the 
presence of 1mM CaCl2. The picture shows one representative plate from the triplicates for 


























































































































Figure 3.5b: Three individual experiments (A, B and C) for the direct effect of CRP on 
M.smegmatis growth. Each bar represents the average number of M.smegmatis CFUs from 
triplicate plates for solvent control and test conditions and error bar shows standard deviation 
(SD) of the triplicates. 















































Figure 3.5c: Direct effect of CRP on M.smegmatis growth. Each bar represents the average of 
three individual experiments and the error bars show standard error of means (SEM). The data 
is presented in percentage, where solvent control is taken as 100% survival and different test 
conditions are compared to it. The graph shows that in vitro CRP has no direct effect on 
inhibiting the growth of M.smegmatis. Non-parametric Kruskal-Wallis test was applied on 
ranks to determine the p-value, which was found to be non-significant (p=0.78) 
 
3.6 Direct effect of Alpha-2-macroglobulin (α2M) on M. smegmatis growth in vitro 
Alpha-2-macroglobulin (α2M) is a blood plasma protein that is mainly synthesized in the liver 
(Feldman et al., 1985) however, other cells including macrophages (White et al., 1980), 
fibroblasts (Mosher and Wing, 1976) can also synthesize α2M. This plasma protein can capture 
and bind a variety of self and foreign peptides and particles using its high-affinity sites and 
play an important role in the host defence (Borth, 1992). α2M was, therefore, used during the 
in vitro screening to check if this plasma protein can directly inhibit the growth of 
mycobacteria. 
Three individual experiments were carried out to find using different concentrations (10µg, 
25µg, 50µg and 100µg/ml) of α2M and a solvent control for α2M (100µl water/ml bacterial 
suspension) according to the protocol mentioned in section 2.2. All the experiments of α2M 
with M.smegmatis showed the same trend (Figure 3.6b). From these experiments, it was 
observed that in vitro α2M in concentrations of up to 100µg/ml had no direct effect on the 
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growth of M.smegmatis as indicated by the similarity in the number of CFUs for α2M treated 
and solvent control M.smegmatis shown in figures 3.6a, 3.6b and 3.6c. Non-parametric 




Figure 3.6a: M.smegmatis CFUs on LB-Agar plates after treatment with different 
concentrations of α2M. Plate (A) is solvent control for α2M (100µl water/ml bacterial 
suspension), Plate (B), Plate (C), Plate (D) and Plate (E) shows the number of M.smegmatis 
CFUs after treatment with 10µg, 25µg, 50µg and 100µg/ml of α2M respectively. The picture 
shows one representative plate from the triplicates for solvent control and different test 





























































































































Figure 3.6b: Three individual experiments (A, B and C) for the direct effect of α2M on 
M.smegmatis growth. Each bar represents the average number of M.smegmatis CFUs from 
triplicate plates for solvent control and test conditions and error bar shows standard deviation 
(SD) of the triplicates. 
 


















































Figure 3.6c: Direct effect of α-2-Macroglobulin on the growth of M.smegmatis. Each bar 
represents the average of three individual experiments and the error bars show standard error 
of means (SEM). The data is presented in percentage, where solvent control is taken as 100% 
survival and different test conditions are compared to it. The graph shows that α2M protein in 
vitro has no direct inhibiting effect on M.smegmatis. Non-parametric Kruskal-Wallis test was 
applied on ranks to determine the p-value, which was found to be non-significant (p=0.47). 
 
3.7 Direct effect of Vitronectin on M. smegmatis growth in vitro 
Vitronectin is a 75kDa glycoprotein present at a concentration of 200-400µg/ml in human 
serum and plays important role in cell adhesion and regulatory processes like fibrinolysis 
(Preissner, 1991). Vitronectin has been shown to prevent the deposition of membrane attack 
complex (MAC) on the surface of gram-negative bacteria helping them in survival, while in 
case of gram-positive bacteria vitronectin facilitated their attachment to the host immune cells 
and their subsequent internalization by the host immune cells (Singh et al., 2010). Therefore, 
this plasma protein was investigated for its direct effect on the growth of mycobacteria. 
Three individual experiments were performed using different concentrations (10µg, 25µg, 
50µg and 100µg/ml) of vitronectin protein and solvent control for vitronectin (100µl water/ml 
bacterial suspension) in order to investigate the in vitro effect of vitronectin on the growth of 
M.smegmatis. All the three experiments showed the same trend (Figure 3.7b) and it was 
observed that vitronectin in concentrations of up to 100µg/ml showed no direct inhibitory effect 
on the growth of M.smegmatis as indicated the number of CFUs for vitronectin treated and 
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solvent control M.smegmatis (Figure 3.7a, 3.7b and 3.7c). Non-parametric Kruskal-Wallis test 
was applied on ranks to determine the p-value, which was found to be non-significant (p=0.25). 
 
 
Figure 3.7a: M.smegmatis CFUs on LB-Agar plates after treatment with different 
concentrations of vitronectin. Plate (A) is solvent control for vitronectin (100µl water/ml 
bacterial suspension), Plate (B), Plate (C), Plate (D) and Plate (E) shows the number of 
M.smegmatis CFUs after treatment with 10µg, 25µg, 50µg and 100µg/ml of vitronectin 
respectively. The picture shows one representative plate from the triplicates for solvent control 








































































































































Figure 3.7b: Three individual experiments (A, B and C) for the direct effect of vitronectin on 
M.smegmatis growth. Each bar represents the average number of M.smegmatis CFUs from 
triplicate plates for solvent control and test conditions and error bar shows standard deviation 
(SD) of the triplicates.  
 


















































Figure 3.7c: Direct effect of Vitronectin on the growth of M.smegmatis. Each bar represents 
the average of three individual experiments and the error bars show standard error of means 
(SEM). The data is presented in percentage, where solvent control is taken as 100% survival 
and different test conditions are compared to it. The graph shows that in vitro vitronectin 
protein has no direct growth inhibiting effect on M.smegmatis. Non-parametric Kruskal-Wallis 
test was applied on ranks to determine the p-value, which was found to be non-significant 
(p=0.25). 
 
3.8 Direct effect of Plasminogen on M. smegmatis growth in vitro 
Plasminogen is a precursor blood plasma protein, synthesized in the liver. It is converted by 
the enzymes urokinase-type plasminogen activator (uPA) and tissue-type plasminogen 
activator (tPA) into an active form, plasmin which helps in the dissolution of fibrin blood clots 
(Cesarman‐Maus and Hajjar, 2005) and has also been shown play important roles in other 
physiological processes including inflammation (Syrovets et al., 2012). Therefore, 
plasminogen was tested in vitro for its ability to inhibit or enhance the growth of mycobacteria. 
Three individual experiments were carried out to find the direct effect of plasminogen on the 
growth of M.smegmatis using different concentrations (10µg, 25µg, 50µg and 100µg/ml) of 
plasminogen protein and solvent control for plasminogen (10µl of 50mM Tris-HCl+100mM 
NaCl/ml of bacterial suspension) according to the protocol mentioned in section 2.2. All the 
three experiments of plasminogen with M.smegmatis showed the same trend (Figure 3.8b) and 
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it was observed that plasminogen protein in concentrations of up to 100µg/ml had no direct 
inhibitory effect on the growth of M.smegmatis as indicated by the number of CFUs for 
plasminogen treated and solvent control M.smegmatis (Figures 3.8a, 3.8b and 3.8c). Non-




Figure 3.8a: M.smegmatis CFUs on LB-Agar plates after treatment with different 
concentrations of plasminogen. Plate (A) is the solvent control for plasminogen (10µl of 50mM 
Tris-HCl+100mM NaCl/ ml of bacterial suspension), Plate (B), Plate (C), Plate (D) and Plate 
(E) shows the number of M.smegmatis CFUs after treatment with 10µg, 25µg, 50µg and 
100µg/ml of plasminogen respectively. The picture shows one representative plate from the 
triplicates for solvent control and different test concentrations of plasminogen used during one 




































































































































Figure 3.8b: Three individual experiments (A, B and C) for the direct effect of plasminogen 
protein on M.smegmatis growth. Each bar represents the average number of M.smegmatis 
CFUs from triplicate plates for solvent control and test conditions and error bar shows standard 
deviation (SD) of the triplicates. 
 


















































Figure 3.8c: Direct effect of plasminogen on the growth of M.smegmatis. Each bar represents 
the average of three individual experiments and the error bars show standard error of means 
(SEM). The data is presented in percentage, where solvent control is taken as 100% survival 
and different test conditions are compared to it. The graph shows that in vitro plasminogen has 
no direct growth inhibiting effect on M.smegmatis. Non-parametric Kruskal-Wallis test was 
used to determine the p-value, which was found to be non-significant (P=0.41). 
 
3.9 Direct effect of Low-Density Lipoproteins (LDL) on M. smegmatis growth in vitro 
Low-density lipoproteins (LDL) are composed of multiple proteins along with cholesterol, 
phospholipids and triglycerides. The major protein in the LDL is apolipoprotein B-100 (apo B-
100), which is a 514 kDa protein (Hevonoja et al., 2000). Peptides derived from apo B-10 of 
LDL were shown to possess antimicrobial properties (Kelly et al., 2010). LDL was investigated 
in different concentration for its direct inhibitory effect on the growth of mycobacteria. 
Three individual experiments were carried out to find the direct effect of LDL on M.smegmatis 
growth using different concentrations (1µg, 2.5µg, 5µg, 10µg and 25µg/ml) of LDL and a 
solvent control for LDL (25µl of 150mM NaCl+0.5M EDTA/ml bacterial suspension) 
according to the protocol mentioned in section 2.2. From these experiments, it was observed 
that in vitro LDL in concentrations of up to 25µg/ml showed no direct inhibitory effect on the 
growth of M.smegmatis as indicated by the similarity in the number of CFUs for LDL treated 
and solvent M.smegmatis shown in figures 3.9a, 3.9b and 3.9c. Non-parametric Kruskal-Wallis 
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Figure 3.9a: M.smegmatis CFUs on LB-Agar plates after treatment with different 
concentrations of LDL. Plate (A) is the solvent control for LDL (25µl of 150mM NaCl+0.5M 
EDTA/ml bacterial suspension), Plate (B), Plate (C), Plate (D), Plate (E) and Plate (F) show 
the number of M.smegmatis CFUs after treatment with 1µg, 2.5µg, 5µg, 10µg and 25 µg/ml of 
LDL respectively. The picture shows one representative plate from the triplicates for solvent 


































































































































Figure 3.9b: Three individual experiments (A, B and C) for the direct effect of LDL on 
M.smegmatis growth. Each bar represents the average number of M.smegmatis CFUs from 
triplicate plates for solvent control and test conditions and error bar shows standard deviation 
(SD) of the triplicates. 
 



















































Figure 3.9c: Direct effect of LDL on the growth of M.smegmatis. Each bar represents the 
average of three individual experiments and the error bars show standard error of means (SEM). 
The data is presented in percentage, where solvent control is taken as 100% survival and 
different test conditions are compared to it. The graph shows that in vitro LDL has no direct 
growth inhibitory effect on M.smegmatis growth. Non-parametric Kruskal-Wallis test was 
applied on ranks to determine the p-value, which was found to be non-significant (p=0.14) 
 
3.10 Direct effect of High-Density Lipoproteins (HDL) on M. smegmatis growth in vitro 
High-Density Lipoproteins (HDL) are small lipoprotein particles that are rich in proteins. The 
most abundant protein present in the HDL is apolipoprotein A-1 (apoA-I), a 234 amino acid 
protein synthesized in the liver (Phillips, 2013). High-density lipoproteins from the blood 
plasma have been shown to suppress the growth of gram-positive bacteria in vitro and the 
growth inhibitory property was suggested to be linked with the apoA-I part of the HDL (Tada 
et al., 1993). Therefore, HDL was investigated in different concentration for its direct 
inhibitory effect on the growth of mycobacteria. 
Three individual experiments were carried out to find the direct effect of HDL on M.smegmatis 
growth using different concentrations (1µg, 2.5µg, 5µg, 10µg and 25µg/ml) of HDL and 
solvent control for HDL (25µl of 150mM NaCl+0.5M EDTA/ml bacterial suspension) 
according to the protocol mentioned in section 2.2. From these experiments, it was observed 
that in vitro HDL in concentrations of up to 25µg/ml showed no direct inhibitory effect on the 
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growth of M.smegmatis as indicated by the similarity in the number of CFUs for HDL treated 
and untreated M.smegmatis (Figures 3.10a, 3.10b and 3.10c). Non-parametric Kruskal-Wallis 




Figure 3.10a: M.smegmatis CFUs on LB-Agar plates after treatment with different 
concentrations of HDL. Plate (A) is solvent control for HDL (25µl of 150mM NaCl+0.5M 
EDTA/ml bacterial suspension), Plate (B), Plate (C), Plate (D), Plate (E) and Plate (F) show 
the number of CFUs after treatment with 1µg, 2.5µg, 5µg, 10µg and 25 µg/ml of HDL 
respectively. The picture shows one representative plate from the triplicates for solvent control 




































































































































Figure 3.10b: Three individual experiments (A, B and C) for the direct effect of HDL on 
M.smegmatis growth. Each bar represents the average number of M.smegmatis CFUs from 
triplicate plates for solvent control and test conditions and error bar shows standard deviation 
(SD) of the triplicates. 
 
 





















































Figure 3.10c: Direct effect of HDL on the growth of M.smegmatis. Each bar represents the 
average of three individual experiments and the error bars show standard error of means (SEM). 
The data is presented in percentage, where solvent control is taken as 100% survival and 
different test conditions are compared to it. The graph shows that in vitro HDL has no direct 
growth inhibitory effect on M.smegmatis growth. Non-parametric Kruskal-Wallis test was 
applied on ranks to determine the p-value, which was found to be non-significant (p=0.87). 
 
3.11 Direct effect of Serotonin on M.smegmatis growth in vitro 
Serotonin is chemically known as 5-Hydroxytryptamine (5-HT) or 3-(β-Aminoethyl)-5-
hydroxyindole. During the process of inflammation, serotonin is released in greater quantities 
due to the activation of different cells such as platelets and mast cells by certain pro-
inflammatory compounds such as PAF (Rubio et al., 2007) and is involved in leukocytes 
recruitment and cell adhesion to the blood vessels (Duerschmied et al., 2013).  
Three individual experiments were carried out to find the direct effect of serotonin on 
M.smegmatis growth using different concentrations (10µg, 25µg, 50µg and 100µg/ml) of 
serotonin and a solvent control for serotonin (10µl DMSO/ml bacterial suspension) according 
to the protocol mentioned in section 2.2. All the experiments show the same trend (Figure 
3.11b) and it was observed that in vitro serotonin in concentrations of up to 100µg/ml showed 
no direct inhibitory effect on the growth of M.smegmatis as indicated by the similarity in the 
number of CFUs for serotonin treated and untreated M.smegmatis (Figure 3.11a, 3.11b and 
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3.11c). Non-parametric Kruskal-Wallis test was applied on ranks to determine the p-value, 
which was found to be non-significant (p=0.72). 
 
 
Figure 3.11a: M.smegmatis CFUs on LB-Agar plates after treatment with different 
concentrations of serotonin. Plate (A) is solvent control for serotonin (10µl DMSO/ml bacterial 
suspension), Plate (B), Plate (C), Plate (D) and Plate (E) shows the number of CFUs after 
treatment with 10µg, 25µg, 50µg and 100µg/ml of serotonin respectively. The picture shows 
one representative plate from the triplicates for solvent control and different test concentrations 
of serotonin used during one of the experiment. 
 
 




























































































































Figure 3.11b: Three individual experiments (A, B and C) for the direct effect of serotonin on 
M.smegmatis growth. Each bar represents the average number of M.smegmatis CFUs from 
triplicate plates for solvent control and test conditions and error bar shows standard deviation 
(SD) of the triplicates. 
 



















































Figure 3.11c: Direct effect of serotonin on the growth of M.smegmatis. Each bar represents the 
average of three individual experiments and the error bars show standard error of means (SEM). 
The data is presented in percentage, where solvent control is taken as 100% survival and 
different test conditions are compared to it. The graph shows that in vitro serotonin has no 
direct inhibitory effect on the growth M.smegmatis. Non-parametric Kruskal-Wallis test was 
applied on ranks to determine the p-value, which was found to be non-significant (p=0.72). 
 
3.12 Direct effect of L-alpha dipalmitoylphosphatidylcholine (DPPC) on M.smegmatis 
growth in vitro 
L-alpha dipalmitoylphosphatidylcholine (DPPC) is the most abundant lung surfactant 
phospholipid (Noutsios & Floros, 2013). DPPC was selected during the in vitro screening to 
investigate if this major alveolar phospholipid has any direct inhibitory effect on mycobacterial 
growth. 
Three independent experiments were carried out to find the direct effect of DPPC on 
M.smegmatis growth using different concentrations (10µg, 25µg, 50µg and 100µg/ml) of 
DPPC and a solvent control for DPPC (10µl ethanol/ml bacterial suspension) according to the 
protocol mentioned in section 2.2. All the experiment showed the same trend (Figure 3.12b) 
and it was observed that in vitro DPPC in concentrations of up to 100µg/ml had no direct 
inhibitory effect on the growth of M.smegmatis (Figures 3.12a, 3.12b and 3.12c). Non-
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parametric Kruskal-Wallis test was applied on ranks to determine the p-value, which was found 
to be non-significant (p=0.35) 
 
 
Figure 3.12a: M.smegmatis CFUs on LB-Agar plates after treatment with different 
concentrations of DPPC. Plate (A) is the solvent control for DPPC (10µl ethanol/ml bacterial 
suspension), Plate (B), Plate (C), Plate (D) and Plate (E) shows the number of M.smegmatis 
CFUs after treatment with 10µg, 25µg, 50µg and 100µg/ml of DPPC respectively. The picture 
shows one representative plate from the triplicates for solvent control and different test 
































































































































Figure 3.12b: Three individual experiments (A, B and C) for the direct effect of DPPC on 
M.smegmatis growth. Each bar represents the average number of M.smegmatis CFUs from 
triplicate plates for solvent control and test conditions and error bar shows standard deviation 
(SD) of the triplicates. 
 


















































Figure 3.12c: Direct effect of DPPC on the growth of M.smegmatis. Each bar represents the 
average of three individual experiments and the error bars show standard error of means (SEM). 
The data is presented in percentage, where control is taken as 100% survival and different test 
conditions are compared to it. The graph shows that DPPC has no direct growth inhibiting 
effect on M.smegmatis growth. Non-parametric Kruskal-Wallis test was applied on ranks to 
determine the p value, which was found to be non-significant (p=0.35). 
 
3.13 Direct effect of Platelet Activating Factor C-16 on M. smegmatis growth in vitro 
Platelet activating factor C-16 (PAF C-16) is a membrane derived alkyl-ether phospholipid 
chemically known as 1-O-hexadecyl-2-O-acetyl-sn-glyceryl-3-phosphocholine (Figure 3.13a). 
During inflammation, PAF C-16 is produced by different and is involved in important 
inflammatory processes such as changes in vascular permeability (Evans et al., 1987). 








Figure 3.13a: Chemical structure of Platelet activating factor C-16 (PAF C-16). 
 
Six individual experiments were carried out in vitro to find the direct effect of PAF C-16 on 
M.smegmatis growth using different concentrations (10µg, 25µg, 50µg and 100µg/ml) of PAF 
C-16 and a solvent control for PAF C-16 (10µl ethanol/ml bacterial suspension) according to 
the protocol mentioned in section 2.2. It was observed that PAF C-16 was able to inhibit the 
growth of M.smegmatis in a dose-dependent manner after treatment for 2 hours (Figure 3.13b). 
All the experiments of PAF C-16 with M.smegmatis showed the same trend of growth 
inhibition (Figure 3.13c). The growth inhibitory effect of PAF C-16 against M.smegmatis was 
more prominent at higher concentrations of 50µg/ml and 100µg/ml, which on average caused 
~70% and ~97% reduction in the number of M.smegmatis CFUs respectively when compared 
to solvent control (Figure 3.13d). Level of significance was determined by applying non-
parametric multiple comparison Kruskal Wallis test on ranks and the p-value was found to be 
significant, p≤0.0001. Individual data sets were compared by applying post hoc Dunn’s 
multiple comparison test and the results were found to be significant only for 50µg/ml PAF C-








Figure 3.13b: M.smegmatis CFUs on LB-Agar plates after treatment with different 
concentrations of PAF C-16. Plate (A) is a solvent control for PAF C-16(10µl ethanol/ml 
bacterial suspension), Plate (B), Plate (C), Plate (D) and Plate (E) shows the number of bacterial 
CFUs after treatment with 10µg, 25µg, 50µg and 100µg/ml of PAF C-16 respectively. The 
picture shows one representative plate from the triplicates for solvent control and different test 
concentrations of PAF C-16 used during one of the experiment. It can be observed that PAF 
C-16 treatment resulted in a decrease in the number of M.smegmatis CFUs.  
 
 






















































































































































































































































Figure 3.13c: Six individual experiments (A, B, C, D, E and F) for the direct effect of PAF C-
16 on M.smegmatis growth. Each bar represents the average M.smegmatis CFUs from triplicate 
plates and error bar shows standard deviation (SD) of triplicates. All the graphs show the same 
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Figure 3.13d: Direct effect of PAF C-16 on M.smegmatis growth. Each bar represents the 
average of six individual experiments and the error bars show the standard error of means 
(SEM). Data is expressed in terms of percentage survival where solvent control is considered 
as 100% survival and different test conditions are compared to it. Multiple-comparison of the 
data sets was performed using non-parametric Kruskal-Wallis test on ranks and the p value was 
found to be significant (p≤0.0001). Individual data sets were compared using Dunn’s multiple 
comparison test and the results were significant for 50µg/ml PAF C-16 vs Solvent control 
**(p≤0.01) and 100µg/ml PAF C-16 vs Solvent control ***(p≤0.001). 
 
3.14 Direct effect of Platelet Activating Factor PAF C-16 on growth of M.bovis BCG in 
vitro 
The direct effect of PAF C-16 on the M.bovis BCG growth in vitro was investigated by treating 
M.bovis BCG with different concentrations of PAF C-16 (10µg, 25µg, 50µg and 100µg/ml) 
and a solvent control for PAF C-16 (10µl ethanol/ml bacterial suspension) according to the 
protocol mentioned in section 2.2. Six independent experiments of PAF C-16 with M.bovis 
BCG were carried out in triplicates. It was observed that PAF C-16 was able to inhibit the 
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growth of M.bovis BCG in a dose-dependent manner after treatment for 2 hours (Figure 3.14a). 
All the experiments of PAF C-16 with M.bovis BCG showed the same trend of growth 
inhibition (Figure 3.14b). The growth inhibitory effect of PAF C-16 against M.bovis BCG was 
more prominent at higher concentrations of 50µg/ml and 100µg/ml, which on average caused 
~65% and ~87% reduction in the number of M.bovis BCG CFUs respectively when compared 
to solvent control (Figure 3.14c). Level of significance was determined by applying non-
parametric multiple comparison Kruskal Wallis test on ranks and the p-value was found to be 
significant, p≤0.0001. Individual data sets were compared by applying post hoc Dunn’s 
multiple comparison test and the results were found to be significant only for 50µg/ml PAF C-
16 vs Solvent control (p≤0.01) and 100µg/ml PAF C-16 vs Solvent control (p≤0.001). 
 
 
Figure 3.14a: M.bovis BCG CFUs on 7H10 plates after treatment with different concentrations 
of PAF C-16. Plate (A) is a solvent control for PAF C-16(10µl ethanol/ml bacterial 
suspension), Plate (B), Plate (C), Plate (D) and Plate (E) show the number of M.bovis BCG 
CFUs after treatment with 10µg, 25µg, 50µg and 100µg/ml of PAF C-16 respectively. The 
picture shows one representative plate from the triplicates for solvent control and different test 
concentrations of PAF C-16 used during one of the experiment. It can be observe that PAF C-
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16 treatment inhibited the growth of M.bovis BCG as indicated by the decrease in the number 










































































































































































































Figure 3.14b: Six individual experiments (A, B, C, D, E and F) for the direct effect of PAF C-
16 on M.bovis BCG growth. Each bar represents the average number of M.bovis BCG CFUs 
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from triplicate plates and error bar shows standard deviation (SD) of triplicates. All the graphs 
show the same trend, where an increase in the concentration of PAF C-16 causes a decrease in 












































Figure 3.14c: Direct effect of PAF C-16 on M.bovis BCG growth. Each bar represents the 
average of six individual experiments and the error bars show the standard error of means 
(SEM). Data is expressed in terms of percentage survival where control is taken as 100% 
survival and different test conditions are compared to it. Multiple-comparison of the data sets 
was performed by applying non-parametric Kruskal-Wallis test on ranks and the p-value was 
found to be significant (p≤0.0001). Individual data sets were compared using Dunn’s multiple 
comparison test and the results were significant for 50µg/ml PAF C-16 vs Solvent control 
**(p≤0.01) and 100µg/ml PAF C-16 vs Solvent control ***(p≤0.001). 
 
3.15 Effect of increase in PAF C-16 incubation time on M.smegmatis growth 
In order to investigate the effect of increase in PAF C-16 treatment time on the growth 
inhibition, M.smegmatis was treated with lower concentrations of PAF C-16 ranging from 
1µg/ml-25µg/ml for extended durations of 6, 12 and 24 hours. Four independent experiments 
were performed in vitro using PAF C-16 in concentrations of 1µg, 2.5µg, 5µg, 10µg and 
25µg/ml and a solvent control for PAF C-16 (2.5µl ethanol/ml bacterial suspension) according 
to the protocol mentioned in section 2.2.  
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PAF C-16 was able to inhibit the growth of M.smegmatis both in a time and dose-dependent 
manner (Figures 3.15a, 3.15b and 3.15c). It was observed that PAF C-16 at a concentration of 
5µg/ml showed a reduction of 55% in the number of surviving M.smegmatis CFUs after 6 hours 
treatment whereas, the same concentration of 5µg/ml resulted in more than 95% reduction in 
the number of CFUs after increased treatment durations of 12 and 24 hours as compared to 
































































































































































Figure 3.15a: Four individual experiments (A, B, C and D) for the effect of PAF C-16 on the 
growth of M.smegmatis after 6 hours of treatment. Each bar represents the average number of 
M.smegmatis CFUs from triplicate plates and error bar shows standard deviation (SD) of 
triplicates. 
 


































































































































































Figure 3.15b: Four individual experiments (A, B, C and D) for the effect of PAF C-16 on the 
growth of M.smegmatis after 12 hours of treatment. Each bar represents the average number of 
M.smegmatis CFUs from triplicate plates and error bar shows standard deviation (SD) of 
triplicates. 



































































































































































Figure 3.15c: Four individual experiments (A, B, C and D) for the effect of PAF C-16 on the 
growth of M.smegmatis after 24 hours of treatment. Each bar represents the average number of 
M.smegmatis CFUs from triplicate plates and error bar shows standard deviation (SD) of 
triplicates. 


















































Figure 3.15d: Comparison of M.smegmatis survival after treatment with PAF C-16 for 6, 12 
and 24 hours. The data is expressed in terms of percentage where solvent control is taken as 
100% survival. Each data point on the graph represent the average CFUs form four independent 
experiments at a particular concentration and the error bars show the standard error of means 
(SEM). 
3.16 Effect of increase in PAF C-16 incubation time M.bovis BCG growth  
The effect of increase in PAF C-16 treatment time was also investigated on the growth 
inhibition of M.bovis BCG. Lower concentrations of PAF C-16 ranging from 1µg/ml-25µg/ml 
were used for extended durations of 6, 12 and 24 hours. Four independent experiments were 
performed in vitro using PAF C-16 in concentrations of 1µg, 2.5µg, 5µg, 10 µg and 25µg/ml 
and a solvent control for PAF C-16 (2.5µl ethanol/ml bacterial suspension) according to the 
protocol mentioned in section 2.2.  
PAF C-16 was also able to inhibit the growth of M.bovis BCG in both time and dose-dependent 
manner (Figures 3.16a, 3.16b and 3.16c). It was observed that PAF C-16 at a concentration of 
5µg/ml showed a reduction of 51% in the number of surviving M.bovis BCG CFUs after 6 
hours treatment, which increased to 83% and 95% reduction treatment durations of 12 and 24 
hours respectively as compared to solvent control (Figure 3.16d). 
 
 





































































































































































Figure 3.16a: Four individual experiments (A, B, C and D) for the direct effect of PAF C-16 
on M.bovis BCG growth after 6 hours treatment. Each bar represents the average number of 

































































(B) 12 Hours Treatment




































































































Figure 3.16b: Four individual experiments (A, B, C and D) for the direct effect of PAF C-16 
on M.bovis BCG growth after 12 hours treatment. Each bar represents the average number of 










































































































































































Figure 3.16c: Four individual experiments (A, B, C and D) for the direct effect of PAF C-16 
on M.bovis BCG growth after 24 hours treatment. Each bar represents the average number of 
M.bovis BCG CFUs from triplicate plates and error bar shows standard deviation (SD) of 
triplicates. 
 
















































Figure 3.16d: Comparison of M.bovis BCG survival after treatment with PAF C-16 for 6, 12 
and 24 hours. The data is expressed in terms of percentage where solvent control is taken as 
100% survival. Each data point on the graph represent the average CFUs form four independent 
experiments at a particular concentration and the error bars show the standard error of means 
(SEM) 
 
3.17 Determining the Minimum Inhibitory Concentration (MIC) for PAF C-16 against 
M.smegmatis 
To determine the lowest concentration of PAF C-16 that can inhibit the growth of 
M.smegmatis, minimum inhibitory concentration (MIC) was determined for PAF C-16. 
Approximately 1x106 M.smegmatis was resuspended in 2ml culture media were incubated at 
37°C for 48 hours with PAF C-16 in 2-fold dilutions, ranging from concentrations100µg/ml-
0.78µg/ml and a solvent control for PAF C-16 (10µl ethanol/ml bacterial suspension) was also 
included in the experiment. The MIC of PAF C-16 against M.smegmatis was found to lie 
between concentrations 3.12µg/ml and 1.56µg/ml of PAF C-16 (Figure 3.17). Optical density 
(O.D600nm) was measured after 48 hours for the control and PAF C-16 treated M.smegmatis 
cultures. The experiment was repeated three times and the optical density (O.D600nm) values for 
control and different test conditions as shown in table 3.1.  
 





Figure 3.17: Minimum inhibitory concentration (MIC) of PAF C-16 against M.smegmatis. The 
M.smegmatis cultures tubes containing 100µg, 50µg, 25µg, 12.5µg, 6.25µg and 3.12µg/ml 
PAF C-16 are clear indicating no visible bacterial growth. The last two tubes with 1.56µg/ml 
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Table 3.1: Optical density (O.D600nm) values for M.smegmatis treated with different 
concentration of PAF C-16 after 48 hours.  
PAF C-16 
concentration 
Optical density of M.smegmatis (O.D600nm) 
Experiment 1 Experiment 2 Experiment 3 
Control 
(10µl/ml 
Ethanol) 0.82 1.04 0.89 
0.78µg/ml 0.82 0.98 0.85 
1.56µg/ml 0.70 0.96 0.74 
3.12µg/ml 0.05 0.16 0.11 
6.25µg/ml 0.03 0.01 0.06 
12.50µg/ml 0.01 0.02 0.01 
25.00µg/ml 0.02 0.01 0.02 
50.00µg/ml 0.01 0.02 0.01 













Mycobacterium tuberculosis (M.tb) infections are the leading cause of human mortality among 
all bacterial pathogens and result in more than 1 million human deaths every year. According 
to WHO, approximately 10 million new cases of M.tb infections were reported worldwide, 
during 2015 (WHO, Global TB report 2016). New challenges such as HIV-TB coinfections 
(Daley et al., 1992) and the emergence of multi-drug resistant stains (Espinal et al., 2003) and 
extensively-drug resistant strains (Tang et al., 2011; Jain and Mondal, 2008) of M.tb have 
amplified the severity of the problem. Furthermore, there are currently a limited number of 
drugs available for treating tuberculosis and the treatment requires a minimum of 6 months 
duration. On the prophylactic side, the current vaccine against TB, Bacillus Calmette Gu´erin 
(BCG) has showed variable efficacy in controlling tuberculosis, especially in the adult 
population (Aronson et al., 2004; Colditz et al., 1994; Palmer and Long, 1966). Therefore, 
novel interventions are required both on the therapeutic and preventive fronts to control the 
global menace of M.tb. 
Infection with pathogen causes a disturbance in the host homeostasis and the host responds by 
producing a non-specific, acute phase inflammatory response to the invading pathogen (Cooper 
and Flynn, 1995). As a result, there is a local reaction at the site of infection characterized by 
rapid blood flow, blood vessels dilation and increase in vascular permeability causing the 
leakage of blood plasma fluid. This exudate is rich in both protein and non-protein factors, 
which are most likely to come in direct contact with the pathogen and immune cells at the site 
of infection. Different immune cells such as polymorphonuclear cells (PMCs) and 
monocytes/macrophages also migrate to the site of infection to eliminate the invading pathogen 
(Shi and Pamer, 2011; Toossi, 2001). These immune cells can also synthesize proteins such as 
complement protein C1q (Kaul and Loos 2001; Loos et al., 1989) phospholipids such as PAF 
C-16 (Camussi et al., 1987) and release acute phase cytokines such as TNF-α, IL-6 and IL-1 
(Gruys et al., 2005) at the site of infection. The acute phase cytokines can later act on different 
target cells and thus lead to a systemic reaction. These cytokines also control the concentration 
of different plasma proteins known as the acute phase proteins (APP) by regulating their 
synthesis rate in the liver (van Miert, 1995). 
In this study, a number of host factors including both proteins and non-proteins present in the 
blood plasma and/or locally at the site of infection were used. We hypothesized that nature has 
given multiple functions to these natural factors apart from their known functions and therefore, 
we explored the unknown effect of these host factors on the growth of mycobacteria by using 
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M.smegmatis and M.bovis BCG as model organisms for M.tb. This information will help in 
understanding the role of these factors in bacterial pathogenesis and their therapeutic utility 
against M.tb. The advantage of screening these factors is that they are produced within the body 
and therefore, they will not excite immunological reactions causing minimum or no side 
effects. The factors screened in the current study for their direct inhibitory effect on the growth 
of mycobacteria included Transferrin, Lactoferrin, Fibrinogen, C-reactive protein (CRP), 
Vitronectin, Plasminogen, Alpha-2-Macroglobulin (α2M), High Density Lipoproteins (HDL), 
Low Density Lipoproteins (LDL), L-alpha dipalmitoyl phosphocholine (DPPC), Serotonin, 
and Platelet Activating Factor (PAF C-16). 
Some of the host factors included in this study such as transferrin, lactoferrin and platelet 
activating factor have previously been shown to possess direct growth inhibitory effect against 
a number of gram positive and/or gram negative bacteria. Lin et al used recombinant human 
transferrin protein at concentrations ranging from 0.6µg-60µg/ml and showed 6µg/ml 
transferrin as the minimum inhibitory concentration for gram positive bacteria S.aureus as well 
as gram negative bacteria A.baumannii, which is substantially lower than the physiological 
concentration of transferrin protein (Lin et al., 2010). Singh et al used lactoferrin protein at a 
concentration range of 10-100µg/ml and showed that lactoferrin protein was able to inhibit the 
growth of gram negative P.aeruginosa significantly at a concentration of 100µg/ml (Singh et 
al., 2002). Similar results were obtained by Bortner et al, as they showed that lactoferrin protein 
at a concentration of 0.09mg/ml (90µg/ml) was able to reduce the viability of a pathogenic 
gram negative bacteria L.pneumophila by approximately 99.99% (Bortner et al., 1989). Steel 
et al screened PAF C-16 and Lyso PAF for their direct growth inhibitory effect against both 
gram positive and gram negative bacteria at a concentration range of 0.25-20µg/ml and showed 
both these phospholipid compounds were able to significantly inhibit the growth of gram 
positive bacteria at concentration as low as 2.5µg/ml, however no significant inhibitory effect 
was observed on gram negative bacteria at any of the concentrations used (Steel et al., 2002). 
Therefore, we followed a similar range of concentrations (1-100µg/ml) during the screening 
experiments for all the test compounds keeping in view the range of concentrations from the 
previously published literature as mentioned above. 
In humans, transferrins are an important class of proteins that consist of iron binding proteins 
(Lambert et al., 2005). Two important members of this group include Transferrin protein and 
Lactoferrin/Lactotransferrin protein. Transferrin protein is abundant in human serum (Cazzola 
et al., 1985), whereas lactoferrin is abundant in milk, mucosal fluids and inside 
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polymorphonuclear leukocytes (Conesa et al., 2008; Levay, and Viljoen, 1995; Broxmeyer et 
al., 1978). In humans, these proteins play a strategic role by maintaining homeostasis as they 
hamper the microbial growth by creating an environment of low iron (Rogan et al., 2004; von 
Bonsdorff et al., 2003). In the current study, the direct effect of both iron binding transferrin 
protein and lactoferrin protein was investigated on the growth of mycobacteria using 
M.smegmatis as a model. However, both these proteins in concentrations of up to 100µg/ml 
failed to show any direct inhibitory effect on the growth of M.smegmatis. Human transferrin 
has previously been shown to possess antimicrobial properties both in vitro and in vivo. Lin et 
al showed that transferrin protein can inhibit the growth of both gram-negative (Acinetobacter 
baumannii) and gram-positive (Staphylococcus aureus) bacteria as well as fungi (Candida 
albicans) in vitro. This transferrin induced growth inhibition was shown to be as a result of 
damage to the cell membrane potential and ATP generation (Lin et al., 2014). In vivo, 
administration of human transferrin in infected mice improved survivability by controlling the 
growth of the above mentioned pathogens (Lin et al., 2014). Similarly, a number of previous 
studies have shown that in vitro lactoferrin also possess direct antibacterial properties bacteria 
such as Escherichia coli, Salmonella typhimurium, Vibrio cholerae, and Streptococcus 
pneumoniae. Lactoferrin inhibits the growth of these bacteria by mechanisms including 
inhibition of the bacterial H+-ATPase complex and damage to the outer membrane in gram-
negative bacteria due to LPS removal (Nibbering et al., 2001; Naidu et al., 1993; Arnold et al., 
1981; Arnold et al., 1977). 
A panel of three positive acute phase proteins comprising of Fibrinogen, C-reactive protein 
(CRP) and Alpha-2-macroglobulin (α2M) was also investigated in vitro for their direct growth 
inhibitory on M.smegmatis.  
Fibrinogen is a precursor plasma protein, which upon activation with thrombin is converted to 
fibrin. The concentration of fibrinogen increases in blood during inflammation and infections 
(Toss et al., 1998). Therefore, we investigated the direct effect of this acute phase protein on 
the growth of mycobacteria. Our experiments with fibrinogen and M.smegmatis showed that 
in vitro fibrinogen in concentrations of up to 100µg/ml was unable to inhibit the growth of the 
M.smegmatis. Påhlman et al showed that treatment of Group A Streptococci such as 
Streptococcus pyogenes with exogenous fibrinogen in combination with thrombin resulted in 
the growth inhibition of these bacteria. Furthermore, this direct growth inhibitory effect was 
shown to be associated with a peptide fragment “GHR28” released from the β chain of 
fibrinogen (Påhlman et al., 2013).  
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CRP is an acute phase plasma protein whose concentration increases by several folds in 
response to stimuli such as infection or tissue injury (Povoa et al., 2005). Increase in 
concentration of CRP in blood during infection and inflammation made CRP an interesting 
candidate to be investigated for its direct effect on the growth of the mycobacteria during the 
screening. However, the results showed that in vitro CRP in concentrations of up to 50µg/ml 
had no direct inhibitory effect on M.smegmatis growth. Previously it has been shown that 
recombinant horseshoe crab C-reactive protein (rCRP2) possess direct bactericidal activity 
against gram-negative bacteria such as Escherichia coli and Pseudomonas aeruginosa but was 
unable affect the growth of gram-positive bacteria such as Staphylococcus aureus (Tan et al., 
2005).  
The plasma α2M protein acts a non-specific proteinase inhibitor and is produced in increased 
quantities during infection and inflammation (Rehman et al., 2013). Our experiments with α2M 
and M.smegmatis showed that in vitro α2M in concentrations of up to 100µg/ml had no direct 
inhibitory effect on M.smegmatis growth. Khan et al suggested a protective role for α2M during 
pathogen infection and showed that administration of exogenous α2M resulted in improved 
survivability in Pseudomonas aeruginosa infected guinea pigs as compared to untreated 
control. The protective effect of α2M was due to its neutralizing effect on the bacterial elastase 
enzyme which are important for bacterial virulence (Khan et al., 1994). However, other reports 
suggested a protective role for α2M on bacterial growth. α2M was shown to bind to different 
pathogenic bacteria such as Streptococci via a bacterial surface protein known as GRAB. This 
binding of α2M to bacterial surfaces is thought to be helpful for bacteria as α2M can provide 
protection to the bacteria from different antibacterial proteinases inside the body (Rasmussen 
et al., 1999). 
Plasma proteins vitronectin and plasminogen were also included in the screening and 
investigated for their direct effect on the growth of M.smegmatis. There is limited information 
about the direct effect of these plasma proteins on the growth of bacteria. Our results showed 
that in vitro both vitronectin and plasminogen proteins had no direct inhibitory effect on the 
growth of M.smegmatis at different concentrations ranging from 10µg-100µg/ml. Vitronectin 
has previously been shown to bind to different bacteria such as Haemophilus influenzae, 
Streptococcus pneumoniae and Moraxella catarrhalis and prevent them from the lytic effects 
of host complement membrane attack complex (MAC) by preventing it deposition on the 
bacterial surface (Hallström et al., 2006; Chhatwal et al., 1987). Plasminogen is an important 
precursor plasma protein that is converted into active form plasmin, which plays important role 
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in fibrinolysis (Aĭsina and Mukhametova, 2014). To the best of our knowledge there is 
currently no information about the direct effect of plasminogen on the growth of mycobacteria. 
Previously it has been shown that plasminogen can interact with bacterial proteases such as 
Streptokinase (SK) and Staphylokinase (SAK) enzymes from Streptococci and Staphylococci 
and may augment the proteolytic invasion of the host by these bacteria (Peetermans et al., 
2016). 
Bacterial infection accompanied by inflammation results in the production of different 
cytokines and some of these cytokines such as IL-6, TNF-α, and IL-1 cause profound changes 
in the concentration, composition and function of the plasma lipid and lipoproteins (Nassaji 
and Ghorbani, 2012; Khovidhunkit et al., 2004). We investigated two blood plasma 
lipoproteins, High-density lipoprotein (HDL) and Low-density Lipoprotein (LDL) for their 
direct inhibitory effect on M.smegmatis growth. However, our results showed that both HDL 
and LDL had no direct inhibitory effect in concentrations up to 25µg/ml on M.smegmatis 
growth. Previously, Apolipoprotein A-1 (Apo A-1), a major protein of HDL was shown to 
possess bactericidal activity against gram-negative bacteria Yersinia enterocolitica (Biedzka-
Sarek et al., 2011). Similarly, transgenic mice lacking plasma LDL Apolipoprotein B-100 (Apo 
B-100) were shown to be more susceptible to Staphylococcus aureus infection (Peterson et al., 
2008) indicating a protective role this LDL protein component against bacterial infection of 
the host. 
Non-protein factors including the major lung surfactant L-alpha dipalmitoyl phosphocholine 
(DPPC) and two pro-inflammatory mediators, serotonin and platelet activating factor (PAF C-
16) were also screened for their direct inhibitory effect on mycobacterial growth. 
L-alpha dipalmitoyl phosphocholine (DPPC) is the most abundant lung surfactant phospholipid 
(Noutsios and Floros, 2013). This lung surfactant was investigated for its direct growth 
inhibitory effect on M.smegmatis. However, our results showed that in vitro DPPC in 
concentrations of up to 100µg/ml was unable to inhibit the growth of M.smegmatis. There are 
previous studies demonstrating the bactericidal activity of leukocyte free bronchoalveolar 
lavage and purified lavage surfactants from rats against Staphylococcus pneumoniae 
suggesting that lung surfactants are involved in protection against pathogens (Coonrod et al., 
1984; O’Neill et al., 1984). 
Serotonin (5-hydroxytryptamine) is released in increased amounts during inflammation from 
different cells such as mast cells (Kushnir-Sukhov et al., 2007) and platelets (Ge et al., 2009) 
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and causes changes in vascular permeability (Cloutier et al., 2012). Our experiments with 
serotonin and M.smegmatis showed that in vitro this compound was unable to inhibit the 
growth of M.smegmatis in concentrations of up to 100µg/ml. A previous study with serotonin 
showed that serotonin possesses direct in vitro antifungal activity and was able to inhibit the 
growth of clinically isolated species of Candida (Lass-Flörl et al., 2002).  
During the screening, PAF C-16, a pro-inflammatory phospholipid was the only compound 
that inhibited the growth of mycobacteria. Treatment of both M.smegmatis and M.bovis BCG 
with exogenous PAF C-16 for 2 hours resulted in the growth inhibition of these bacteria in a 
dose-dependent manner. The growth inhibitory effect of PAF C-16 was more noticeable at 
higher concentrations of 50µg/ml and 100µg/ml and caused significant levels (p≤0.01-≤0.001) 
of reduction in the number of M.smegmatis and M.bovis BCG CFUs when compared with the 
solvent control. PAF C-16 treatment also affected the colony morphology of the surviving 
bacteria on agar plates as the colonies appeared thinner when compared to the control 
indicating that the surviving bacteria were under stress. To the best of our knowledge, there is 
no previous study that shows the direct inhibitory effect of PAF C-16 on the growth of 
mycobacteria. A single previous study by Steel et al showed that exogenous PAF C-16 was 
able to directly inhibit the growth of gram-positive bacteria such as Staphylococcus aureus, 
Staphylococcus epidermidis, Staphylococcus saprophyticus and Streptococcus mutans in 
cultures and had no inhibitory effect on the growth of gram-negative bacteria such as 
Escherichia coli, Pseudomonas aeruginosa, Salmonella typhimurium and Klebsiella 
pneumoniae. The mechanism for PAF C-16 induced bacterial growth inhibition was suggested 
to be through disruption of microbial K+ transport (Steel et al., 2002). However, the exact 
mechanism of PAF C-16 induced growth inhibition in gram-positive bacteria and its 
ineffectiveness against gram-negative requires further investigation. Furthermore, PAF C-16 
was also shown to inhibit the growth of lower eukaryotes such as yeast in a dose-dependent 
manner when added to the growth medium and this growth inhibitory effect of PAF C-16 was 
partially mitigated by pre-treatment with PAF receptor antagonists suggesting that the growth 
inhibitory activity of PAF C-16 was mediated through its receptor (Nigam et al., 2013). 
Although PAF C-16 was able to inhibit the growth of mycobacteria during the initial screening, 
the concentrations of PAF C-16 that caused significant growth inhibition of M.smegmatis and 
M.bovis BCG were very high. There are a number of adverse side effects associated with higher 
concentrations of PAF C-16 such as increased vascular permeability, hypotension, decreased 
cardiac output, asthma and gastrointestinal and inflammatory disorders. (Stafforini et al., 
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2003). Therefore, we investigated the growth inhibitory effect of PAF C-16 at lower 
concentrations and increased incubation duration on mycobacteria. It was observed that by 
increasing the treatment duration to 6 hours, PAF C-16 at a concentration of 5µg/ml caused 
~50% reduction in M.smegmatis and M.bovis BCG CFUs (p≤0.01) as compared to the solvent 
control. The growth inhibition at 5µg/ml PAF C-16 increased to ≥80% (p≤0.001) when the 
treatment times were extended to 12 and 24 hours. These results indicated that the growth 
inhibitory effect of PAF C-16 was also dependent on treatment time. Minimum inhibitory 
concentration (MIC) for PAF C-16 against M.smegmatis was also determined and was found 
to lie between concentrations 3.12µg/ml and 1.56µg/ml of PAF C-16. For the sake of 
convenience, all further experiments with PAF C-16 or its structural analogues were performed 
at concentrations 10µg, 25µg, 50µg and 100µg/ml with 2 hours treatment time as in principle 
we have established that PAF C-16 can inhibit the growth of both M.smegmatis and M.bovis 
BCG at the lower concentration as well. 
In conclusion, as a result of our screening, novel direct mycobacterial growth inhibition activity 
was detected for PAF C-16. The inhibitory effect of PAF C-16 on the growth of M.smegmatis 
and M.bovis BCG was shown to be both dose-dependent and time-dependent.
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Chapter 4: Investigating the effect of changes in structure of PAF 
C-16 on the growth of mycobacteria and the mechanism of PAF C-
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4.1 Introduction  
After showing in vitro the direct inhibitory effect of PAF C-16 on the growth of M.smegmatis 
and M.bovis BCG in a dose and time-dependent manner, we focused on the structure-activity 
relationship of PAF C-16. For this purpose, different PAF C-16 structural analogues were used 
and their effect on mycobacterial growth was investigated in vitro. Previous research has shown 
that small changes in the structure of PAF C-16 can alter its biological activity in mammals, 
with effects ranging from complete inactivation to decreased potency during different 
physiological processes (Stewart and Grigoriadis, 1991). 
Structurally PAF C-16 consists of a glycerol backbone with a phosphocholine head at position 
sn-3, an acetyl group at position sn-2 and a 16-carbon atoms aliphatic tail attached via ether 
bond at position sn-1 (Hanahan et al., 1980) (Figure 3.13a). In order to localize the active 
portion of PAF C-16 that is responsible for its growth inhibitory effect against mycobacteria, 
compounds with structures similar to different portions of PAF C-16 were used. 
PAF C-16 performs its diverse biological activities in eukaryotic organisms by binding to G-
protein coupled transmembrane receptors known as PAF receptors (PAFR) on the cell 
membrane (Ishii et al., 2002). However, there is currently no information about the interaction 
of PAF C-16 with mycobacteria or the presence of PAFR on mycobacteria or any other 
bacteria. Also, limited research has been done to establish the mechanism through which PAF 
C-16 may inhibit the growth of prokaryotic organisms (Steel et al., 2002). Therefore, in this 
chapter we further investigated the effects of small modifications in PAF C-16 structure on its 
growth inhibition activity, structurally active portion of PAF C-16 and the mechanism for PAF 
C-16 induced mycobacterial growth inhibition.  
Aims: 
1) Investigating in vitro the direct effect of PAF C-16 structure analogues on the growth 
of mycobacteria. 
2) Localization of active portion of PAF C-16 involved in mycobacterial growth 
inhibition. 
3) Understanding the mechanism of PAF C-16 induced direct growth inhibition of 
mycobacteria.  
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4.2 PAF C-16 analogues and their growth inhibition potency against mycobacteria 
A number of PAF C-16 structure analogues were investigated for their direct inhibitory effect 
on the growth of mycobacteria. These PAF C-16 structure analogues were selected in a way 
that each analogue represented a change of different functional group. Various PAF C-16 
analogues used in this study included: 
a) Lyso-PAF 
b) PAF C-18 
c) Hexanolamino PAF 
d) 2-O-Methyl PAF 
e) Pyrrolidino PAF 
 
4.2.1 Direct effect of Lyso-Platelet Activating Factor (Lyso-PAF) on M.smegmatis growth 
in vitro 
Lyso-Platelet Activating Factor (Lyso-PAF) is the precursor form of naturally occurring PAF 
C-16, chemically known as 1-O-hexadecyl-sn-glyceryl-3-phosphorylcholine (Figure 4.2.1a). 
This precursor form is considered to be biologically inactive and the direct effect of this de-
acylated PAF on the growth of mycobacteria has not been investigated. 
 
 
Figure 4.2.1a: Chemical structure of Lyso-PAF. Lyso-PAF contains a hydroxyl group at 
position sn-2 instead of an acetyl group, which is shown in the red circle. 
The direct effect of Lyso-PAF on the growth of M.smegmatis was investigated according to 
the protocol in chapter 2.2. Six individual experiments (Exp1, 2, 3, 4, 5 and 6) were performed 
by treating M.smegmatis with different concentrations of Lyso-PAF (10µg, 25µg, 50µg and 
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100µg/ml of bacterial suspension) for 2 hours. A solvent control for Lyso-PAF (10µl 
ethanol/ml bacterial suspension) was also included in the experiment. 
It was observed that Lyso-PAF was able to inhibit the growth of M.smegmatis in a dose-
dependent manner as indicated by the reduction in the number of colony forming units (CFUs) 
when compared with the solvent control (Figure 4.2.1b). All the experiments of Lyso-PAF with 
M.smegmatis showed the same trend of growth inhibition (Figure 4.2.1c). The growth 
inhibitory effect of Lyso-PAF against M.smegmatis was more prominent at higher 
concentrations of 50µg/ml and 100µg/ml, which on average caused ~68% and ~95% reduction 
in the number of M.smegmatis CFUs respectively (Figure 4.2.1d). Non-parametric multiple 
comparison Kruskal Wallis test was applied on ranks and the p-value was found to be 
significant, p≤0.0001. Individual data sets were compared by applying post hoc Dunn’s 
multiple comparison test and the results were found to be significant only for 50µg/ml Lyso-
PAF vs Solvent control (p≤0.01) and 100µg/ml Lyso-PAF vs Solvent control (p≤0.001). 
These results suggest that substituting the acetyl group (CH3O) of PAF C-16 at position sn-2 
with a hydroxyl group (OH) did not affect the growth inhibitory activity against M.smegmatis. 
 
 
Figure 4.2.1b: M.smegmatis CFUs on LB-Agar plates after treatment with different 
concentrations of Lyso-PAF. Plate (A) is a solvent control for Lyso-PAF (10µl ethanol/ml 
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bacterial suspension), Plate (B), Plate (C), Plate (D) and Plate (E) shows the number of CFUs 
after treatment with 10µg, 25µg, 50µg and 100µg/ml of Lyso-PAF respectively. The picture 
shows one representative plate from the triplicate for solvent control and different 



















































































































































































































































Figure 4.2.1c: Six independent experiments (Exp1, 2, 3, 4, 5 and 6) showing the direct effect 
of Lyso-PAF on M.smegmatis growth. Each bar represents the average number of M.smegmatis 
CFUs from triplicate plates for solvent control and test conditions and error bar shows standard 


















































Figure 4.2.1d: Direct effect of Lyso-PAF on M.smegmatis growth. Data is expressed in terms 
of percentage, where solvent control is considered as 100% survival and different Lyso-PAF 
treated test conditions are compared to it. Each bar represents the average of six independent 
experiments and the error bars show the standard error of means (SEM). The graph represents 
the numbers of M.smegmatis CFUs after treatment with different concentrations of Lyso-PAF 
for 2 hours. Non-parametric multiple-comparison Kruskal-Wallis test was applied on ranks to 
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calculate the p-value which was found to be significant (p≤0.0001). Individual data sets were 
compared using Dunn’s multiple comparison test, where 50µg/ml Lyso-PAF vs Solvent control 
**(p≤0.01) and 100µg/ml Lyso-PAF vs Solvent control ***(p≤0.001). 
 
4.2.2 Direct effect of Lyso-Platelet Activating Factor (Lyso-PAF) on M.bovis BCG growth 
in vitro 
Lyso-PAF was also investigated for its direct inhibitory effect on slow growing M.bovis BCG. 
Six individual experiments (Exp1, 2, 3, 4, 5 and 6) were performed using different 
concentrations of Lyso-PAF (10µg, 25µg, 50µg and 100µg/ml bacterial suspension) and a 
solvent control for Lyso-PAF (10µl ethanol/ml bacterial suspension) according to the protocol 
mentioned in section 2.2. These experiments showed that Lyso-PAF was able to inhibit the 
growth of M.bovis BCG in a dose-dependent manner as indicated by a decrease in the number 
of M.bovis BCG CFUs when compared with the solvent control (Figure 4.2.2a). All the 
experiments of Lyso-PAF with M.bovis BCG showed the same trend of growth inhibition 
(Figure 4.2.2b). Lyso-PAF treatment of M.bovis BCG at concentrations of 50µg/ml and 
100µg/ml on average caused ~64% and ~88% reduction in the number of CFUs respectively 
when compared with the solvent control (Figure 4.2.2c). The level of significance was 
determined by applying non-parametric multiple comparison Kruskal Wallis test on ranks and 
the p-value was found to be significant, p≤0.0001. Individual data sets were compared through 
post hoc Dunn’s multiple comparison test and the results were found to be significant only for 

















Figure 4.2.2a M.bovis BCG CFUs on 7H10 plates after treatment with different concentrations 
of Lyso-PAF. Plate (A) is a solvent control for Lyso-PAF (10µl ethanol/ml bacterial 
suspension), Plate (B), Plate (C), Plate (D) and Plate (E) shows the number of M.bovis BCG 
CFUs after treatment with 10µg, 25µg, 50µg and 100µg/ml of Lyso-PAF respectively. The 
picture shows one representative plate from the triplicates, for solvent control and different 





















































































































































































































































Figure 4.2.2b: Six independent experiments (Exp1, 2, 3, 4, 5 and 6) showing the direct effect 
of Lyso-PAF on M.bovis BCG growth. Each bar represents the average number of M.smegmatis 
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CFUs from triplicate plates for solvent control and test conditions and error bar shows standard 














































Lyso-PAF and M.bovis BCG
 
Figure 4.2.2c: Direct effect of Lyso-PAF on M.bovis BCG growth. Each bar represents the 
average of six individual experiments and the error bars show the standard error of means 
(SEM). Data is expressed in terms of percentage survival where solvent control is considered 
as 100% survival and different test conditions are compared to it. Non-parametric multiple-
comparison Kruskal-Wallis test was applied on ranks to calculate the p-value which was found 
to be significant (p≤0.0001). Individual data sets were compared using Dunn’s multiple 
comparison test, where 50µg/ml Lyso-PAF vs Solvent control **(p≤0.01) and 100µg/ml Lyso-
PAF vs Solvent control ***(p≤0.001). 
 
4.2.3 Direct effect of Platelet Activating Factor C-18 (PAF C-18) on M.smegmatis and 
M.bovis BCG growth in vitro 
PAF C-18 is a naturally produced PAFC-16 analogue, chemically known as, 1-O-octadecyl-2- 
acetyl-sn-glyceryl-3-phosphorylcholine. The difference between PAF C-16 and PAF C-18 is 
the longer carbon tail with two additional carbon atoms in PAF C-18 (Figure 4.2.3a). 
 




Figure 4.2.3a: Chemical structure of PAF C-18. The carbon tail in PAF C-18 is octadecyl, 
having two additional carbons shown in the red circle as compared to PAF C-16. 
The direct effect of PAF C-18 on the growth of M.smegmatis and M.bovis BCG was 
investigated according to the protocol in chapter 2.2. Three independent experiments (Exp1, 2 
and 3) were performed for each M.smegmatis and M.bovis BCG by treating them with different 
concentrations of PAF C-18 (10µg, 25µg, 50µg and 100µg/ml of bacterial suspension) for 2 
hours. A solvent control for PAF C-18 (10µl ethanol/ml bacterial suspension) was included in 
each experiment. 
It was observed that PAF C-18 was able to inhibit the growth of both M.smegmatis and M.bovis 
BCG in a dose-dependent manner after treatment for 2 hours as indicated by a reduction in the 
number of CFUs when compared with the solvent control. The experiments of PAF C-18 with 
M.smegmatis and PAF C-18 with M.bovis BCG showed the same trend of growth inhibition 
(Figures 4.2.3b and 4.2.3c). The growth inhibitory effect of PAF C-18 was more prominent at 
higher concentrations of 50µg/ml and 100µg/ml. On average, PAF C-18 treatment of 
M.smegmatis at concentrations of 50µg/ml and 100µg/ml resulted in ~69% and ~98% 
reduction in the number of CFUs respectively when compared with the solvent control (Figure 
4.2.3d graph (i)). In case of M.bovis BCG, PAF C-18 treatment at concentrations 50µg/ml and 
100µg/ml on average caused ~57% and ~93% growth inhibition respectively (Figure 4.2.3d 
graph (ii)). Non-parametric multiple comparison Kruskal Wallis test was applied on ranks and 
the p-value was found to be significant in case of both M.smegmatis (p=0.008) and M.bovis 
BCG (p=0.008). Individual data sets were compared by post hoc Dunn’s multiple comparison 
test and the results were found to be significant only for 100µg/ml PAF C-18 vs Solvent control 
(p≤0.01). 
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These results showed that increase in the length of the aliphatic carbon tail in PAFC-16 has no 





























































































































Figure 4.2.3b: Three independent experiments (Exp1, 2 and 3) for the direct effect of PAF C-
18 on M.smegmatis growth. Each bar represents the average number of M.smegmatis CFUs 
from triplicate plates for solvent control and test conditions and error bar shows standard 
































































































































Figure 4.2.3c: Three independent experiments (Exp1, 2 and 3) for the direct effect of PAF C-
18 on M.bovis BCG growth. Each bar represents the average number of M.smegmatis CFUs 
from triplicate plates for solvent control and test conditions and error bar shows standard 
deviation (SD) of the triplicates. 
 
 























(i) PAF C-18 and M.smegmatis













































(ii) PAF C-18 and M.bovis BCG
























Figure 4.2.3d: Effect of PAF C-18 on M.smegmatis and M.bovis BCG growth. Each bar 
represents the average of three independent experiments and the error bars show the standard 
error of means (SEM). Data is expressed in terms of percentage survival where solvent control 
is taken as 100% survival and different PAF C-18 treated test conditions are compared to it. 
The p-value was found to be significant in case of both M.smegmatis (p=0.008) and M.bovis 
BCG (p=0.008) and was determined by applying non-parametric Kruskal-Wallis test on ranks. 
Individual data sets were compared using Dunn’s multiple comparison test and 100µg/ml PAF 
C-18 vs Solvent control was found significant for both M.smegmatis and M.bovis BCG 
**(p≤0.01). 
 
4.2.4 Direct effect of Hexanolamino PAF on M.smegmatis and M.bovis BCG growth in 
vitro 
Hexanolamino PAF is chemically known as 1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho 
(N,N,N-trimethyl). This analogue differs from naturally occurring PAF C-16 in the position of 
the terminal amino group, which is attached by 4 additional carbon atoms to the phosphate 
group of the phosphocholine head portion (Figure 4.2.4a) 
 




Figure 4.2.4a: Structure of Hexanolamino PAF. Red circle shows the 4 additional carbon atoms 
that attaches the amino group to the phosphate group in the phosphocholine head portion of the 
compound.  
 
The direct effect of Hexanolamino PAF on the growth of M.smegmatis and M.bovis BCG was 
investigated according to the protocol in chapter 2.2. Three independent experiments (Exp1, 2 
and 3) were performed for each M.smegmatis and M.bovis BCG by treating them with different 
concentrations of Hexanolamino PAF (10µg, 25µg, 50µg and 100µg/ml of bacterial 
suspension) for 2 hours. A solvent control for Hexanolamino PAF (10µl ethanol/ml bacterial 
suspension) was also included in each experiment. 
The results showed that Hexanolamino PAF was able to inhibit the growth of both 
M.smegmatis and M.bovis BCG in a dose-dependent manner after treatment for 2 hours as 
indicated by a reduction in the number of CFUs when compared with the solvent control. The 
experiments of Hexanolamino PAF with M.smegmatis and Hexanolamino PAF with M.bovis 
BCG showed the same trend of growth inhibition (Figures 4.2.4b, 4.2.4c). The growth 
inhibitory effect of Hexanolamino PAF was more prominent at higher concentrations of 
50µg/ml and 100µg/ml. On average, Hexanolamino PAF treatment of M.smegmatis at 
concentrations of 50µg/ml and 100µg/ml resulted in ~62% and ~95% reduction in the number 
of CFUs respectively when compared to the solvent control (Figure 4.2.4d, graph (i)). In case 
of M.bovis BCG, Hexanolamino PAF treatment at concentrations 50µg/ml and 100µg/ml on 
average caused ~65% and ~94% reduction in the number of CFUs respectively when compared 
to the solvent control (Figure 4.2.4d, graph (ii)). Non-parametric multiple comparison Kruskal 
Wallis test was applied on ranks and the p-value was found to be significant in case of both 
M.smegmatis (p=0.009) and M.bovis BCG (p=0.008). Individual data sets were compared by 
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applying post hoc Dunn’s multiple comparison test and the results were found to be significant 
only for 100µg/ml Hexanolamino PAF vs Solvent control (p≤0.01). 
These results showed that changing the position terminal amino group in the phosphocholine 
head region of PAF C-16 did not affect the growth inhibitory properties against M.smegmatis 



























































































































Figure 4.2.4b: Three independent experiments (Exp1, 2 and 3) for the direct effect of 
Hexanolamino PAF on M.smegmatis growth. Each bar represents the average number of 
M.smegmatis CFUs from triplicate plates and error bar shows standard deviation (SD) of 
triplicates.  
 


























































































































Figure 4.2.4c: Three independent experiments (Exp1, 2 and 3) for the direct effect of 
Hexanolamino PAF on M.bovis BCG growth. Each bar represents the average number of 
M.smegmatis CFUs from triplicate plates for solvent control and test conditions and error bar 
shows standard deviation (SD) of the triplicates. 
 







































































(ii) Hexanolamino PAF and M.bovis BCG
























Figure 4.2.4c: Direct effect of Hexanolamino PAF on M.smegmatis and M.bovis BCG growth. 
Each bar represents the average of three independent experiments and the error bars show the 
standard error of means (SEM). Data is expressed in terms of percentage survival where solvent 
control is taken as 100% survival and different test conditions are compared to it. The p-value 
was found to be significant in case of both M.smegmatis (p=0.009) and M.bovis BCG (p=0.008) 
and was determined by applying non-parametric Kruskal-Wallis test on ranks. Individual data 
sets were compared using Dunn’s multiple comparison test and 100µg/ml Hexanolamino PAF 
vs Solvent control was significant for both M.smegmatis and M.bovis BCG **(p≤0.01). 
 
4.2.5 Direct effect of 2-O-methyl PAF C-16 on M.smegmatis and M.bovis BCG growth in 
vitro 
2-O-methyl PAF C-16 is a synthetic PAF C-16 analogue. This structure analogue has a methyl 
group at the sn-2 position instead of acetyl group. Chemically it is known as 1-O-hexadecyl-2-
O-methyl-sn-glyceryl-3-phosphocholine (Figure 4.2.5a) 
 




Figure 4.2.5a: Chemical structure of 2-O-methyl PAF. The red circle shows a methyl group 
attached at position sn-2 instead of an acetyl group. 
The direct effect of 2-O-methyl PAF on the growth of M.smegmatis and M.bovis BCG was 
investigated according to the protocol in chapter 2.2. Three independent experiments (Exp1, 2 
and 3) were performed with each M.smegmatis and M.bovis BCG, by treating them with 
different concentrations of 2-O-methyl PAF (10µg, 25µg, 50µg and 100µg/ml of bacterial 
suspension) for 2 hours. A solvent control for 2-O-methyl PAF (10µl ethanol/ml bacterial 
suspension) was included in each experiment. 
It was observed that 2-O-methyl PAF was able to inhibit the growth of both M.smegmatis and 
M.bovis BCG in a dose-dependent manner after treatment for 2 hours as indicated by a 
reduction in the number of CFUs when compared to the solvent control. All the experiments 
of 2-O-methyl PAF with M.smegmatis and 2-O-methyl PAF with M.bovis BCG showed the 
same trend of growth inhibition (Figures 4.2.5b, 4.2.5c). The growth inhibitory effect of 2-O-
methyl PAF was more prominent at higher concentrations of 50µg/ml and 100µg/ml. On 
average, 2-O-methyl PAF treatment of M.smegmatis at concentrations of 50µg/ml and 
100µg/ml resulted in ~61% and ~92% reduction in the number of CFUs respectively as 
compared to the solvent control (Figure 4.2.5d, graph (i)). In case of M.bovis BCG, 2-O-methyl 
PAF treatment at concentrations 50µg/ml and 100µg/ml on average caused ~70% and ~97% 
growth inhibition respectively (Figure 4.2.5d, graph (ii)). The level of significance was 
determined by applying non-parametric multiple comparison Kruskal Wallis test on ranks and 
the p-value was found to be significant in case of both M.smegmatis (p=0.01) and M.bovis BCG 
(p=0.008). Individual data sets were compared by applying post hoc Dunn’s multiple 
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comparison test and the results were found to be significant only for 100µg/ml 2-O-methyl 
PAF vs Solvent control (p≤0.01). 
These results suggested that substituting the acetyl group (CH3O) of PAF C-16 with methyl 






























































































































Figure 4.2.5b: Three independent experiments (Exp1, 2 and 3) for the direct effect of 2-O-
methyl PAF on M.smegmatis growth. Each bar represents the average number of M.smegmatis 
CFUs from triplicate plates for solvent control and test conditions and error bar shows standard 
deviation (SD) of the triplicates. 
 
























































































































Figure 4.2.5c: Three independent experiments (Exp1, 2 and 3) for the direct effect of 2-O-
methyl PAF on M.bovis BCG growth. Each bar represents the average number of M.smegmatis 
CFUs from triplicate plates for solvent control and test conditions and error bar shows standard 
deviation (SD) of the triplicates. 
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(ii) 2-O-methyl PAF and M.bovis BCG
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Figure 4.2.5d: Direct effect of 2-O-methyl PAF C-16 on M.smegmatis and M.bovis BCG 
growth. Each bar represents the average of three independent experiments and the error bars 
show the standard error of means (SEM). Data is expressed in terms of percentage survival 
where solvent control is considered as 100% survival and different test conditions are compared 
to it. p-value was determined by applying non-parametric Kruskal-Wallis test on ranks and was 
found to be significant in case of both M.smegmatis (p=0.01) and M.bovis BCG (p=0.008). 
Individual data sets were compared using Dunn’s multiple comparison test and 100µg/ml 2-O-
methlyl PAF vs Solvent control was significant for both M.smegmatis and M.bovis BCG 
**(p≤0.01). 
 
4.2.6 Direct effect of Pyrrolidino PAF on M.smegmatis growth in vitro 
Pyrrolidino PAF C-16 is a synthetic analogue of PAF C-16. Chemically it is known as 1-O-
hexadecyl-2-O-acetyl-sn-glyceryl-3-phosphoryl-N-methyl-pyrrolodinium ethanol and has 5-
member lactam ring attached to the phosphate group (Figure 4.2.6) 
 
 




Figure 4.2.6a: Chemical structure of Pyrrolidino PAF. The red circle shows the 5-membered 
lactam ring attached to the phosphate group instead of an amino group in the phosphocholine 
head portion of the compound. 
The direct effect of Pyrrolidino PAF on the growth of M.smegmatis was investigated according 
to the protocol in chapter 2.2. Three independent experiments (Exp1, 2 and 3) were performed 
by treating M.smegmatis with different concentrations of Pyrrolidino PAF (10µg, 25µg, 50µg 
and 100µg/ml of bacterial suspension) for 2 hours. A solvent control for Pyrrolidino PAF (10µl 
ethanol/ml bacterial suspension) was also included in the experiment. 
It was observed that Pyrrolidino PAF was able to inhibit the growth of M.smegmatis in a dose-
dependent manner after treatment for 2 hours as indicated by the reduction in the number of 
CFUs when compared with the solvent control. All the experiments of Pyrrolidino PAF with 
M.smegmatis showed the same trend of growth inhibition (Figure 4.2.6b). The growth 
inhibitory effect of Pyrrolidino PAF against M.smegmatis was more prominent at higher 
concentrations of 50µg/ml and 100µg/ml and on average caused ~58% and ~98% growth 
inhibition of M.smegmatis respectively (Figure 4.2.6c). The level of significance was 
determined by applying non-parametric multiple comparison Kruskal Wallis test on ranks and 
the p-value was found to be significant, p=0.008. Individual data sets were compared by 
applying post hoc Dunn’s multiple comparison test and the results were found to be significant 
only for 100µg/ml Pyrrolidino PAF vs Solvent control (p≤0.01). 
These experiments suggested that replacing the terminal group of PAF C-16 with a 5 member 
lactam ring did not affect the growth inhibitory properties of PAF C-16. 




























































































































Figure 4.2.6b: Three independent experiments (Exp1, 2 and 3) for the direct effect of 
Pyrrolidino PAF on M.smegmatis growth. Each bar represents the average number of 
M.smegmatis CFUs from triplicate plates for solvent control and test conditions and error bar 
shows standard deviation (SD) of the triplicates. 
 














































Pyrrolidino PAF and M.smegamtis
 
Figure 4.2.6c: Direct effect of Pyrrolidino PAF on M.smegmatis growth. Each bar represents 
the average of three independent experiments and the error bars show the standard error of 
means (SEM). Data is expressed in terms of percentage survival where solvent control is taken 
as 100% survival and different test conditions are compared to it. p-value was determined by 
applying non-parametric Kruskal-Wallis test on ranks and was found to be significant 
(p=0.008). Individual data sets were compared using Dunn’s multiple comparison test and 
100µg/ml Pyrrolidino PAF vs Solvent control was found to be significant **(p≤0.01). 
4.3 Comparison of growth inhibitory potential of PAF C-16 and various PAF C-16 
structural analogues against M.smegmatis and M.bovis BCG 
PAF C-16 and different PAF C-16 structure analogues were compared to check the effect of 
small modifications in structure of PAF C-16 on the growth inhibitory potency against both 
M.smegmatis and M.bovis BCG. However, similar levels of M.smegmatis and M.bovis BCG 
growth inhibition were observed for PAF C-16 and all the analogues tested, suggesting that 
these small modification in structure of PAF C-16 do not decrease its mycobacterial growth 
inhibition potency (Figure 4.3a and 4.3b).  




Figure 4.3a: Comparison of M.smegmatis growth inhibition by PAF C-16 and different PAF 
analogues in vitro. The data is expressed as percentage where solvent control is considered as 
100% survival. Each data point represents the average number of M.smegmatis CFUs from 
three individual experiments for test compounds (in µM concentrations) and solvent control 
and the error bars show the standard errors of mean (SEM). 
 
Figure 4.3b: Comparison of M.bovis BCG growth inhibition by PAF C-16 and different PAF 
structural analogues in vitro. The data is expressed as percentage where solvent control is 
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considered as 100% survival. Each data point represents the average number of M.bovis BCG 
CFUs from three individual experiments at different concentrations of test compounds (in µM 
concentrations) and a solvent control and the error bars show the standard errors of mean 
(SEM). 
 
4.4 Structural dissection of PAF C-16 to localize the active portion involved in 
mycobacterial growth inhibition 
In order to localize the active portion of PAF C-16 that contributes to its growth inhibitory 
properties against mycobacteria, compounds with chemical structures similar to different 
portions of PAF C-16 were investigated for their direct growth inhibitory activity using 
M.smegmatis as model organism. Different compounds tested in this study for their direct 
growth inhibitory activity included: 
a) Palmitic acid 
b) Phosphocholine chloride calcium tetrahydrate salt 
c) 1-O-Hexadecyl-sn-glycerol 
d) Miltefosine 
e) Hexadecyl lactate 
f) Palmitoleic Acid and Oleic Acid 
 
4.4.1 Direct effect of Palmitic acid on M.smegmatis growth in vitro 
Palmitic acid is also known as hexadecanoic acid and comprises of a linear 16carbon atoms 
chain attached to a carboxyl group (Figure 4.4.1a). The carbon chain in palmitic acid does not 
contain any double bonds chain and is similar to the carbon tail of PAF C-16 in the number of 
carbon atoms. Therefore, palmitic acid was tested for its growth inhibition activity against 
M.smegmatis to investigate the role of PAF C-16 carbon tail in its growth inhibition activity. 
 




Figure 4.4.1a: Chemical structure of palmitic acid. The carbon chain contains 16 carbon atoms 
with no double bonds and is similar to that of PAF C-16. 
Three independent experiments (Exp1, 2 and 3) were performed in vitro to investigate the direct 
inhibitory effect of palmitic acid on M.smegmatis growth using different concentrations of 
palmitic acid (10µg, 25µg, 50µg and 100µg/ml of bacterial suspension) and a solvent control 
for palmitic acid (10µl ethanol/ml of bacterial suspension) according to the protocol mentioned 
in section 2.2.  
All the three experiments showed the same trend and it was observed that palmitic acid in 
concentrations of up to 100µg/ml was unable to directly inhibit the growth of M.smegmatis as 
indicated by the number of CFUs which was similar to the solvent control. Treatment of 
palmitic acid with M.smegmatis in fact caused in a slight increase in the number of 
M.smegmatis CFUs as compared to the solvent control (Figures 4.4.1b and 4.4.1c). These 
results suggested that the carbon tail of PAF C-16 on its own does not possess bacterial growth 
inhibition potential. 




























































































































Figure 4.4.1b: Three individual experiments (Exp1, 2 and 3) for the direct effect of palmitic 
acid on M.smegmatis growth. Each bar represents the average number of M.smegmatis CFUs 
from triplicate plates for solvent control and test conditions and error bar shows standard 
deviation (SD) of the triplicates. 
 
 













































Palmitic acid and M.smegmatis
 
Figure 4.4.1c: Direct effect of palmitic acid on M.smegmatis growth. Each bar represents the 
average of three independent experiments and the error bars show the standard error of means 
(SEM). Data is expressed in terms of percentage where solvent control is considered as 100% 
survival and different test conditions are compared to it. p-value was calculated by applying 
non-parametric Kruskal-Wallis test on ranks and was found to be non-significant (p=0.14). 
 
4.4.2 Direct effect of Phosphocholine chloride calcium tetrahydrate on M.smegmatis 
growth in vitro 
Phosphocholine chloride calcium tetrahydrate is similar in structure to the phosphocholine head 
portion of PAF C-16 that is attached at position sn-3 of the glycerol backbone (Figure 4.4.2a). 
Phosphocholine chloride calcium tetrahydrate was, therefore, tested for its direct inhibitory 
effect on M.smegmatis to investigate the role of phosphocholine head portion of PAF C-16 in 
its growth inhibition activity against mycobacteria. 
 




Figure 4.4.2a: Chemical structure of Phosphocholine chloride calcium tetrahydrate. This 
compound has a similar structure to the phosphocholine head portion of PAF C-16. 
Three independent experiments (Exp1, 2 and 3) were performed according to the protocol in 
section 2.2 to investigate the direct inhibitory effect of phosphocholine chloride calcium 
tetrahydrate on M.smegmatis growth in different concentrations (10µg, 25µg, 50µg and 
100µg/ml of bacterial suspension). A solvent control for phosphocholine chloride calcium 
tetrahydrate (20µl water/ml of bacterial suspension) was also included in each experiment.  
All the three experiments showed that phosphocholine chloride calcium tetrahydrate had no 
direct inhibitory effect on M.smegmatis growth in concentrations of up to 100µg/ml as 
indicated by the similar number of CFUs when compared with the solvent control. These results 
suggested that the phosphocholine head portion of PAF C-16 on its own does not possess the 
bacterial growth inhibition activity of PAF C-16 (Figure 4.4.2b and 4.4.2c). 
 
































































































































Figure 4.4.2b: Three individual experiments (Exp1, 2 and 3) for the direct effect of 
phosphocholine chloride calcium tetrahydrate on M.smegmatis growth. Each bar represents the 
average number of M.smegmatis CFUs from triplicate plates for solvent control and test 
conditions and error bar shows standard deviation (SD) of the triplicates.  
 























Phosphocholine chloride calcium salt and M.smegmatis























Figure 4.4.2c: Direct effect of Phosphocholine chloride calcium salt on M.smegmatis growth. 
Each bar represents the average of three independent experiments performed and the error bars 
show the standard error of means (SEM). Data is expressed in terms of percentage where 
solvent control is considered as 100% survival and different test conditions are compared to it. 
Multiple-comparison non-parametric Kruskal-Wallis test was applied on ranks and the p-value 
was non-significant (p=0.88). 
 
4.4.3 Direct effect of 1-O-hexadecyl-sn-glycerol on M.smegmatis growth in vitro 
1-O-hexadecyl-sn-glycerol is an ether lipid with a 16 carbon atoms chain. This compounds is 
similar to PAF C-16 as it contains a glycerol backbone with a 16 carbon atoms chain attached 
to it via an ether bond (Figure 4.4.3a). 
 




Figure 4.4.3a: Chemical structure of 1-O-hexadecyl-sn-glycerol. The compound contains a 16 
carbon atoms chain attached to the glycerol backbone via an ether bond.   
The direct effect of 1-O-hexadecyl-sn-glycerol on the growth of M.smegmatis was investigated 
according to the protocol in chapter 2.2. Three independent experiments (Exp1, 2 and 3) were 
performed by treating different concentrations of 1-O-hexadecyl-sn-glycerol (10µg, 25µg, 
50µg and 100µg/ml of bacterial suspension) with M.smegmatis for 2 hours. A solvent control 
for 1-O-hexadecyl-sn-glycerol (10µl ethanol/ml bacterial suspension) was also included in 
each experiment. 
It was observed that 1-O-hexadecyl-sn-glycerol was able to inhibit the growth of M.smegmatis 
in a dose-dependent manner as indicated by a reduction in the number of CFUs when compared 
to the solvent control. All the experiments of 1-O-hexadecyl-sn-glycerol with M.smegmatis 
showed the same trend of growth inhibition (Figure 4.4.3b). On average, 1-O-hexadecyl-sn-
glycerol at concentrations of 25µg/ml, 50µg/ml and 100µg/ml caused a reduction of ~42% 
~63% and ~83% in the number of M.smegmatis CFUs respectively (Figure 4.4.3c). The level 
of significance was determined by applying non-parametric multiple comparison Kruskal 
Wallis test on ranks and the p-value was found to be significant, p=0.008. Individual data sets 
were compared by applying post hoc Dunn’s multiple comparison test and the results were 
found to be significant only for 100µg/ml 1-O-hexadecyl-sn-glycerol vs Solvent control 
(p≤0.01). 
 





























































































































Figure 4.4.3b: Three individual experiments (Exp1, 2 and 3) for the direct effect of 1-O-
hexadecyl-sn-glycerol on M.smegmatis growth. Each bar represents the average number of 
M.smegmatis CFUs from triplicate plates for solvent control and test conditions and error bar 
shows standard deviation (SD) of the triplicates. 
 
 















































Figure 4.3.3c: Direct effect of 1-O-hexadecyl-sn-glycerol on M.smegmatis growth. Each bar 
represents the average of three independent experiments and the error bars show the standard 
error of means (SEM). Data is expressed in terms of percentage survival where control is taken 
as 100% survival and different test conditions are compared to it. Multiple-comparison of the 
data sets was performed using non-parametric Kruskal-Wallis test (p=0.008). Individual data 
sets were compared using Dunn’s multiple comparison test and only for 100µg/ml 1-O-
hexadecyl-sn-glycerol vs Solvent control was found to be significant **(p≤0.01). 
 
4.4.4 Direct effect of Miltefosine on M.smegmatis growth in vitro 
Miltefosine is an alkyl-phosphocholine, chemically known as hexadecyl phosphocholine or 
Hexadecyl 2-(trimethylammonio)ethyl phosphate. Miltefosine consists of a 16 carbon atoms 
chain with no double bonds attached to the phosphate group of a phosphocholine head by ester 
bond (Figure 4.4.4a). Structurally miltefosine is similar to PAF C-16 as it contains a 16 carbon 
atoms chain and a phosphocholine portion, however, it lacks the glycerol backbone and the 
acetyl group of PAF C-16.   
 




Figure 4.4.4a: Chemical structure of miltefosine. Miltefosine has a 16 carbon atoms chain 
attached via ester bond to the phosphate group of phosphocholine portion. 
The direct effect of miltefosine on the growth of M.smegmatis was investigated according to 
the protocol in chapter 2.2. Three independent experiments (Exp1, 2 and 3) were performed by 
treating different concentrations of miltefosine (10µg, 25µg, 50µg and 100µg/ml of bacterial 
suspension) with M.smegmatis for 2 hours. A solvent control for miltefosine (20µl water/ml 
bacterial suspension) was also included in each experiment. 
It was observed that miltefosine was able to inhibit the growth of M.smegmatis in a dose-
dependent manner as indicated by a reduction in the number of CFUs when compared with the 
solvent control. All the experiments of miltefosine with M.smegmatis showed the same trend 
of growth inhibition (Figure 4.4.4b). On average, miltefosine at concentrations of 25µg/ml, 
50µg/ml and 100µg/ml caused ~70% ~89% and ~99% reduction in the number of M.smegmatis 
CFUs respectively when compared with the number of CFUs for solvent control (Figure 
4.4.4c). The level of significance was determined by applying non-parametric multiple 
comparison Kruskal Wallis test on ranks and the p-value was found to be significant, p=0.008. 
Individual data sets were compared by applying post hoc Dunn’s multiple comparison test and 
the results were found to be significant only for 50µg/ml miltefosine vs Solvent control 


































































































































Figure 4.4.4b: Three independent experiments (Exp1, 2 and 3) for the direct effect of 
miltefosine on M.smegmatis growth. Each bar represents the average number of M.smegmatis 
CFUs from triplicate plates for solvent control and test conditions and error bar shows standard 
deviation (SD) of the triplicates. 
 

















































Figure 4.4.4c: Direct effect of miltefosine on the growth of M.smegmatis. Each bar represents 
the average of three independent experiments and the error bars show the standard error of 
mean (SEM). Data is expressed in terms of percentage survival where control is taken as 100% 
and different test conditions are compared to it. Non-parametric multiple comparison Kruskal-
Wallis test was applied on ranks and was p-value was found to be significant, p=0.008. 
Individual data sets were compared using Dunn’s multiple comparison test, where 50µg/ml 
miltefosine vs Solvent control *(p≤0.05) and 100µg/ml miltefosine vs Solvent control 
**(p≤0.01) were found to be significant. 
 
4.4.5 Direct effect of Hexadecyl lactate on M.smegmatis growth in vitro 
Hexadecyl lactate consists of a 16 carbon atoms chain with no double bonds attached to a lactyl 
group via ester linkage (Figure 4.4.5a). This compounds contains a similar length carbon chain 
to PAF C-16, however, the carbon chain differs from PAF C-16 in its attachment as it is 
attached via ester linkage.  




Figure 4.4.5a: Chemical structure of hexadecyl lactate. Hexadecyl lactate has a 16 carbon 
atoms chain attached by ester bond to a lactyl group. 
Three independent experiments (Exp1, 2 and 3) were performed to investigate the effect of 
hexadecyl lactate on the growth of M.smegmatis according to the protocol in chapter 2.2. 
Hexadecyl lactate in different concentrations (10µg, 25µg, 50µg and 100µg/ml of bacterial 
suspension) was treated with M.smegmatis for 2 hours. A solvent control for hexadecyl lactate 
(10µl DMSO/ml bacterial suspension) was also included in all the experiments. 
It was observed that hexadecyl lactate was able to inhibit the growth of M.smegmatis in a dose-
dependent manner as indicated by a reduction in the number of CFUs when compared with the 
solvent control. All the experiments of hexadecyl lactate with M.smegmatis showed the same 
trend of growth inhibition (Figure 4.4.5b). On average, hexadecyl lactate at concentrations of 
50µg/ml and 100µg/ml caused a reduction of ~50% and ~83% in the number of M.smegmatis 
CFUs respectively (Figure 4.4.5c). The level of significance was determined by applying non-
parametric multiple comparison Kruskal Wallis test on ranks and the p-value was found to be 
significant, p=0.008. Individual data sets were compared by applying post hoc Dunn’s multiple 
comparison test and the results were found to be significant only for 100µg/ml hexadecyl 
lactate vs Solvent control (p≤0.01). 
 


























































































































Figure 4.4.5b: Three independent experiments (Exp1, 2 and 3) for the direct effect of hexadecyl 
lactate on the growth of M.smegmatis. Each bar represents the average number of M.smegmatis 
CFUs from triplicate plates for solvent control and test conditions and error bar shows standard 
deviation (SD) of the triplicates. 
 















































Hexadecyl lactate and M.smegmatis
 
Figure 4.3.5c: Direct effect of Hexadecyl lactate on the growth of M.smegmatis. Each bar 
represents the average of three individual experiments and the error bars show the standard 
error of means (SEM). Data is expressed in terms of percentage survival where control is taken 
as 100% and different test conditions are compared to it. Non-parametric multiple comparison 
Kruskal-Wallis test was applied on ranks and was p-value was found to be significant, p=0.008. 
Individual data sets were compared using Dunn’s multiple comparison test, where 100µg/ml 
hexadecyl lactate vs Solvent control **(p≤0.01) was found to be significant. 
 
4.4.6 Direct effect of Palmitoleic acid and Oleic acid on M.smegmatis growth in-vitro 
To investigate effect of conformational changes in the aliphatic carbon chain on the bacterial 
growth inhibition activity, two unsaturated fatty acids, palmitoleic acid and oleic acid were 
used. These compounds comprise of 16 carbon atoms and 18 carbon atoms chains respectively 
which are attached to a carboxyl group. Both these compounds contain a single double bond 
which changes the linear structure of the carbon chain to bend and induces a kink in these 
compounds (Figure 4.4.6a). 




Figure 4.4.6a: Chemical structure of Palmitoleic acid and Oleic acid. The portion in red circle 
shows the double bond between two carbon atoms of the aliphatic tail which causes the carbon 
chain to bend. 
To check the effect of presence of double bond in the carbon tail on growth of M.smegmatis, 
palmitoleic acid and oleic acid in concentrations of 10µg, 25µg, 50µg and 100µg/ml and a 
solvent control (10µl ethanol/ml of bacterial suspension) were directly treated with 
M.smegmatis according to the protocol in section 2.2. It was observed that both these 
compounds were able to inhibit M.smegmatis growth even at the lowest concentration of 
10µg/ml (Figure 4.4.5b). These results suggested that changes in the confirmation of the carbon 
chain can contribute to it bacterial growth inhibition potential of compounds.  
 


















































































Figure 4.4.6b: Direct effect of palmitoleic acid and oleic acid on M.smegmatis growth. Each 
bar represents the average number of M.smegmatis CFUs from triplicate plates and error bar 
shows standard deviation (SD) of triplicates. The graphs show that both palmitoleic acid and 
oleic acid are effective inhibitors of M.smegmatis growth. 
 
4.5 Effect of PAF C-16 treatment on mycobacterial cell membrane 
Microscopy and flow cytometry using cell viability dyes such as Trypan blue and Propidium 
iodide (PI) were performed to investigate the effect of PAF C-16 treatment on mycobacterial 
cell membrane. 
4.5.1 Light Microscopy with PAF C-16 treated M.smegmatis and M.bovis BCG 
Trypan blue is a cell viability dye that stains only the bacteria with damaged cell membranes. 
M.smegmatis and M.bovis BCG were treated with PAF C-16 (100µg/ml) and solvent control 
for PAF C-16 (10µl ethanol/ml) for 4 hours were stained with trypan blue according the 
protocol mentioned in chapter 2.3.1.  
The effect of PAF C-16 treatment on the mycobacterial cell membrane was detected by 
visualizing both PAF C-16 treated and solvent control M.smegmatis and M.bovis BCG at a 
400X magnification using a light microscope. PAF C-16 treated M.smegmatis and M.bovis 
BCG showed positive staining with trypan blue whereas the bacteria in the solvent control 
remained unstained (Figure 4.5.1a and 4.5.1b). These results suggested that PAF C-16 
treatment has a damaging effect on the mycobacterial cell membrane that makes the bacteria 
permeable to the otherwise impermeable trypan blue dye. Moreover, the PAF C-16 treated 
mycobacteria appeared fragmented suggesting cell death. 




Figure 4.5.1a: Trypan blue staining of M.smegmatis to detect cell membrane damage. 
Microscopic images of M.smegmatis at 400X magnification. Slide (A) is the solvent control: 
10µl ethanol/ml of bacterial suspension. The rod shaped M.smegmatis have not taken any dye, 
suggesting that the cell membrane is intact. Slide (B) is PAF C-16 treated test: 100µg PAF C-
16/ml of bacterial suspension. PAF C-16 treated M.smegmatis appeared blue indicating entry 
of trypan blue in to the cell suggesting damage to the cell membrane of M.smegmatis. 
Moreover, the bacteria appeared fragmented indicating cell death. 
 
 
Figure 4.5.1b: Trypan blue staining of M.bovis BCG to detect cell membrane damage. 
Microscopic images of M.bovis BCG at 400X magnification. Slide (A) is the solvent control: 
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10µl ethanol/ml of bacterial suspension. There is no positive staining of the bacteria suggesting 
the cell membrane is intact. Slide (B) is PAF C-16 treated test: 100µg PAF C-16/ml of bacterial 
suspension. PAF C-16 treated M.bovis BCG appeared blue due entry of trypan blue suggesting 
damage to the cell membrane and also appeared to be fragmented. 
 
4.5.2 Fluorescence microscopy with PAF C-16 treated M.smegmatis and M.bovis BCG 
The results from light microscopy indicating that PAF C-16 treatment has a damaging effect 
on M.smegmatis and M.bovis BCG cell membrane were re-confirmed by performing 
fluorescence microscopy. PAF C-16 treated (100µg/ml) and control M.smegmatis and M.bovis 
BCG were stained with a nucleic acid binding dye, Propidium Iodide (PI) according to the 
protocol in chapter 2.3.2 and the bacteria were visualised by using the bright field and the CY3 
channels of a Leica DM4000® microscope. 
It was observed that most of the M.smegmatis and M.bovis BCG treated with PAF C-16 
(100µg/ml) for 2 hours were positively stained with PI whereas, no PI staining was detected in 
the solvent control M.smegmatis and M.bovis BCG (Figure 4.5.2a and 4.5.2b). Heat treated 
(100°C for 10min) M.smegmatis and M.bovis BCG were included as positive control for PI 
staining in each experiment. These fluorescent microscopy results showing the entry of PI in 
PAF C-16 treated mycobacteria suggested that PAF C-16 had a damaging effect on the 
mycobacterial cell membrane. 
 





Figure 4.5.2a: PI staining of M.smegmatis to detect cell membrane damage. Each slide shows 
a merger for M.smegmatis in Bright field channel and CY3 channel (PI) at 400X magnification. 
Side A is the solvent control (10µl ethanol/ml of bacterial suspension) where majority of the 
bacteria remained unstained. Slide B shows heat treated (100oC for 10 minutes) M.smegmatis, 
used as a positive control and almost all M.smegmatis showed positive staining for PI. Slide C 
shows M.smegmatis after treatment with 100µg/ml PAF C-16 for 2 hours and most of 
M.smegmatis showed positive staining for PI suggesting PAF C-16 has damaging effect on 
M.smegmatis cell membrane. 
 
(A)Solvent Control (B)Heat treated 
(C) PA C-16 treated 





Figure 4.5.2b: PI staining of M.bovis BCG to detect cell membrane damage. Each slide shows 
a merger of Bright field channel and CY3 channel (PI) for M.bovis BCG at 400X magnification. 
Slide A is the solvent control (10µl ethanol/ml of bacterial suspension). The bacterial cell 
membrane is intact and no PI staining was observed. Slide B shows heated treated (100oC for 
10 minutes) M.bovis BCG used as a positive control where majority of bacteria appeared red 
indicating the entry of PI into the cell. Slide C shows PAF C-16 (100µg/ml) treated M.bovis 
BCG. PAF C-16 treatment caused an increase in number of M.bovis BCG to be stained 
positively with PI as compared to solvent control suggesting that PAF-C16 causes membrane 





(A)Solvent Control (B)Heat treated 
(C)PAF C-16 treated 
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4.5.3 Flow cytometry analysis of PAF-C16 treated M.smegmatis and M.bovis BCG 
To quantitate the number of M.smegmatis and M.bovis BCG with damaged cell membrane due 
PAF C-16 treatment, flow cytometry was performed. Nucleic acid binding fluorescent dye, PI 
was used to detect the cell membrane integrity of M.smegmatis and M.bovis BCG. Bacteria that 
showed positive staining for PI were considered dead or injured due to the damage to their cell 
membrane and all the unstained cells with intact cell membrane were considered healthy. 
Three independent flow cytometry experiments were performed with both M.smegmatis and 
M.bovis BCG according to the protocol in chapter 2.4. For each PAF C-16 (100µg/ml) treated, 
solvent control (10µl ethanol/ml) and heat (100oC for 10 minutes) treated M.smegmatis or 
M.bovis BCG, 20,000- 30,000 events were collected and the data was analysed using 
NovoExpress® software.  
Density plots showing the percentage of PI stained and unstained bacteria were generated for 
PAF C-16 treated and control conditions. It was observed that PAF C-16 treatment of 
M.smegmatis at a concentration of 100µg/ml for 2 hours resulted in 49.8% M.smegmatis to be 
positively stained with PI as compared to the solvent control where only 2.0% of M.smegmatis 
were PI positive (Figure 4.5.3a). Similarly, 41.0% M.bovis BCG were stained positively with 
PI after treatment with PAF C-16 (100µg/ml) for 2 hours as compared to the solvent control 
where only 2.0% of M.bovis BCG showed positive staining for PI (Figure 4.5.3b).  
Furthermore, the histogram overlay showed peak shift in case of both PAF C-16 treated 
M.smegmatis and M.bovis BCG when compared to solvent control (Figure 4.5.3c). The values 
of mean channel fluorescence for PI (MeanX) were higher for PAF C-16 treated bacteria as 
compared to the solvent control. For M.smegmatis, the MeanX for solvent control was 74 which 
increased to 318 after treatment with 100µg/ml PAF C-16. Similarly for M.bovis BCG, the 
MeanX for solvent control was 7 which increased to 135 when the bacteria were treated with 
100µg/ml PAF C-16.     




Figure 4.5.3a: Flow cytometry density plots for PI stained M.smegmatis. Slide A is the density 
plot for solvent control M.smegmatis (10µl ethanol/ml). Slide B is the density plot for heat 
treated (100oC for 10 minutes) positive control M.smegmatis. Slide C is the density plot for 
PAF C-16 treated M.smegmatis (100µg/ml). Each plot shows the percentage of PI stained (Q2-
1) and unstained (Q2-3) M.smegmatis in quadrants. X-axis shows the forward scatter indicating 
cell size and Y-axis shows the fluorescence intensity for PI.  




Figure 4.5.3b: Flow cytometry density plots for PI stained M.bovis BCG. Slide A is the density 
plot for solvent control M.bovis BCG (10µl ethanol/ml). Slide B is the density plot for heat 
treated (100oC for 10 minutes) positive control M.bovis BCG. Slide C is the density plot for 
PAF C-16 treated M.bovis BCG (100µg/ml). Each plot shows the percentage of PI stained (Q2-
1) and unstained (Q2-3) M.smegmatis in quadrants. X-axis shows the forward scatter indicating 
cell size and Y-axis shows the fluorescence intensity for PI.  




Figure 4.5.3c: Histogram overlay for PAF C-16 treated and control M.smegmatis and M.bovis 
BCG. The slides A and B shows histogram overlay for controls and PAF C-16 (100µg/ml) 
treated M.smegmatis and M.bovis BCG respectively. X-axis represents the fluorescence 
intensity of PI and Y-axis is the number of events at each intensity value. The red colour graph 
represent solvent control, the green colour graph is for positive control comprising of heat 
treated and the blue colour graph for PAF C-16 treated M.smegmatis or M.bovis BCG. 
 
4.6 Effect of PAF receptor antagonists on PAF-C16 induced growth inhibition 
There are a number of naturally occurring and synthetic compounds that can bind in vivo and 
in vitro to PAF receptor (PAFR) on mammalian cells with high affinity. These compounds are 
known as PAFR antagonists and can potentially abolish the actions of PAF C-16 by blocking 
the PAFR (Singh et al., 2013). 
Two different PAFR antagonists, ABT-491 and WEB-2086 were used in vitro to check if they 
can prevent PAF C-16 induced growth inhibition of M.smegmatis. Three independent 
experiments (Exp1, 2 and 3) were performed with each ABT-491 and WEB-2086 according to 
the protocol in chapter 2.5. M.smegmatis was treated with 100µg/ml of ABT-491 or WEB-
2086 for 1 hour prior to treatment with 50µg/ml and 100µg/ml PAF C-16 for 2 more hours. 
It was observed that both PAFR antagonists, ABT-491 and WEB-2086 were unable to prevent 
PAF C-16 induced growth inhibition of M.smegmatis. The number of CFUs for M.smegmatis 
treated with PAFR antagonist (ABT-491 or WEB-2086) as well as PAF C-16 was similar to 
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the number of CFUs for PAF C-16 only treated bacteria (Figure 4.6a and 4.6b). Furthermore, 
both PAFR antagonists, ABT-491 and WEB-2086 showed no effect on the growth of 




































































































































































































Figure 4.6a: Three individual experiments (Exp1, 2 and 3) showing the effect of ABT-491 on 
PAF C-16 induced M.smegmatis growth inhibition. Each bar represents the average number of 
M.smegmatis CFUs from triplicate plates and error bar shows standard deviation (SD) of 
triplicate. Test 1 consists of 100µg/ml ABT-491 and 50µg/ml PAF C-16. Test 2 consists of 
100µg/ml ABT-491 and 100µg/ml PAF C-16. 













































































































































































































Figure 4.6b: Three individual experiments (Exp1, 2 and 3) showing the effect of WEB-2086 
on PAF C-16 induced M.smegmatis growth inhibition. Each bar represents the average number 
of M.smegmatis CFUs from triplicate plates and error bar shows standard deviation (SD) of 
triplicate. Test 1 consists of 100µg/ml WEB-2086 and 50µg/ml PAF C-16. Test 2 consists of 
100µg/ml WEB-2086 and 100µg/ml PAF C-16. 
 
These results suggested that PAF C-16 might be acting via a different receptor on bacteria as 
compared to mammalian cells or the growth inhibition of bacteria can be through a receptor 
independent mechanism. BLAST search was performed for human PAFR complete coding 
sequence (CDS) against mycobacteria using BLSAT utility tool at NCBI to find a similar 
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nucleotide sequences. However, the results showed no significant nucleotide similarity 
between human PAFR CDS and mycobacteria genome (Figure 4.6c). 
 
 
Figure 4.6c: Nucleotide BLAST for Human Platelet Activing Factor Receptor (PAFR) against 
mycobacteria genome. The figure shows the level of similarity between human PAFR and 
nucleotide sequences similar in mycobacteria. The number of identical nucleotide sequences 
between the genomes is indicated by different colours. 
 
4.7 Effect of phospholipase inhibitors on PAF C-16 induced growth inhibition  
Phospholipase A2 enzyme hydrolyses phospholipids in to short chain fatty acids. These short 
chain fatty acids have a damaging effect on the cell membrane (Balsinde et al., 2002). In order 
to investigate the role of phospholipases in PAF C-16 induced growth inhibition, two 
Phospholipase A2 inhibitors, dexamethasone and benzenesulfonamide were used.  
Three individual experiments (Exp1, 2 and 3) were performed with each dexamethasone and 
benzenesulfonamide respectively according to the protocol in chapter 2.5 to check whether 
these phospholipase inhibitors can prevent PAF C-16 induced growth inhibition in 
M.smegmatis. M.smegmatis was treated with 100µg/ml of dexamethasone or 
benzenesulfonamide for 1 hour prior to treatment with 50µg/ml and 100µg/ml PAF C-16 for 2 
more hours. 
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It was observed that both dexamethasone and benzenesulfonamide were unable to prevent PAF 
C-16 induced growth inhibition of M.smegmatis as indicated by the similarity in number of 
M.smegmatis CFUs for Phospholipase A2 inhibitor (dexamethasone or benzenesulfonamide) 
as well as PAF C-16 treated to the number of CFUs for PAF C-16 only treated condition (Figure 
4.7a and 4.7b). Furthermore, dexamethasone and benzenesulfonamide showed no effect on the 

















































































































































































































Figure 4.7a: Three individual experiments (Exp1, 2 and 3) showing the effect of 
dexamethasone on PAF C-16 induced growth inhibition of M. smegmatis. Each bar represents 
the average number of M.smegmatis CFUs from triplicate plates and error bar shows standard 
deviation (SD) of triplicate. Test 1 consists of 100µg/ml dexamethasone and 50µg/ml PAF C-
16. Test 2 consists of 100µg/ml dexamethasone and 100µg/ml PAF C-16. 





















































































































































































































Figure 4.7b: Three individual experiments (Exp1, 2 and 3) showing the effect of 
benzenesulfonamide on PAF C-16 induced M. smegmatis growth inhibition. Each bar 
represents the average number of M.smegmatis CFUs from triplicate plates and error bar shows 
standard deviation (SD) of triplicate. Test 1 consists of 100µg/ml benzenesulfonamide and 
50µg/ml PAF C-16. Test 2 consists of 100µg/ml benzenesulfonamide and 100µg/ml PAF C-
16. 
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4.8 Effect of exogenous fatty acids on PAF C-16 induced M.smegmatis growth inhibition 
Fatty acid are essential for bacterial survival and are used during the synthesis of bacterial 
membranes (Zheng et al., 2005). Two saturated fatty acids, stearic acid and palmitic acid were 
used to check their effect on the PAF C-16 induced growth inhibition of M.smegmatis. 
Three individual experiments (Exp1, 2 and 3) were performed with each stearic acid and 
palmitic acid respectively according to the protocol in chapter 2.5. M.smegmatis was treated 
with 200µg/ml of stearic acid or palmitic acid for 1 hour prior to treatment with 100µg/ml PAF 
C-16 for 2 more hours. 
It was observed that prior addition of stearic acid or palmitic acid had no effect on the PAF C-
16 induced growth inhibition of M.smegmatis. The results showed that the number of CFUs 
for M.smegmatis treated with both fatty acid (stearic acid or palmitic acid) and PAF C-16 was 
similar to the number of CFUs for PAF C-16 only treated M.smegmatis, suggesting that 
exogenous fatty acids were unable to prevent PAF C-16 induced M.smegmatis growth 











































































































































































Figure 4.8a: Three individual experiments (Exp1, 2 and3) showing the direct effect of stearic 
acid on PAF C-16 induced M.smegmatis growth inhibition. Each bar represents the average 
number of M.smegmatis CFUs from triplicate plates and error bar shows standard deviation 











































































































































































Figure 4.8b: Three individual experiments (Exp1, 2 and 3) showing the effect of palmitic acid 
PAF C-16 induced M.smegmatis growth inhibition. Each bar represents the average number of 
M.smegmatis CFUs from triplicate plates and error bar shows standard deviation (SD) of 
triplicate. Test consists of 200µg/ml palmitic acid and 100µg/ml PAF C-16. 
 
4.9 Effect of α-Tocopherol (Vitamin E) on PAF C-16 induced M.smegmatis growth 
inhibition 
α-tocopherol serves as an antioxidant and can protect cell membrane from free radicals. This 
compound also acts as a membrane stabilizer by forming physiochemical association with the 
fatty acids in the cell membrane giving stability to the membrane and preventing damage of 
the membrane permeability barrier (Topinka et al., 1989; Kagan, 1989). 
The effect of α-tocopherol on PAF C-16 induced M.smegmatis growth inhibition was 
investigated according to the protocol in chapter 2.5. Three independent experiments (Exp1, 2 
and 3) were performed by treating M.smegmatis with 100µg/ml α-tocopherol for 1 hour prior 
to treatment with 50µg/ml and 100µg/ml PAF C-16 for 2 more hours. 
It was observed that prior treatment of M.smegmatis with α-tocopherol was able to partially 
mitigate the inhibitory effect of PAF C-16 on the growth of M.smegmatis. The same trend was 
observed during all three experiments where treatment of M.smegmatis with α-tocopherol prior 
to PAF C-16 increased the number of M.smegmatis CFUs when compared to the number CFUs 
from PAF C-16 only treated M.smegmatis (Figure 4.9a). On average, α-tocopherol treatment 
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at concentrations of 100µg/ml increased the number of M.smegmatis CFUs by 58-60% when 
compared to the number of CFUs from PAF C-16 (100µg/ml) only treated M.smegmatis 
(Figure 4.9b). The level of significance was determined by applying non-parametric Mann 
Whitney test on individual data sets and was found significant for “Test 1” vs 50µg/ml PAF C-












































































































































































































Figure 4.9a: Three individual experiments (Exp1, 2 and 3) showing the effect of α-tocopherol 
on PAF C-16 induced M.smegmatis growth inhibition. Each bar represents the average number 
of M.smegmatis CFUs from triplicate plates and error bar shows standard deviation (SD) of 
triplicate. Test 1 consists of 100µg/ml α-tocopherol and 50µg/ml PAF C-16. Test 2 consists of 
100µg/ml α-tocopherol and 100µg/ml PAF C-16. 










































































Figure 4.9b: Effect of α-tocopherol on PAF C-16 induced growth inhibition of M.smegmatis. 
Each bar represents the average of three independent experiments and the error bars show the 
standard error of mean (SEM). Data is expressed in terms of percentage survival where control 
is taken as 100% and different test conditions are compared to it. Test 1 consists of 100µg/ml 
α-tocopherol and 50µg/ml PAF C-16. Test 2 consists of 100µg/ml α-tocopherol and 100µg/ml 
PAF C-16. Non-parametric Mann Whitney test was used to determine the level of significance 
between individual data sets and the p-value was significant for “Test 1” vs 50µg/ml PAF C-
16 only *(p=0.02) and “Test 2” vs 100µg/ml PAF C-16 only *(p=0.02). 
 
4.10 Effect of Ascorbic acid (Vitamin C) on PAF C-16 induced M.smegmatis growth 
inhibition  
Ascorbic acid is antioxidant in nature and can prevent the plasma membrane from intracellular 
free radical attacks (Bendich et al., 1986). 
Three individual experiments (Exp1, 2 and 3) were performed with ascorbic acid according to 
the protocol in chapter 2.5. M.smegmatis was treated with 100µg/ml ascorbic acid for 1 hour 
prior to treatment with 50µg/ml and 100µg/ml PAF C-16 for 2 hours. It was observed during 
all the experiments ascorbic acid was unable to prevent PAF C-16 induced growth inhibition 
of M.smegmatis (Figure 4.10). The results showed that the number of M.smegmatis CFUs after 
treatment with both ascorbic acid and PAF C-16 was similar to the number of CFUs for PAF 
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C-16 only treated M.smegmatis, suggesting that the inhibitory action of PAF C-16 on 




















































































































































































































Figure 4.10: Three independent experiments (Exp1, 2 and 3) showing the effect of ascorbic 
acid on PAF C-16 induced M.smegmatis growth inhibition. Each bar represents the average 
number of M.smegmatis CFUs from triplicate plates and error bar shows standard deviation 
(SD) of triplicate. Test 1 consists of 100µg/ml ascorbic acid and 50µg/ml PAF C-16. Test 2 
consists of 100µg/ml ascorbic acid and 100µg/ml PAF C-16. 
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4.11 Effect of Tween-80 and Tween-20 on PAF C-16 induced M.smegmatis growth 
inhibition  
Non-ionic surfactants such as Tween-80 and Tween-20 were also investigated as these 
compounds have been shown to reduce the antimicrobial activity of hydrophobic compounds 
such as essential oils and antibiotics like rifampicin (Nielsen et al., 2016). 
The effect of Tween-80 and Tween-20 on PAF C-16 induced M.smegmatis growth inhibition 
was investigated according to the protocol in chapter 2.5. Three independent experiments 
(Exp1, 2 and 3) were performed by treating M.smegmatis with 1% v/v Tween-80 or Tween-20 
for 1 hour prior to treatment with 100µg/ml PAF C-16 for 2 more hours. 
It was observed that prior treatment of M.smegmatis with Tween-80 or Tween-20 was able to 
partially reverse the inhibitory effect of PAF C-16 on the growth of M.smegmatis. The same 
trend was observed during all three experiments where treatment of M.smegmatis with Tween-
80 or Tween-20 prior to PAF C-16 increased the number of M.smegmatis CFUs when 
compared to the number CFUs from PAF C-16 only treated M.smegmatis (Figure 4.11a and 
4.11c). On average, 1% v/v Tween-80 prior treatment increased the number of M.smegmatis 
CFUs by 87% as compared to the number CFUs from PAF C-16 only treated M.smegmatis 
(Figure 4.9b). The level of significance was determined using non-parametric Mann Whitney 
test on individual data sets and was found significant, p=0.02 for “Test” (1% v/v Tween-80 
and 100µg/ml PAF C-16) vs 100µg/ml PAF C-16 only. Similarly, in case of Tween-20 prior 
treatment the number of M.smegmatis CFUs on average increased by 83% as compared to the 
number CFUs from PAF C-16 only treated M.smegmatis (Figure 4.9d). The level of 
significance was determined using non-parametric Mann Whitney test, and was found 
significant, p=0.02 for “Test” (1% v/v Tween-20 and 100µg/ml PAF C-16) vs 100µg/ml PAF 
C-16 only. 
 





















































































































































Figure 4.11a: Three independent experiments (Exp1, 2 and 3) showing the effect of Tween-80 
on PAF C-16 induced M.smegmatis growth inhibition. Each bar represents the average number 
of M.smegmatis CFUs from triplicate plates and error bar shows standard deviation (SD) of 

































































Figure 4.11b: Effect of Tween-80 on PAF C-16 induced growth inhibition of M.smegmatis. 
Data is expressed in terms of percentage survival where control is taken as 100% and different 
test conditions are compared to it. Each bar represents the average of three independent 
experiments and the error bars show the standard error of mean (SEM). Test consists 0f 1% 
v/v Tween-80 and 100µg/ml PAF C-16. Non-parametric Mann Whitney test was used to 
determine the level of significance between individual data sets and the p-value was significant 

























































































































































Figure 4.11c: Three independent experiments (Exp1, 2 and 3) showing the effect of Tween-20 
on PAF C-16 induced growth inhibition of M.smegmatis. Each bar represents the average 
number of M.smegmatis CFUs from triplicate plates and error bar shows standard deviation 
(SD) of triplicate. Test consists of 1%v/v Tween-20 and 100µg/ml PAF C-16. Non-parametric 
Mann Whitney test was used to determine the level of significance between individual data sets 































































Figure 4.11d: Effect of Tween-20 on PAF C-16 induced growth inhibition of M.smegmatis. 
Data is expressed in terms of percentage survival where control is taken as 100% and different 
test conditions are compared to it. Each bar represents the average of three independent 
experiments and the error bars show the standard error of mean (SEM). Test consists 0f 1% v/v 
Tween-20 and 100µg/ml PAF C-16. 
  




After showing the direct inhibitory effect of exogenous PAF C-16 on the growth of 
mycobacteria (M.smegmatis and M.bovis BCG), we investigated the structure-activity 
relationship for PAF C-16 and the mechanism of PAF C-16 induced mycobacterial growth 
inhibition.  
PAF C-16 structure analogues are compounds similar to PAF C-16 but with small structural 
modifications such as variations in functional groups or carbon tail length. Previous studies 
with PAF C-16 analogues in mammalian systems have shown that these small structural 
modifications can affect the activity of PAF C-16 during biological processes such as platelet 
aggregation and macrophage activation (Stewart and Grigoriadis, 1991; O'Flaherty et al., 1983; 
Ténce et al., 1981). To the best of our knowledge, PAF C-16 structure analogues have not been 
investigated for their direct effect on the growth of mycobacteria. Therefore, different PAF C-
16 structure analogues were assessed in vitro for their growth inhibitory potential against 
M.smegmatis and M.bovis BCG. PAF C-16 structure analogues used in this study were selected 
in a way that each analogue represented a change of a different functional group. The results 
showed that all the PAF C-16 structure analogs tested were able to inhibit the growth of both 
M.smegmatis and M.bovis BCG and they showed comparable levels of growth inhibition to 
PAF C-16. 
Lyso-PAF C-16 is the immediate precursor form of naturally produced PAF C-16. It has been 
shown that Lyso-PAF lacks most of the biological activity associated with PAFC-16 such as 
aggregation of platelets, release of serotonin from platelets, pulmonary functions and 
cardiovascular functions (McManus et al., 1981; Cuss et al., 1986). In this study, Lyso-PAF 
was investigated for its direct inhibitory effect on the growth of mycobacteria. The results 
showed that this precursor form was able to inhibit the growth of both M.smegmatis and 
M.bovis BCG in a dose-dependent manner and at levels comparable to PAF C-16. On structural 
level, these results suggested that replacing the acetyl functional group with a hydroxyl group 
at position sn-2 has no effect on the bacterial growth inhibition activity of PAF C-16. Since 
Lyso-PAF is the inactive analogue and does not possess most of the side effects associated with 
PAF C-16, this compound needs further investigation for its anti-M.tb properties. 
Most of the naturally produced PAF occurs as hexadecyl, having a 16-carbon atoms chain 
attached at sn-1 position (Clay et al., 1984). However, there are naturally produced analogues, 
which are octadecyl with 18-carbon atoms chain (Mallet and Cunningham, 1985; Oda et al., 
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1985). Increase in length of carbon chain at position sn-1 has been shown to be associated with 
reduced potency during different biological activities such as neutrophil chemotaxis (Carolan 
and Casale, 1990) and stimulation of cell proliferation in mouse embryos (Stoddart et al., 
2001). Therefore, PAF C-18 was investigated for its direct inhibitory effect on the growth of 
mycobacteria and the results showed that in vitro PAF C-18 was able to inhibit the growth of 
both M.smegmatis and M.bovis BCG in a dose-dependent manner at comparable levels to PAF 
C-16. On a structural level, these results suggested that increase in carbon tail by 2 carbon 
atoms had a no effect on the in vitro bacterial growth inhibition potency. 
Hexanolamino PAF is another important PAF C-16 analogue that differs from PAF C-16 in the 
position of the terminal amino group. In Hexanolamino PAF the terminal amino group is 
attached via 4 additional carbon atoms to the phosphate group. Hexanolamino PAF was 
investigated for its direct growth inhibitory effect against mycobacteria. The results showed 
that in vitro Hexanolamino PAF inhibited the growth of both M.smegmatis and M.bovis BCG 
in a dose-dependent manner. Hexanolamino PAF has previously been shown perform 
biological activities that are different from PAF C-16 and this structure analogue can act as a 
PAF C-16 antagonist or agonist in mammals (Merendino et al., 1999; Rouis et al., 1988). 
However, our result showed Hexanolamino PAF was able to inhibit the growth of both 
M.smegmatis and M.bovis BCG at comparable levels to PAF C-16. On structural level these 
results indicated that the attachment of the terminal amino group to the phosphate group via 4 
additional carbon atoms did not affect the mycobacterial growth inhibition potency. 
Similar results were obtained for two synthetic PAF C-16 analogues: 2-O-methyl PAF and 
Pyrrolidino PAF when tested for their direct growth inhibition activity against mycobacteria. 
In 2-O-methyl PAF, a methyl group substitutes for the acetyl group at position sn-2, whereas 
in Pyrrolidino PAF, the terminal amino group in the phosphocholine head is replaced by a 5-
member lactam ring attached to the phosphate group. The results showed that these 
modifications had no effect on the bacterial growth inhibition activity and both these 
compounds were effective in inhibiting the growth of mycobacteria in a dose-dependent 
manner and at levels similar to PAF C-16.  
 
Structurally, PAF C-16 consists of a glycerol backbone having a 16 carbon atoms chain 
attached via ether bond at position sn-1, an acetyl group at position sn-2 and a phosphocholine 
group attached at sn-3 position (Prescott et al., 1990). Different compounds with structures 
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similar to the phosphocholine head and the aliphatic carbon tail of PAF C-16 were tested to 
localize the structurally active portion of PAF C-16 that might be involved in the bacterial 
growth inhibition using M.smegmatis as a model. Palmitic acid is a saturated fatty acid with a 
16-carbon atoms chain similar to PAF C-16 carbon tail in length and Phosphocholine chloride 
calcium tetra-hydrate salt is similar in structure to the phosphocholine head portion of PAF C-
16. Both these compounds were tested in vitro for their direct growth inhibitory effect against 
M.smegmatis. However, the results showed that both these compounds in concentrations of up 
to 100µg/ml were unable to directly inhibit the growth of M.smegmatis. In fact, treatment of 
M.smegmatis with palmitic acid resulted in a slight growth-enhancing effect, which could be 
due to the utilization of this exogenous fatty acid by the bacteria for the synthesis of its 
phospholipids (Parsons et al., 2011). Another compounds, 1-O-hexadecyl-sn-glycerol was 
tested to investigate the role of 1-O-alkyl chain and ether bond at sn-1 position. 1-O-hexadecyl-
sn-glycerol is similar to PAF C-16 as it consists of a 16 carbon atoms chain attached via ether 
bond to the sn-1 position of a glycerol backbone. The results showed that 1-O-hexadecyl-sn-
glycerol was able to inhibit the growth of M.smegmatis in a dose-dependent manner after 2 
hours of treatment. On structural level these results suggested that the attachment of carbon tail 
to glycerol backbone via ether bond (1-O-alkyl chain) in PAF C-16 might be responsible for 
its bacterial growth inhibition activity. Two additional compounds, miltefosine and hexadecyl 
lactate, each having a 16 carbon atoms chain attached by ester bond were also included in the 
study and investigated in vitro for their direct growth inhibitory effect against M.smegmatis. 
Both miltefosine and hexadecyl lactate also inhibited the growth of M.smegmatis in a dose-
dependent manner, suggesting that the growth inhibition of M.smegmatis is not limited to the 
attachment of carbon chain via ether bond and compounds with a carbon chain attached via 
ester bond also possess mycobacterial growth inhibition potential. To the best of our 
knowledge, there is currently no information about the inhibitory effect of 1-O-hexadecyl-sn-
glycerol, hexadecyl lactate and miltefosine on mycobacterial growth and our results show a 
novel activity for these compounds. Therefore, these compounds need further investigation for 
their direct inhibitory effect on the growth of M.tb and if found effective they have the potential 
to be used as anti-TB drugs. Miltefosine is currently used for the treatment of Leishmaniasis 
(Machado et al., 2010) and has also been shown to inhibit the growth pathogenic bacteria such 
as Streptococcus pneumoniae (Llull et al., 2007) and fungi such as Aspergillus fumigatus and 
Candida species (Biswas et al., 2013; Widmer et al., 2006). 
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PAF C-16 performs most of the biological functions in mammals by its binding to specific G-
protein coupled receptors known as PAF receptor on target cells (Honda et al., 2002). PAF 
receptor antagonists are compounds that bind to PAF receptor on eukaryotic cells with high 
affinity and are effective inhibitors of PAF C-16 induced changes (Singh et al., 2013). 
Currently, there is no information about the presence of any PAF receptor on bacteria. We 
hypothesized that mycobacteria may have a similar PAF receptor to eukaryotic cells and used 
two high-affinity PAF receptor antagonists, ABT-491 and WEB-2086 to check whether they 
can mitigate PAF C-16 induced growth inhibition of M.smegmatis. The results showed that 
prior treatment of PAF receptor antagonists, ABT-491 or WEB-2086 had no effect on the PAF 
C-16 induced growth inhibition of M.smegmatis. The complete sequence of genes coding PAF 
receptor is known in humans (Nakamura et al., 1991). BLAST search for the coding sequence 
of human PAF receptor against mycobacteria genome was performed using the BLAST search 
utility available at NCBI to find similar nucleotide sequences. However, the results did not 
show any significant sequence similarity, suggesting that mycobacteria may possess different 
PAF receptor or the growth inhibition may be through a receptor-independent mechanism. 
Next, the effect of PAF C-16 treatment on mycobacterial morphology was investigated by 
performing microscopy and flow cytometry using cell viability dyes, Trypan Blue and 
Propidium Iodide (PI). The results showed that treatment of M.smegmatis and M.bovis BCG 
with PAF C-16 at a concentration 100µg/ml caused a large number of bacteria to be stained 
with Trypan Blue or PI as compared to the bacteria in solvent control, where little or no staining 
was observed. These results indicated that PAF C-16 had a damaging effect on the cell 
membrane of both M.smegmatis and M.bovis BCG which could be responsible for the growth 
inhibition of these bacteria.  
There are a number of mechanisms through which different compounds can damage bacterial 
cell membrane and lead to their growth inhibition. We first investigated the involvement of 
bacterial Phospholipase A2 (PLA2) enzyme in PAF C-16 induced mycobacterial growth 
inhibition by using PLA2 inhibitors, dexamethasone and benzenesulfonamide. However, the 
results showed that treating M.smegmatis with PLA2 inhibitors, dexamethasone or 
benzenesulfonamide prior to PAF C-16 treatment had no effect on the PAF C-16 induced 
growth inhibitory suggesting that the growth inhibitory effect of PAF C-16 is not through 
activation of bacterial PLA2. In eukaryotes, PLA2 enzyme is involved in lipid digestion, 
microbial degradation, cell signalling, membrane remodelling and inflammation (Murakami 
and Kudo, 2001). PAF C-16 signalling through its receptor can result in the activation of PLA2 
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enzyme in eukaryotic cells (Balsinde et al., 2002). Membrane-bound and secretory forms of 
PLA2 have also been reported in different bacteria such as Helicobacter pylori and 
Campylobacter coli (Istivan and Coloe, 2006; Grant et al., 1997; Slomiany and Slomiany, 
1992). It has been shown that activated PLA2 enzyme can hydrolyse membrane phospholipids 
in mammalian cells resulting in the production of polyunsaturated fatty acids, mostly 
arachidonic acid (Axelrod et al., 1988). Excess hydrolysis of the cell membrane by PLA2 can 
cause damage to the cell membrane. Additionally, the unsaturated fatty acids produced during 
the PLA2 hydrolysis have also been shown to possess cell membrane damaging properties 
(Farooqui et al., 1997).  
Another possible mechanism of damage to the bacterial cell membrane is through inhibition of 
bacterial fatty acid synthase system involved in the production of fatty acid, that are used in 
the synthesis of membrane phospholipids by providing the acyl chains (Zhang et al., 2006; 
Heath et al., 2001). In this study, stearic acid and palmitic acid were used as exogenous sources 
of fatty acids and their effect was investigated on PAF C-16 induced growth inhibition of 
M.smegmatis. However, the results showed that both these saturated fatty acids were unable to 
prevent the growth inhibitory effect of PAF C-16 on M.smegmatis suggesting that PAF C-16 
induced growth inhibition is not through disruption of fatty acid synthesis. Administration of 
exogenous saturated fatty acids such as palmitic acid or stearic acid have been shown to revert 
cell membrane damage in bacteria such as Staphylococcus aureus (Zheng et al., 2005).  
α-tocopherol, a well-known antioxidant (Patra et al., 2001) and membrane stabilizer (Kagan, 
1989) was also investigated for its effect on PAF C-16 induced growth inhibition of 
M.smegmatis. The results showed that prior treatment of M.smegmatis with α-tocopherol 
partially mitigated the growth inhibitory effect of PAF C-16. Since α-tocopherol can function 
both as antioxidant and membrane stabilizer, ascorbic acid another potent antioxidant 
(Padayatty et al., 2003) was also investigated for its effect on PAF C-16 induced M.smegmatis 
growth inhibition. However, ascorbic acid was unable to prevent the growth inhibitory effect 
of PAF C-16. These results suggested that the protective role of α-tocopherol was due to its 
membrane stabilizing activity. It has been shown that α-tocopherol can interact with the 
hydrophobic core of plasma membranes due to its lipid soluble nature through its carbon chain 
and can lead to changes in the physical properties of the lipid membranes such as increase in 
fluidity (Fukuzawa et al., 1980). The chromanol head of α-tocopherol binds to the plasma 
membrane phospholipids acyl chains and limit their mobility within the membrane resulting in 
plasma membrane stabilization (Urano et al., 1988).  
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Two non-ionic surfactants, tween-80 and tween-20 were also investigated for their effect on 
PAF C-16 induced growth of M.smegmatis. The results showed that treatment of M.smegmatis 
with tween-80 or tween-20 prior to PAF C-16 partially abolished the PAF C-16 induced growth 
inhibition of M.smegmatis. Nielsen et al showed that tween-80 treatment decreased the 
antimicrobial activity of hydrophobic compounds including rifampicin and isoeugenol, which 
acts mostly by damaging the bacterial membrane and suggested a protective effect for tween-
80 on bacterial cell membrane (Nielsen et al., 2016). Although most of the biological functions 
associated with PAF C-16 are mediated through PAF receptor on target cells, there are certain 
PAF C-16 activities that are independent of receptor binding. One such PAF C-16 activity is 
its detergent-like effect during which PAF C-16 gets incorporated in lipid membranes and 
disturb the molecular organization of these membrane (lipid-lipid interactions and lipid-protein 
interactions) and hence membrane functions (Sawyer and Andersen, 1989). The mycobacterial 
growth inhibition by PAF C-16 can, therefore, be attributed to its detergent-like effect causing 
damage to the bacterial cell membrane. 
Unsaturated fatty acids (C16:1, C18:1, C20:1) have previously been shown to inhibit the 
growth of different bacteria by damaging the cell membrane (Kanetsuna, 1985; Saito et al., 
1984). In the current study, we also confirmed that unsaturated fatty acids such as palmitoleic 
acid (C16:1) and oleic acid (C18:1) were able to inhibit M.smegmatis growth. The exact 
mechanism of bacterial growth inhibition by unsaturated fatty acid is complex and is still not 
completely understood. One of the proposed mechanisms is the detergent-like activity of 
unsaturated fatty acid due to their amphipathic structure (Boyaval et al., 1995) and the “kink 
effect” (Desbois and Smith, 2010). Unsaturated fatty acids have double bonds between adjacent 
carbon atoms, which cause a bend in the carbon chain by up to 30 degrees. When these 
unsaturated fatty acids interact with the plasma membrane they get inserted in membrane, 
pushing the adjacent phospholipid molecules wide apart due to their kinked structure. As a 
result pores are produced in the cell membrane that ultimately leads to cell death due to changes 
in the osmotic pressure of the cell, efflux of cytoplasmic contents and the influx of water 
(Heipeiper et al., 2003). We, therefore, think that PAF C-16 might be acting through a similar 
mechanism where the polar phosphocholine head at sn-3 and the ether bond at sn-1 produce 
skewness in the PAF C-16 molecule causing the carbon tail to bend. When this skewed PAF 
C-16 molecule interacts with the bacteria, the aliphatic carbon tail is inserted into the bacterial 
cell membrane and the bend in the PAF C-16 causes the lipid molecules in the cell membrane 
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to move apart. As a result, pores are formed in the bacterial cell membrane and the bacterial 
cells are no longer able to maintain their osmotic pressure and ultimately die. 
In conclusion, it was shown that small modification in structure of PAF C-16 had no effect on 
the direct mycobacterial growth inhibition activity of PAF C-16. The attachment of aliphatic 
carbon tail via ether bond at position sn-1 of the glycerol backbone seemed to be important for 
the mycobacterial growth inhibition activity of PAF C-16. PAF C-16 treatment was shown to 
have damaging effect on the mycobacterial cell membrane. Membrane stabilizers such as α-
tocopherol, tween-80 and tween-20 were able to partially mitigate the growth inhibitory effect 
of PAF C-16. In addition, other compounds such as miltefosine and hexadecyl lactate having 
16 carbon atoms chain attached via ester bonds were also shown to be effective in inhibiting 
the growth of M.smegmatis. The data from different compounds investigated for their direct 
growth inhibitory effect against M.smegmatis and M.bovis BCG is summarized in table 4.1. 
Table 4.1: Summary for direct growth inhibitory effect of different compounds used against 












 of M.bovis BCG 
Direct growth 
inhibitory effect on 
other bacteria 
PAF C-16 + + S.aureus 
(Steel et al., 2002) 
Lyso PAF + + S.aureus 
(Steel et al., 2002) 
PAF C-18 + + Not investigated 
2-O-methyl PAF + + Not investigated 
Hexanolamino PAF + + Not investigated 
Pyrrolidino PAF + Not investigated Not investigated 
Palmitic acid _ Not investigated N.gonorrhoeae  




_ Not investigated Not investigated 
1-O-hexadecyl-sn-
glycerol 
+ Not investigated Not investigated 
Miltefosine + Not investigated S.pneumoniae 
( Llull et al., 2007) 
Hexadecyl lactate + Not investigated Not investigated 
Palmitoleic acid + Not investigated S.pyogenes 
( Zheng et al., 2005) 
Oleic acid + Not investigated S.pyogenes 
( Zheng et al., 2005) 
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“+” indicates intracellular growth inhibition and “–” indicates lack of intracellular growth 
inhibition. 
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Chapter 5: Investigating the effect of PAF C-16 and its structural 
analogues on the growth of intracellular mycobacteria and 































PAF C-16 is a phospholipid compound that is involved in a number of important physiological 
processes in mammals, including its well-known function of platelet aggregation (Chesney et 
al., 1982) and key roles in inflammation and allergic responses (Henderson et al., 2000). The 
biological activity of PAF C-16 results from binding to specific G-protein coupled receptors 
known as PAF receptor (PAFR) on target cells (Ishii et al., 2002). This binding leads to the 
activation of different downstream signalling pathways including different kinases such as 
protein tyrosine kinase and protein kinase C pathways, phospholipases activation as well as the 
production of cytokines such as TNF-α, IL-1 etc. and prostaglandins (Honda et al., 2002; Ishii 
and Shimizu, 2000). 
Exogenous PAF C-16 has previously been shown to inhibit the growth of different intracellular 
pathogenic protozoans such as Leishmania and Trypanosoma inside human and mouse 
macrophages by causing the production of reactive oxygen and nitrogen species (Borges et al., 
2017; Lonardoni et al., 2000; Aliberti et al., 1999). Similarly, administration of exogenous 
PAF C-16 in mice infected with lethal doses of Candida albicans reduced the number of the 
pathogens and improved the survival by causing the production of NO and TNF-α in the 
infected hosts (Kim et al., 2008; Im et al., 1997).  
However, to the best of our knowledge, there has been no study that shows the effect of 
exogenous PAF C-16 on the growth on intracellular mycobacteria. Therefore, in this chapter, 
PAF C-16 and a number of PAF C-16 structure analogues were investigated for their effect on 
the growth of intracellular mycobacteria inside human monocytes derived THP-1 cells in vitro.  
Aims: 
1) Investigating in vitro the effect of exogenous PAF C-16 and different PAF C-16 
structure analogues on the growth of intracellular mycobacteria inside phagocytic cells. 
2) Understanding the underlying mechanism of PAF C-16 induced growth inhibition of 
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5.2 Effect of PAF C-16 on M.smegmatis growth inside THP-1 cells 
The effect of exogenous PAF C-16 on the growth of intracellular M.smegmatis was 
investigated according to the protocol in chapter 2.7. Four individual experiments (Exp1, 2, 3 
and 4) were performed by treating M.smegmatis infected THP-1 cells with PAF C-16 in 
concentrations of 1µg, 5µg and 10µg/ml for 24 hours. The effect of PAF C-16 treatment on the 
growth of intracellular M.smegmatis was determined by comparing the number of CFUs from 
different PAF C-16 treated test conditions with the solvent control for PAF C-16 (2µl ethanol 
/ml cell suspension). 
The results showed that PAF C-16 was able to inhibit the growth of intracellular M.smegmatis 
during all four experiments. Furthermore, PAF C-16 treatment at a concentration of 1µg/ml 
showed greater inhibition of intracellular M.smegmatis as compared to 5µg and 10µg/ml 
(Figure 5.2a). On average, PAF C-16 treatment of M.smegmatis infected THP-1 cells at 
concentrations 1µg, 5µg and 10µg/ml resulted in 49.1%, 7.5% and 19.7% decrease in the 
growth of intracellular M.smegmatis respectively as indicated by the number of CFUs when 
compared with the solvent control (Figure 5.2b). The level of significance was determined by 
applying non-parametric multiple comparison Kruskal Wallis test on ranks and the p-value was 
found to be significant, p=0.002. Individual data sets were compared by applying post hoc 





































































































































































Figure 5.2a: Four individual experiments (Exp1, 2, 3, and 4) for the effect of PAF C-16 on 
intracellular M.smegmatis growth. Each bar represents the average number of M.smegmatis 













































Figure 5.2b: Effect of PAF C-16 on the growth of intracellular M.smegmatis. Each bar 
represents the average of four individual experiments and the error bars show standard error of 
means (SEM). The data is expressed in terms of percentage, where solvent control is taken as 
100% survival and different PAF C-16 treated test conditions are compared to it. Level of 
significance was determined by applying non-parametric multiple comparison Kruskal-Wallis 
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test on ranks, p=0.002. Individual data sets were compared through post hoc Dunn’s multiple 
comparison test where PAF C-16 (1µg/ml) vs solvent control was found to be significant, 
***(p≤0.001). 
 
Lower concentrations of PAF C-16 (0.001µg, 0.01µg, 0.1µg and 1µg/ml of cell suspension) 
were also investigated for their inhibitory effect on the growth of intracellular M.smegmatis 
inside THP-1 cells. Four individual experiments (Exp1, 2, 3 and 4) were performed according 
to the protocol in section 2.7. It was observed that treatment of M.smegmatis infected THP-1 
cells with PAF C-16 at concentrations 0.001µg, 0.01µg and 0.1µg/ml for 24 hours had 
insignificant inhibitory effect on the growth of intracellular M.smegmatis as indicated by the 
similar number of CFUs when compared with the solvent control (Figure 5.2c). However, as 
seen previously, treatment of M.smegmatis infected THP-1 cells with PAF C-16 at 1µg/ml 
inhibited the growth of intracellular M.smegmatis during all four experiments (Figure 5.2c). 
On average, PAF C-16 treatment at concentrations 0.1µg/ml and 1µg/ml caused 14.3% and 
58.25% reduction in the number of surviving M.smegmatis CFUs respectively when compared 
to the solvent control (Figure 5.2d). The level of significance was determined by applying non-
parametric multiple comparison Kruskal Wallis test on ranks and the p-value was found to be 
significant, p=0.003. Individual data sets were compared by applying post hoc Dunn’s multiple 






























































































































































































Figure 5.2c: Four individual experiments (Exp1, 2, 3 and 4) for the effect of PAF C-16 (low 
concentrations) on intracellular M.smegmatis growth. Each bar represents the average number 




















































Figure 5.2d: Effect of PAF C-16 on intracellular M.smegmatis growth (low concentrations). 
Each bar represents the average of four individual experiments and the error bars show standard 
error of means (SEM). The data is expressed in terms of percentage, where solvent control is 
taken as 100% survival and different PAF C-16 treated test conditions are compared to it. Level 
of significance was calculated by applying multiple-comparison non-parametric Kruskal-
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Wallis test on ranks, p=0.003 and individual data sets were compared through post hoc Dunn’s 
multiple comparison test where PAF C-16 (1µg/ml) vs solvent control was found to be 
significant, **(p≤0.01). 
 
5.3 Effect of Lyso PAF on M.smegmatis growth inside THP-1 cells 
Lyso PAF is the precursor form PAF C-16 and lacks most of the biological activities associated 
with PAF C-16 (Montrucchio et al., 2000; Aliberti et al., 1999; Pendino et al., 1993). This PAF 
C-16 structural analogue contains a hydroxyl group at position sn-2 instead of an acetyl group 
as shown in figure 4.2.1a. In results chapter 4, Lyso PAF was shown in vitro to inhibit the 
growth of both M.smegmatis and M.bovis BCG directly in a dose-dependent manner. 
Therefore, Lyso PAF was also investigated for its inhibitory effect on the growth of 
intracellular M.smegmatis inside THP-1 cells. 
Four individual experiments (Exp1, 2, 3 and 4) were performed according to the protocol in 
chapter 2.7 by treating Lyso PAF in different concentrations (1µg, 5µg and 10µg/ml of cell 
suspension) with M.smegmatis infected THP-1 cells for 24 hours. During all four experiments, 
Lyso PAF did not show any inhibitory effect on the growth of intracellular M.smegmatis as 
indicated by the similar number of CFUs for Lyso PAF treated test conditions and solvent 
control (Figure 5.3a and 5.3b). Statistical analysis of the data by non-parametric multiple 





































































































































































Figure 5.3a: Four individual experiments (Exp1, 2, 3 and 4) for the effect of Lyso PAF on 
intracellular M.smegmatis growth. Each bar represents the average number of CFUs from 












































Figure 5.3b: Effect of Lyso PAF on intracellular M.smegmatis growth. Each bar represents the 
average of four individual experiments and the error bars show standard error of means (SEM). 
The data is expressed in terms of percentage, where solvent control is taken as 100% survival 
and different Lyso PAF treated test conditions are compared to it. Multiple-comparison of the 
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data sets using non-parametric Kruskal-Wallis test showed the results to non-significant, 
p=0.18. 
 
5.4 Effect of 2-O-methyl PAF on M.smegmatis growth inside THP-1 cells  
2-O-methyl PAF is a synthetic PAF C-16 analogue having a methyl group at the sn-2 position 
instead of an acetyl group as shown in figure 4.2.5a. 2-O-methyl PAF was used to investigate 
the effect of a methyl group at the sn-2 position on the growth inhibition of intracellular 
M.smegmatis. 
Four individual experiments (Exp1, 2, 3 and 4) were performed according to the protocol in 
section 2.7 by treating 2-O-methyl PAF in different concentrations (1µg, 5µg and 10µg/ml of 
cell suspension) with M.smegmatis infected THP-1 cells with for 24 hours. During all four 
experiments, 2-O-methyl PAF was unable to inhibit the growth of intracellular M.smegmatis 
as indicated by the similar number of CFUs for 2-O-methyl PAF treated test conditions and 
solvent control (Figure 5.4a and 5.4b). Non-parametric multiple comparison Kruskal-Wallis 




































































































































































Figure 5.4a: Four individual experiments (Exp1, 2, 3 and 4) for the effect of 2-O-methyl PAF 
on intracellular M.smegmatis growth. Each bar represents the average number of CFUs from 












































Figure 5.4b: Effect of 2-O-methyl PAF on intracellular M.smegmatis growth. Each bar 
represents the average of four individual experiments and the error bars show standard error of 
means (SEM). The data is expressed in terms of percentage, where solvent control is taken as 
100% survival and different 2-O-methyl PAF treated test conditions are compared to it. 
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Multiple-comparison of the data sets using non-parametric Kruskal-Wallis test showed the 
results to non-significant, p=0.14. 
 
5.5 Effect of PAF-C18 on M.smegmatis growth inside THP-1 cells  
PAF C-18, a structure analogue was used to investigate the effect of an increase in the number 
of carbon atoms in the aliphatic tail on the growth inhibition of intracellular M.smegmatis. The 
structure analogue PAF C-18 has two additional carbon atoms in the aliphatic carbon tail 
attached at position sn-1 as shown in figure 4.2.3a. 
Four individual experiments (Exp1, 2, 3 and 4) were performed in vitro according to the 
protocol in chapter 2.7 to investigate the effect of PAF C-18 treatment in different 
concentrations (1µg, 5µg and 10µg/ml of cell suspension) on the growth of intracellular 
M.smegmatis. It was observed that PAF C-18 was able to inhibit the growth of intracellular 
M.smegmatis during all four experiments. Furthermore, PAF C-18 at a concentration of 1µg/ml 
was more potent in inhibiting the growth of intracellular M.smegmatis as compared to 5µg and 
10µg/ml (Figure 5.5a). On average, treatment of M.smegmatis infected THP-1 cells with PAF 
C-18 at concentrations of 1µg, 5µg and 10µg/ml resulted in 49.9%, 9.2% and 7.2% reduction 
in the growth of intracellular M.smegmatis respectively as indicated by comparing the number 
of CFUs with solvent control (Figure 5.5b). The level of significance was determined by 
applying non-parametric multiple comparison Kruskal Wallis test on ranks and the p-value was 
found to be significant, p=0.01. Individual data sets were compared by applying post hoc 
Dunn’s multiple comparison test and 1µg/ml PAF C-18 vs Solvent control was found to be 
significant, p≤0.01. 
 





























































































































































Figure 5.5a: Four individual experiments (Exp1, 2, 3 and 4) for the effect of PAF C-18 on 
intracellular M.smegmatis growth. Each bar represents the average number of M.smegmatis 
CFUs for triplicate plates and error bars show standard deviation (SD) of the triplicates.  
 













































Figure 5.5b: Effect of PAF C-18 on intracellular M.smegmatis growth. Each bar represents the 
average of four individual experiments and the error bars show standard error of means (SEM). 
The data is expressed in terms of percentage, where solvent control is taken as 100% survival 
and different test conditions are compared to it. Level of significance was calculated by 
applying non-parametric multiple-comparison Kruskal-Wallis test on ranks, p=0.01 and 
individual data sets were compared through post hoc Dunn’s multiple comparison test where 
PAF C-18 (1µg/ml) vs solvent control was found to be significant, **(p≤0.01). 
 
5.6 Effect of Hexanolamino PAF on M.smegmatis growth inside THP-1 cells  
The structure analogue Hexanolamino PAF was used to investigate the effect of a change in 
position of the terminal amino group of PAF C-16 on the growth inhibition of intracellular 
M.smegmatis. In Hexanolamino PAF, the terminal amino group is attached the phosphate group 
via an additional 4-carbon atoms chain as shown in figure 4.2.4a.  
Four individual experiments (Exp1, 2, 3 and 4) were performed to investigate in vitro the effect 
of Hexanolamino PAF treatment in different concentrations (1µg, 5µg and 10µg/ml of cell 
suspension) on the growth of intracellular M.smegmatis according to the protocol in chapter 
2.7. It was observed that Hexanolamino PAF was able to inhibit the growth of intracellular 
M.smegmatis during all four experiments. Hexanolamino PAF at a concentration of 5µg/ml 
was more potent in inhibiting the growth of intracellular M.smegmatis as compared to 1µg and 
10µg/ml (Figure 5.6a). On average, treatment of M.smegmatis infected THP-1 cells with 
Hexanolamino PAF at concentrations of 1µg, 5µg and 10µg/ml resulted in 6.1%, 42.6% and 
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9.6% reduction in the growth of intracellular M.smegmatis respectively as indicated by 
comparing the number of test CFUs to solvent control (Figure 5.6b). The level of significance 
was determined by applying non-parametric multiple comparison Kruskal Wallis test on ranks 
and the p-value was found to be significant, p=0.01. Individual data sets were compared by 
applying post hoc Dunn’s multiple comparison test and 5µg/ml Hexanolamino PAF vs Solvent 






























































































































































Figure 5.6a: Four individual experiments (Exp1, 2, 3 and 4) showing the effect of 
Hexanolamino PAF on the growth of M.smegmatis. Each bar represents the average number of 
M.smegmatis CFUs for triplicate plates and error bars show standard deviation (SD) of the 
triplicates.  















































Figure 5.6b: Effect of Hexanolamino PAF on intracellular M.smegmatis growth. Each bar 
represents the average of four individual experiments and the error bars show standard error of 
means (SEM). The data is expressed in terms of percentage, where solvent control is taken as 
100% survival and different test conditions are compared to it. Level of significance was 
determined by applying non-parametric multiple-comparison Kruskal-Wallis test on ranks, 
p=0.01 and individual data sets were compared through post hoc Dunn’s multiple comparison 
test where Hexanolamino PAF (5µg/ml) vs solvent control was found to be significant, 
**(p≤0.01). 
 
5.7 PAF receptor antagonists partially reverse PAF C-16 induced growth inhibition of 
intracellular M.smegmatis 
PAF C-16 activates different signalling pathways in target cells by binding to specific G-
protein coupled receptors known as PAF receptor (PAFR) (Honda et al., 2002). A number of 
naturally occurring and synthetic compounds known as PAFR antagonists can bind to PAFR 
with high affinity and prevent the biological effects of PAF C-16 due to blocking of PAFR 
(Singh et al., 2013).  
Two synthetic PAFR antagonists, ABT-491 and WEB-2086 were used to investigate the effect 
of prior treatment of these PAFR antagonists on PAF C-16 induced growth inhibition of 
intracellular M.smegmatis inside THP-1 cells. 
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5.7.1 Effect of ABT-491 on PAF C-16 induced intracellular M.smegmatis growth 
inhibition 
Four individual experiments (Exp1, 2, 3 and 4) were performed with PAFR antagonist ABT-
491 according to the protocol in chapter 2.10. M.smegmatis infected THP-1 cells were treated 
with ABT-491 at a concentration of 2µg/ml for 1 hour prior to treatment with 1µg/ml PAF C-
16 for 24 hours. All the four experiments showed that prior treatment of M.smegmatis infected 
THP-1 cells with ABT-491 partially mitigated the intracellular growth inhibition of 
M.smegmatis due to PAF C-16 as indicated by an increase in the number CFUs when compared 
to 1µg/ml PAF C-16 only (Figure 5.7.1a). Furthermore, 2µg/ml ABT-491 on its own had no 
inhibitory effect on the growth of intracellular M.smegmatis (Figure 5.7.1a). On average, 
treatment of M.smegmatis infected THP-1 cells with ABT-491 prior to PAF C-16 increased the 
number of intracellular M.smegmatis by 24.5% as indicated by the number of CFUs when 
compared to the number of CFUs from 1µg/ml PAF C-16 only treated THP-1 cells (Figure 
5.7.1b). Non-parametric Mann Whitney test was used to determine the level of significance for 
“Test” (ABT-491 2µg/ml and PAF C-16 1µg/ml) versus 1µg/ml PAF C-16 only conditions and 
























































































































































































































Figure 5.7.1a: Four individual experiments (Exp1, 2, 3 and 4) for the effect of ABT-491 on 
PAF C-16 induced intracellular M.smegmatis growth inhibition. Each bar represents the 
average number of M.smegmatis CFUs from triplicate plates and error bars show standard 


























































Figure 5.7.1b: Effect of ABT-491 prior treatment on PAF C-16 induced intracellular 
M.smegmatis growth inhibition. Each bar represents the average of four independent 
experiments and the error bars show standard error of means (SEM). Test consists of 2µg/ml 
ABT-491 and 1µg/ml PAF C-16. The data is expressed in terms of percentage, where solvent 
control is taken as 100% survival and test conditions are compared to it. By applying Mann 
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Whitney test, the p-value was found to be significant for Test (2µg/ml ABT-491 and 1µg/ml 
PAF C-16) vs 1µg/ml PAF C-16, *(p=0.02). 
 
5.7.2 Effect of WEB-2086 on PAF C-16 induced intracellular M.smegmatis growth 
inhibition 
Four individual experiments (Exp1, 2, 3 and 4) were performed by treating M.smegmatis 
infected THP-1 cells with WEB-2086 at a concentration of 2µg/ml for 1 hour prior to treatment 
with 1µg/ml PAF C-16 for 24 hours. It was observed that prior treatment with WEB-2086 
partially mitigated the PAF C-16 induced growth inhibition of intracellular M.smegmatis 
during all four experiments as indicated by an increase in the number CFUs when compared to 
1µg/ml PAF C-16 only (Figure 5.7.2a). Furthermore, 2µg/ml WEB-2086 on its own showed 
no inhibitory effect on the growth of intracellular M.smegmatis. On average, WEB-2086 
treatment of M.smegmatis infected THP-1 cells with WEB-2086 prior to PAF C-16 increased 
the number of intracellular M.smegmatis by 20% when compared to the number of CFUs from 
1µg/ml PAF C-16 only treated cells (Figure 5.7.2b). Non-parametric Mann Whitney test was 
used to determine the level of significance for “Test” (WEB-2086 2µg/ml and PAF C-16 





















































































































































































































Figure 5.7.2a: Four individual experiments (Exp1, 2, 3 and 4) for the effect of WEB-2086 on 
PAF C-16 induced intracellular M.smegmatis growth inhibition. Each bar represents the 
average number of M.smegmatis CFUs from triplicate plates and error bar shows standard 





















































Figure 5.7.2b: Effect of WEB-2086 prior treatment on PAF C-16 induced intracellular 
M.smegmatis growth inhibition. Each bar represents the average of four independent 
experiments and the error bars show standard error of means (SEM). Test consists of 2µg/ml 
WEB-2086 and 1µg/ml PAF C-16. The data is expressed in terms of percentage, where solvent 
control is taken as 100% survival and test conditions are compared to it. p-value was calculated 
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by applying Mann Whitney test for Test (2µg/ml WEB-2086 and 1µg/ml PAF C-16) vs 1µg/ml 
PAF C-16 and was found to be significant, *(p=0.02). 
 
5.8 Investigating the role PAF C-16 intracellular signalling pathway components in the 
PAF C-16 indeed intracellular growth inhibition of M.smegmatis 
Binding of PAF C-16 to its receptor on the target cells results in the activation of intracellular 
signalling components such as phosphoinositide phospholipase C (PLC) and cytosolic 
phospholipase A2 (cPLA2) enzymes. The activated PLC further causes the metabolism of 
phosphatidylinositol 4,5-bisphosphate (PIP2) and leads to the production of second messengers 
such as diacylglycerol (DAG) and inositol trisphosphate (IP3). The activated cPLA2 leads to 
the production of intracellular arachidonic acid (AA) that is used for the production of 
prostaglandins and the leukotrienes (Montrucchio et al., 2000). 
Potent PLC and cPLA2 inhibitors were used to block these enzymes and investigate their role 
in PAF C-16 induced intracellular growth inhibition of M.smegmatis. In addition, signalling 
pathway components such as DAG and AA were also investigated in vitro for their direct effect 
on the growth of M.smegmatis. 
 
5.8.1 Effect of PLC inhibitor “U-73122” on PAF C-16 induced intracellular M.smegmatis 
growth inhibition 
PLC inhibitor, U-73122 was used to investigate the role of PLC in PAF C-16 induced growth 
inhibition of intracellular M.smegmatis. 
Four individual experiments (Exp1, 2, 3 and 4) were performed with U-73122 according to the 
protocol in chapter 2.10. M.smegmatis infected THP-1 cells were treated with U-73122 at a 
concentration of 2µM for 30min prior to treatment with 1µg/ml PAF C-16 for 24 hours. It was 
observed that U-73122 at a concentration of 2µM was partially effective in mitigating the 
inhibitory effect PAF C-16 on the growth of intracellular M.smegmatis during all four 
experiments (Figure 5.8.1). On average, treatment of M.smegmatis infected THP-1 cells with 
U-73122 prior to PAF C-16 increased the number of intracellular M.smegmatis by 25.2% when 
compared to the number of CFUs from 1µg/ml PAF C-16 only treated cells (Figure 5.8.2a). 
Non-parametric Mann Whitney test was used to determine the level of significance for “Test” 
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(2µM U-73122 and PAF C-16 1µg/ml) versus 1µg/ml PAF C-16 only  and the p-value was 
















































































































































































































Figure 5.8.1a: Four individual experiments (Exp1, 2, 3 and 4) for the effect of U-73122 on PAF 
C-16 induced intracellular M.smegmatis growth inhibition. Each bar represents the average 
number of M.smegmatis CFUs from triplicate plates and error bar shows standard deviation 
(SD) of the triplicates. Test consists of 2µM U-73122 and PAF C-16 1µg/ml. 
























































Figure 5.8.1b: Effect of U-73122 on PAF C-16 induced intracellular M.smegmatis growth 
inhibition. Each bar represents the average of four independent experiments and the error bars 
show standard error of means (SEM). Test consists of 2µM U-73122 and 1µg/ml PAF C-16. 
The data is expressed in terms of percentage, where solvent control is taken as 100% survival 
and test conditions are compared to it. P value was calculated by applying Mann Whitney test 
for “Test” (2µM U-73122 and 1µg/ml PAF C-16) vs 1µg/ml PAF C-16 and was found to be 
significant, *(p=0.02). 
 
5.8.2 Effect of cPLA2 inhibitor “Benzenesulfonamide” on PAF C-16 induced intracellular 
M.smegmatis growth inhibition 
PAF C-16 also causes the activation of cytosolic phospholipase A2 (cPLA2). This activated 
cPLA2 further leads to the intracellular production of arachidonic acid (AA) and 
lysophosphatidylcholine. Benzenesulfonamide, a cPLA2 inhibitor, was used to investigate the 
role of cPLA2 in PAF C-16 induced growth inhibition of intracellular M.smegmatis. 
Four individual experiments (Exp1, 2, 3 and 4) were performed with benzenesulfonamide 
according to the protocol in chapter 2.10. M.smegmatis infected THP-1 cells were treated with 
benzenesulfonamide at a concentration of 23nM (IC50) or 56nM (2IC50) for 30min prior to 
treatment with 1µg/ml PAF C-16 for 24 hours. It was observed that benzenesulfonamide at 
concentrations of 23nM and 56nM partially mitigated the inhibitory effect PAF C-16 on the 
growth of intracellular M.smegmatis during all four experiments (Figure 5.8.2a). On average, 
treatment of M.smegmatis infected THP-1 cells with benzenesulfonamide at concentrations 
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23nM (Test 1) or 56nM (Test 2) prior to 1µg/ml PAF C-16 treatment increased the number of 
intracellular M.smegmatis by 25.5% and 30.1% respectively when compared to the number of 
CFUs from 1µg/ml PAF C-16 only treated cells (Figure 5.8.2b). Non-parametric Mann 
Whitney test was used to determine the level of significance for “Test 1 vs 1µg/ml PAF C-16 






















































































































































































































Figure 5.8.2a: Four individual experiments (Exp1, 2, 3 and 4) for the effect of 
benzenesulfonamide on PAF C-16 induced intracellular M.smegmatis growth inhibition. Each 
bar represents the average number of M.smegmatis CFUs from triplicate plates and error bar 
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shows standard deviation (SD) of the triplicates. Test 1 consists of 23nM benzenesulfonamide 




























































Figure 5. 8.2b: Effect of cPLA2 inhibitor benzenesulfonamide on PAF C-16 induced growth 
inhibition of intracellular M.smegmatis. Each bar represents the average of four independent 
experiments and the error bars show standard error of means (SEM). The data is expressed in 
terms of percentage, where solvent control is taken as 100% survival and test conditions are 
compared to it. Test 1 consists of 23nM benzenesulfonamide and 1µg/ml PAF C-16, Test 2 
consists of 56nM benzenesulfonamide and 1µg/ml PAF C-16. P-value was calculated by 
applying Mann Whitney test was found to be significant for Test 1 vs 1µg/ml PAF C-16 and 
Test 2 vs 1µg/ml PAF C-16 only, *(p=0.02). 
 
5.8.3 Direct effect of Diacylglycerol (DAG) on M.smegmatis growth in vitro 
Diacylglycerol (DAG) is a second messenger produced during PAF C-16 signalling pathway. 
Chemically DAG consists of two fatty acid chains attached to a glycerol backbone via ester 
bonds as shown in the figure 5.8.3a. 




Figure 5.8.3a: Chemical structure of diacylglycerol. Two fatty acid chains (R1 and R2) are 
attached via ester bonds to the glycerol backbone. 
Three individual experiments (Exp1, 2 and 3) were performed to investigate the direct effect 
of DAG in different concentrations (5µg, 10µg, 25µg, 50µg and 100µg/ml of bacterial 
suspension) on the growth of M.smegmatis according to the protocol in section 2.2. The results 
showed that in vitro DAG in concentrations of up to 100µg/ml had no direct inhibitory effect 
on the growth of M.smegmatis as indicated by the similar number of CFUs for DAG treated 
and solvent control M.smegmatis (Figure 5.8.3b and 5.8.3c). The level of significance was 
determined by applying non-parametric Kruskal-Wallis test on ranks and the p-value was found 







































































































































Figure 5.8.3b: Three individual experiments (Exp1, 2 and 3) for the direct effect of DAG on 
the growth of M.smegmatis. Each bar represents the average number of M.smegmatis CFUs 


















































Figure 5.8.3c: Direct effect of DAG on M.smegmatis growth. Each bar represents the average 
of three individual experiments and the error bars show standard error of means (SEM). The 
data is expressed in terms of percentage, where solvent control is taken as 100% survival and 
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different test conditions are compared to it. Non-parametric Kruskal-Wallis test was used to 
determine the p-value, which was found to be non-significant, p=0.23. 
 
5.8.4 Direct effect of arachidonic acid (AA) on M.smegmatis growth in vitro 
Arachidonic acid (AA) is produced by activated cPLA2 from intracellular phospholipids during 
PAF C-16 signalling pathway. Chemically, AA is a carboxylic acid containing 20 carbon atoms 
chain with four double bonds as shown in figure 5.8.4a. 
 
Figure 5.8.4a: Chemical structure of arachidonic acid. The compound contains a 20 carbon 
atoms chain with 4 double bonds at positions 5, 8, 11 and 14.  
Three individual experiments (Exp1, 2 and 3) were performed to investigate the direct effect 
of AA in different concentrations (5µg, 10µg, 25µg, 50µg and 100µg/ml of bacterial 
suspension) on the growth of M.smegmatis according to the protocol in section 2.2. AA 
inhibited the growth of M.smegmatis in all three experiments (Figure 5.8.4b). On average, more 
than 98% M.smegmatis growth inhibition was observed at all concentrations (Figure 5.8.4c). 
The level of significance was determined by applying non-parametric multiple comparison 
Kruskal Wallis test on ranks and the p-value was found to be significant, p=0.007.  
 










































































































































Figure 5.8.4b: Three individual experiments (Exp1, 2 and 3) for the direct effect of AA on 
M.smegmatis growth. Each bar represents the average of triplicate values and error bar shows 
standard deviation (SD) of the triplicates from the average. 
 



















































Figure 5.8.4c: Direct effect of AA on M.smegmatis growth. Each bar represents the average of 
three individual experiments and the error bars show standard error of means (SEM). The data 
is expressed in terms of percentage, where control is taken as 100% survival and different test 
conditions are compared to it. Level of significance was determined using non-parametric 
Kruskal-Wallis test and the p-value was found to be significant *** (P=0.007). 
 
Furthermore, lower concentrations of AA were also investigated for their direct growth 
inhibitory effect against M.smegmatis. Three independent experiments (Exp1, 2 and 3) were 
performed using lower concentrations of AA (0.1µg, 0.5µg and 1µg and 2.5µg/ml bacterial 
suspension) and a solvent control for AA (2.5µl ethanol/ml bacterial suspension) according to 
the protocol in section 2.2. The results showed dose-dependent growth inhibition of 
M.smegmatis during all the experiments (Figure 5.8.4d). AA at concentrations of 2.5µg/ml and 
1µg/ml on average caused a reduction of 86.4% and 36% respectively in the number of 
M.smegmatis CFUs as compared to solvent control (Figure 5.8.4e). The level of significance 
was determined by applying non-parametric multiple comparison Kruskal Wallis test on ranks 
and the p-value was found to be significant, p=0.008. By applying post hoc Dunn’s multiple 
comparison test only 2.5µg/ml AA versus control was found to be significant, p≤0.01. 
 









































































































































Figure 5.8.4d: Three individual experiments (Exp1, 2 and 3) for the direct effect of AA (lower 
concentrations) on M.smegmatis growth. Each bar represents the average of triplicate values 
and error bar shows standard deviation (SD) of the triplicates from the average.  




















































Figure 5.8.4e: Direct effect of AA (lower concentrations) on M.smegmatis growth. Each bar 
represents the average of three individual experiments and the error bars show standard error 
of means (SEM). The data expressed in terms of percentage, where control is taken as 100% 
survival and different test conditions are compared to it. Non-parametric Kruskal-Wallis test 
was applied on ranks to determine the p-value, which was found to be significant (p=0.008). 
Individual data sets were compared using Dunn’s multiple comparison test and the results were 
significant for 2.5µg/ml AA vs solvent control, **(p≤0.01). 
 
5.9 Investigating the mechanism of PAF C-16 induced growth inhibition of intracellular 
M.smegmatis  
Immune cells such as macrophages can inhibit the growth intracellular mycobacteria by 
various mechanisms including apoptosis and production of reactive nitrogen species (Navarre 
and Zychlinsky, 2000; MacMicking et al., 1997). Therefore, these growth inhibitory 
mechanisms were also investigated for their role in PAF C-16 induced growth inhibition of 
intracellular M.smegmatis.  
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5.9.1 Investigating PAF C-16 induced apoptosis in THP-1 cells 
PAF C-16 has previously been shown to induce apoptosis in neuronal cells, epithelial cells and 
keratocytes (Brewer et al., 2002; Chandrasekher et al., 2002; Barber et al., 1998). Therefore, 
PAF C-16 treated THP-1 cells were also analyzed by flow cytometry to detect apoptosis. 
Three independent experiments were performed to detect PAF C-16 induced apoptosis in THP-
1 cells using fluorescence dyes; Annexin-V conjugated FITC and PI. THP-1 cells treated with 
PAF C-16 at a concentration of 1µg/ml for 24 hours were stained with apoptosis detection dyes 
and analyzed by performing flow cytometry. A solvent control (2µl ethanol/ml) and a positive 
control for apoptosis (2µM staurosporine) were also included in the experiment. The data was 
collected by acquiring 20,000 cells for each experimental condition and visualized on a density 
plot using NovoExpress® software. 
The figure 5.9.1a shows the density plots for solvent control (2µl ethanol/ml) (slide A), positive 
control (2µM staurosporine) (slide B) and PAF C-16 (1µg/ml) (slide C) treated THP-1 cells. 
The results showed no appreciable increase in the percentage of Annexin-V conjugated FITC 
positive cells in Q5-4 representing cells in early apoptotic stages or the percentage of Annexin-
V conjugated FITC and PI double positive cells in Q5-2 indicating late apoptosis after 
treatment with 1µg/ml PAF C-16 (slide C) when compared with the solvent control for PAF 
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Figure 5.9.1a: Flow cytometry analysis for detection of apoptosis in PAF C-16 treated THP-1 
cells. The data is presented on a density plot where X-axis shows the fluorescence intensity for 
Annexin-V conjugated FITC and Y-axis represents the fluorescence intensity of PI. Slide A is 
the negative control (THP-1 cells treated with the solvent for PAF C-16, 2µl ethanol/ml), slide 
B is the positive control (THP-1 cells treated with 2µM staurosporine) and slides C is the Test 
(THP-1 cells treated with 1µg/ml PAF C-16). Live cells (Q5-3) are negative for both Annexin-
V conjugated FITC and PI. Early apoptotic cells (Q5-4) are Annexin-V conjugated FITC 
positive and PI negative. Late apoptotic/necrotic cells (Q5-2) are double positive and show 
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staining for both Annexin-V conjugated FITC and PI whereas necrotic cells (Q5-1) are only PI 
positive. 
 
5.9.2 Investigating PAF C-16 induced apoptosis in M.smegmatis infected THP-1 cells  
Although there was no evident apoptosis in PAF C-16 treated THP-1 cells, however, further 
investigation was done for detection of PAF C-16 induced apoptosis in M.smegmatis infected 
THP-1 treated with PAF C-16. 
Three independent experiments were performed by treating M.smegmatis infected THP-1 cells 
with 1µg/ml PAF C-16 for 24 hours. The cells were analyzed by flow cytometry using 
apoptosis detection dyes; Annexin-V conjugated FITC and PI. Appropriate controls including 
two solvent controls (THP-1 cells only and M.smegmatis infected THP-1 cells treated with 2µl 
ethanol/ml) and a positive control for apoptosis (THP-1 cells treated with 2µM staurosporine) 
were also included in the experiment. The data was collected by acquiring 20,000 events for 
each experimental condition and visualized on a density plot using NovoExpress® software.  
The figure 5.9.2a shows the density plots for solvent control THP-1 cells only (2µl ethanol/ml) 
(slide A), positive control THP-1 cells (2µM staurosporine) (slide B), solvent control THP-1 
cells infected with M.smegmatis (2µl ethanol/ml) (slide C) and test THP-1 cells having 
intracellular M.smegmatis treated with 1µg/ml PAF C-16 (Slide D). 
The density plots in figure 5.9.2a showed that phagocytosis of M.smegmatis by THP-1 cells 
(slide C) induced apoptosis in these cells as indicated by the increase in the percentage of 
Annexin-V conjugated FITC positive cells in Q5-4 and Annexin V conjugated FITC and PI 
double positive cells in Q5-2 when compared with solvent control THP-1 cells without any 
intracellular M.smegmatis (Slide A). Furthermore, treatment of PAF C-16 (1µg/ml) with 
M.smegmatis infected THP-1 cells with for 24 hours did not induce or enhance the apoptosis 
as there was no increase in the percentage of Annexin-V conjugated FITC positive THP-1 cells 
(Q5-4) representing early apoptosis or Annexin-V conjugated FITC and PI double positive 
cells (Q5-2) indicating late apoptosis (Slide D) when compared to solvent control M.smegmatis 
infected THP-1 cells (Slide C) (Figure 5.9.2a).  
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Figure 5.9.2a: Flow cytometry analysis for detection of PAF C-16 induced apoptosis in 
M.smegmatis infected THP-1 cells. The data is presented on a density plot where X-axis shows 
the fluorescence intensity for Annexin-V conjugated FITC and Y-axis represents the 
fluorescence intensity of PI. Slide A shows solvent control THP-1 cells only (THP-1 cells 
without M.smegmatis treated with 2µl ethanol/ml), slide B is the positive control (THP-1 cells 
treated with 2µM Staurosporine), slides C shows solvent control M.smegmatis infected THP-1 
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cells treated with 2µl ethanol/ml and slide D shows M.smegmatis infected THP-1 cells treated 
with 1µg/ml PAF C-16 for 24 hours. Live cells (Q5-3) are negative for both Annexin V 
conjugated FITC and PI. Early apoptotic cells (Q5-4) are Annexin-V conjugated FITC positive 
and PI negative. Late apoptotic/necrotic cells (Q5-2) are double positive and show staining for 
both Annexin-V conjugated FITC and PI whereas, necrotic cells (Q5-1) are only PI positive. 
5.10 Effect of nitric oxide synthase inhibitor on PAF C-16 induced growth inhibition of 
intracellular M.smegmatis  
PAF C-16 has previously been shown to activate iNOS expression and inhibit the growth of 
intracellular parasites such as Leishmania and Trypanosoma via production of reactive nitrogen 
species (Lonardoni et al., 2000; Aliberti et al., 1999). Since, reactive nitrogen species are also 
effective in eliminating intracellular mycobacteria, an iNOS inhibitor, Aminoguanidine 
hemisulfate (AG), was used to check whether PAF C-16 was inhibiting the growth of 
intracellular M.smegmatis by causing the production of reactive nitrogen species in THP-1 
cells. 
Four individual experiments (Exp1, 2, 3 and 4) were performed to investigate the effect of 
iNOS inhibitor, Aminoguanidine hemisulfate (AG) on PAF C-16 induced intracellular 
M.smegmatis growth inhibition according to the protocol in section 2.10. During all four 
experiments, treatment of M.smegmatis infected THP-1 cells with 1mM AG for 30min prior to 
treatment with 1µg/ml PAF C-16 partially reversed PAF C-16 induced growth inhibition of 
intracellular M.smegmatis as indicated by an increase in the number CFUs when compared to 
1µg/ml PAF C-16 only (Figure 5.10a). On average, prior treatment with 1mM AG increased 
the growth of intracellular M.smegmatis by 23.4% when compared to 1µg/ml PAF C-16 only 
as indicated by a comparison of the number of CFUs (Figure 5.10b). The level of significance 
for “Test” (1mM AG and 1µg/ml PAF C-16) versus 1µg/ml PAF C-16 only was determined 
using non-parametric Mann Whitney test and the p-value was found to be significant, p=0.02. 
 









































































































































































































Figure 5.10a: Four individual experiments (Exp1, 2, 3 and 4) for the effect of Aminoguanidine 
hemisulfate on PAF C-16 induced intracellular M.smegmatis growth inhibition. Each bar 
represents the average number of M.smegmatis CFUs from triplicate plates and error bar shows 
standard deviation (SD) of triplicate. Test consists of THP-1 cells treated with 1mM AG and 
1µg/ml PAF C-16. 
 

























































Figure 5.10b: Effect of Aminoguanidine hemisulfate prior treatment on PAF C-16 induced 
intracellular M.smegmatis growth inhibition. Each bar represents the average of four individual 
experiments and the error bars show standard error of means (SEM). The data is expressed in 
terms of percentage, where solvent control is considered as 100% survival and test conditions 
are compared to it. Test consists of THP-1 cells treated with 1mM AG and 1µg/ml PAF C-16. 
The p-value for Test (1mM AG and 1µg/ml PAF C-16) vs 1µg/ml PAF C-16 was calculated 
using Mann Whitey test and was significant, *(p=0.02). 
 
5.11 Effect of TNF-α, IL-6, and IL-10 neutralization on PAF C-16 induced intracellular 
M.smegmatis growth inhibition 
PAF C-16 can cause the production of cytokines such as IL-1, TNF-α etc. (Thivierge and Rola-
Pleszczynski, 1992; Poubelle et al., 1991). Different cytokines have previously been shown to 
play important roles in facilitating the elimination of intracellular mycobacteria. Therefore, the 
role of a few cytokines in PAF C-16 induced growth inhibition of intracellular M.smegmatis 
was investigated by blocking them with neutralizing antibodies. 
5.11.1 Effect of anti-TNF-α on PAF C-16 induced intracellular M.smegmatis growth 
inhibition 
Four individual experiments (Exp1, 2, 3 and 4) were performed according to the protocol in 
chapter 2.10. M.smegmatis infected THP-1 cells were treated with 10µg/ml mouse anti-human 
TNF-α antibody and 1µg/ml PAF C-16 for 24 hours. Appropriate controls comprising of 
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M.smegmatis infected THP-1 cells treated with 2µl ethanol/ml, 1µl PAF C-16/ml, 10µg/ml 
mouse anti-human TNF-α antibody and isotype control (10µg/ml mouse IgG + 1µg/ml PAF C-
16) were also included in the experiment. 
All four experiments showed that treatment of 10µg/ml mouse anti-human TNF-α (neutralizing 
antibody) partially mitigated the PAF C-16 induced growth inhibition of intracellular 
M.smegmatis as indicated by an increase in the number CFUs compared to isotype control 
(10µg/ml mouse IgG + 1µg/ml PAF C-16) and control treated with 1µg/ml PAF C-16 only 
(Figure 5.11.1a). On average, intracellular M.smegmatis growth increased by 17% in the 
presence of 10µg/ml anti-TNF-α neutralizing antibody as compared to the isotype control 
condition and by 18.7% as compared to 1µg/ml PAF C-16 only condition (Figure 5.11.1b). The 
level of significance was determined using non-parametric Mann Whitney test, and was found 
significant, p=0.02 for “Test” (10µg/ml anti-TNF-α and 1µg/ml PAF C-16) vs Isotype control 
(10µg/ml mouse IgG + 1µg/ml PAF C-16) and “Test” (10µg/ml anti-TNF-α and 1µg/ml PAF 






































































































































































































































Figure 5.11.1a: Four individual experiments (Exp1, 2, 3 and 4) for the effect anti-TNF-α 
neutralizing antibody on PAF C-16 induced intracellular M.smegmatis growth inhibition. Each 
bar represents the average number of M.smegmatis CFUs from triplicate plates and error bar 
shows standard deviation (SD) of triplicates. Test consists of 10µg/ml anti-TNF-α and 1µg/ml 





























































Figure 5.11.1b: Effect of anti-TNF-α neutralizing antibody on PAF C-16 induced intracellular 
M.smegmatis growth inhibition. Each bar represents the average of four individual experiments 
and the error bars show standard error of means (SEM). The data is expressed in terms of 
percentage, where solvent control is considered as 100% survival and test conditions are 
                                                                                                                                                                  Chapter 5 
255 
 
compared to it. Test consists of 10µg/ml anti-TNF-α and 1µg/ml PAF C-16 and Isotype 
control consists of 10µg/ml anti-IgG + 1µg/ml PAF C-16. The level of significance for Test 
(10µg/ml anti-TNF-α and 1µg/ml PAF C-16) vs Isotype control (10µg/ml mouse IgG + 1µg/ml 
PAF C-16) and Test (10µg/ml anti-TNF-α and 1µg/ml PAF C-16) vs 1µg/ml PAF C-16 only 
was calculated by non-parametric Mann Whitney test, and was found significant, *(p=0.02). 
 
5.11.2 Effect of anti-IL-6 on PAF C-16 induced intracellular M.smegmatis growth 
inhibition 
Four individual experiments (Exp1, 2, 3 and 4) were performed according to the protocol in 
chapter 2.10. M.smegmatis infected THP-1 cells were treated with 10µg/ml rat anti-human IL-
6 neutralizing antibody and 1µg/ml PAF C-16 for 24 hours. Appropriate controls comprising 
of M.smegmatis infected THP-1 cells treated with 2µl ethanol/ml, 1µl PAF C-16/ml, 10µg/ml 
rat anti-human IL-6 antibody and isotype control (10µg/ml rat IgG + 1µg/ml PAF C-16) were 
also included in the experimental design. 
All four experiments showed that treatment of 10µg/ml mouse anti-human IL-6 (neutralizing 
antibody) showed no effect on PAF C-16 induced growth inhibition of intracellular 
M.smegmatis as indicated by a similar number CFUs compared to isotype control (10µg/ml rat 
IgG + 1µg/ml PAF C-16) and control treated with 1µg/ml PAF C-16 only (Figure 5.11.2a and 
Figure 5.11.2b). The level of significance was determined using non-parametric Mann Whitney 
test, and was found non-significant, p=0.68 and p=0.88 for “Test” (10µg/ml anti-IL-6 and 
1µg/ml PAF C-16) vs Isotype control (10µg/ml rat IgG + 1µg/ml PAF C-16) and “Test” 
(10µg/ml anti-IL-6 and 1µg/ml PAF C-16) vs 1µg/ml PAF C-16 only. 
 




































































































































































































































Figure 5.11.2a: Four individual experiments (Exp1, 2, 3 and 4) for the effect anti-IL-6 
neutralizing antibody on PAF C-16 induced intracellular M.smegmatis growth inhibition. Each 
bar represents the average number of M.smegmatis CFUs from triplicate plates and error bar 
shows standard deviation (SD) of triplicates. Test consists of 10µg/ml anti-IL-6 and 1µg/ml 
PAF C-16 v and Isotype control of 10µg/ml rat IgG + 1µg/ml PAF C-16. 
 






























































Figure 5.11.2b: Effect of anti-IL-6 neutralizing antibody on PAF C-16 induced intracellular 
M.smegmatis growth inhibition. Each bar represents the average of four individual experiments 
and the error bars show standard error of means (SEM). The data is expressed in terms of 
percentage, where solvent control is considered as 100% survival and test conditions are 
compared to it. Test consists of 10µg/ml anti-IL-6 and 1µg/ml PAF C-16 v and Isotype control 
of 10µg/ml rat IgG + 1µg/ml PAF C-16. The level of significance for Test (10µg/ml anti-IL-6 
and 1µg/ml PAF C-16) vs Isotype control (10µg/ml rat IgG + 1µg/ml PAF C-16) and Test 
(10µg/ml anti-IL-6 and 1µg/ml PAF C-16) vs 1µg/ml PAF C-16 only was calculated by non-
parametric Mann Whitney test, and was found non-significant, p=0.68 and p=0.88. 
 
5.11.3 Effect of anti-IL-10 on PAF C-16 induced intracellular M.smegmatis growth 
inhibition 
Four individual experiments (Exp1, 2, 3 and 4) were performed according to the protocol in 
chapter 2.10. M.smegmatis infected THP-1 cells were treated with 10µg/ml rat anti-human IL-
10 neutralizing antibody and 1µg/ml PAF C-16 for 24 hours. Appropriate controls comprising 
of M.smegmatis infected THP-1 cells treated with 2µl ethanol/ml, 1µl PAF C-16/ml, 10µg/ml 
rat anti-human IL-10 antibody and isotype control (10µg/ml rat IgG + 1µg/ml PAF C-16) were 
also included in the experimental design. 
All four experiments showed that treatment of 10µg/ml rat anti-human IL-10 (neutralizing 
antibody) showed no effect on PAF C-16 induced growth inhibition of intracellular 
M.smegmatis as indicated by a similar number CFUs compared to isotype control (10µg/ml rat 
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IgG + 1µg/ml PAF C-16) and control treated with 1µg/ml PAF C-16 only (Figure 5.11.3a and 
Figure 5.11.3b). The level of significance was determined using non-parametric Mann Whitney 
test, and was found non-significant, p=0.66 and p=0.73 for “Test” (10µg/ml anti-IL-10 and 
1µg/ml PAF C-16) vs Isotype control (10µg/ml rat IgG + 1µg/ml PAF C-16) and “Test” 




































































































































































































































Figure 5.11.3a: Four individual experiments (Exp1, 2, 3 and 4) for the effect anti-IL-10 
neutralizing antibody on PAF C-16 induced intracellular M.smegmatis growth inhibition. Each 
bar represents the average number of M.smegmatis CFUs from triplicate plates and error bar 
shows standard deviation (SD) of triplicates. Test consists of 10µg/ml anti-IL-10 and 1µg/ml 
PAF C-16 and Isotype control consists of 10µg/ml rat IgG + 1µg/ml PAF C-16. 































































Figure 5.11.3b: Effect of anti-IL-10 neutralizing antibody on PAF C-16 induced growth 
inhibition of intracellular M.smegmatis. Each bar represents the average of four individual 
experiments and the error bars show standard error of means (SEM). The data is expressed in 
terms of percentage, where solvent control is considered as 100% survival and test conditions 
are compared to it. Test consists of 10µg/ml anti-IL-10 and 1µg/ml PAF C-16 and Isotype 
control consists of 10µg/ml anti-IgG + 1µg/ml PAF C-16. The level of significance for “Test” 
(10µg/ml anti-IL-10 and 1µg/ml PAF C-16) vs Isotype control (10µg/ml anti-IgG + 1µg/ml 
PAF C-16) and “Test” (10µg/ml anti-IL-10 and 1µg/ml PAF C-16) vs 1µg/ml PAF C-16 only 
was calculated by non-parametric Mann Whitney test, and was found to be non-significant, 
p=0.66 and p=0.73. 
 
5.12 Effect of PAF C-16 on M. bovis BCG growth inside THP-1 cells 
The effect of PAF C-16 on the growth of intracellular M.bovis BCG was investigated according 
to the protocol in chapter 2.7. Four individual experiments (Exp1, 2, 3 and 4) were performed 
by treating M.bovis BCG infected THP-1 cells with PAF C-16 in different concentrations 
(0.01µg, 0.1µg, 1µg, 5µg and 10µg/ml of cell suspension) for 24 hours. The effect of PAF C-
16 treatment on the growth of intracellular M.bovis BCG was determined by comparing the 
number of CFUs from different PAF C-16 treated test conditions to the solvent control for PAF 
C-16 (2µl ethanol /ml cell suspension). 
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However, the results obtained were inconsistent and no particular trend of growth inhibition 
was observed during all four experiments performed (Figure 5.12a and Figure 5.12b). 
Statistical analysis of the results by applying non-parametric multiple comparison Kruskal 



















































































































































































Figure 5.12a: Four individual experiments (Exp1, 2, 3 and 4) for the effect of PAF C-16 on 
intracellular M.bovis BCG growth. Each bar represents the average CFUs for triplicate plates 
and error bars show standard deviation (SD) of the triplicates. 
 

















































Figure 5.12b: Effect of PAF C-16 on intracellular M.bovis BCG growth. Each bar represents 
the average of four individual experiments and the error bars show standard error of means 
(SEM). The data is expressed in terms of percentage, where solvent control is taken as 100% 
survival and different PAF C-16 treated test conditions are compared to it. Level of significance 
was calculated by applying multiple comparison non-parametric Kruskal-Wallis test on ranks 
and was found to be non-significant, p=0.57. 
 
5.13 Effect of PAF C-16 treatment with THP-1 on the phagocytosis of M.smegmatis  
The effect of exogenous PAF C-16 on the phagocytosis of M.smegmatis by THP-1 cells was 
investigated according to the protocol in chapter 2.11. Four individual experiments (Exp1, 2, 3 
and 4) were performed by treating THP-1 cells with different concentrations of PAF C-16 
0.01µg, 0.1µg, 1µg and 5µg/ml for 2 hours. The PAF C-16 treated THP-1 cells were then 
incubated with M.smegmatis for 2 hour to allow phagocytosis of bacteria. Finally the effect of 
PAF C-16 treatment on phagocytosis of M.smegmatis was determined by lysing the THP-1 
cells with intracellular M.smegmatis and comparing the number of CFUs from different PAF 
C-16 treated test conditions to the solvent control for PAF C-16 (1µl ethanol /ml cell 
suspension). 
It was observed that PAF C-16 treatment of THP-1 cells decreased the phagocytosis of 
M.smegmatis during all four experiments (Figure 5.13a). On average, PAF C-16 treatment of 
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THP-1 cells at concentrations 0.01µg, 0.1µg, 1µg and 5µg/ml resulted in 78.1%, 79.3%, 80.5% 
and 74.4% decrease in the phagocytosis of M.smegmatis respectively as indicated by the 
number of CFUs when compared to the solvent control (Figure 5.13b). The level of 
significance was determined by applying non-parametric multiple comparison Kruskal Wallis 
test on ranks and the p-value was found to be significant, p=0.036. Individual data sets were 
compared by applying post hoc Dunn’s multiple comparison test and 0.01µg, 0.1µg and 1µg/ml 





























































































































































Figure 5.13a: Four individual experiments (Exp1, 2, 3, and 4) for the effect of PAF C-16 on 
THP-1 cells phagocytosis of M.smegmatis. Each bar represents the average number of 
M.smegmatis CFUs from triplicate plates and error bars show standard deviation (SD) of the 
triplicates. 


















































Figure 5.13b: Effect of PAF C-16 on THP-1 cells phagocytosis of M.smegmatis. Each bar 
represents the average of four individual experiments and the error bars show standard error of 
means (SEM). The data is expressed in terms of percentage, where solvent control is taken as 
100% phagocytosis and different PAF C-16 treated test conditions are compared to it. Level of 
significance was calculated by applying multiple-comparison non-parametric Kruskal-Wallis 
test on ranks, p=0.036 and individual data sets were compared through post hoc Dunn’s 













In this chapter, the effect of exogenous PAF C-16 on the growth of intracellular mycobacteria 
was investigated in vitro. Phagocytic THP-1 cells infected with mycobacteria were used as a 
model to investigate the growth inhibitory effect of PAF C-16. THP-1 cells are human 
leukaemia derived monocytic cells that mimic blood-derived monocytes and are a valuable tool 
for research because of their homogenous genetic background (Chanput et al., 2014). THP-1 
cells have previously been used to study intracellular mycobacteria (Iona et al., 2012; Fontán 
et al., 2008; Rohan et al., 2008; Rajavelu and Das, 2007). THP-1 cells used during most of the 
previous studies were treated with phorbol 12-myristate 13-acetate (PMA) in order to 
differentiate them into macrophages. However, PMA treatment of THP-1 cells has been shown 
to cause the rearrangement of macrophage-specific kinome that leads to the activation of 
various genes such as IL-1β, IL-8 and TNF-α and hence make these THP-1 cells biased towards 
a more pro-inflammatory type of response (Richter et al., 2016). In this study, unmanipulated 
THP-1 cells were used to investigate the effect of PAF C-16 on the growth of intracellular 
mycobacteria. In our lab, we have previously shown that THP-1 cells without PMA stimulation 
can inhibit mycobacterial growth (Shawayat, 2017). 
PAF C-16 can activate monocytes/macrophages through interaction with specific cell 
membrane receptors known as PAFR (Simon et al., 1994) and has been shown to stimulate the 
production of different cytokines such as TNF-α, IL-1β, reactive oxygen species and reactive 
nitrogen species in these cells (Muehlmann et al., 2012; Poubelle et al., 1991; Bonavida et al., 
1989; Hartung et al., 1983) suggesting that PAF C-16 may play a protective role during 
pathogen infection. Therefore, we investigated the effect of exogenous PAF C-16 in different 
concentrations on the growth of M.smegmatis inside THP-1 cells. PAF C-16 was able to inhibit 
the growth of intracellular M.smegmatis only at a concentration of 1µg/ml. On average, 1µg/ml 
PAF C-16 treatment for 24 hours caused ~50% reduction (p≤0.001) in the growth of 
intracellular M.smegmatis as indicated by the number of surviving M.smegmatis CFUs when 
compared with the solvent control. PAF C-16 treatment at higher concentrations (5µg/ml and 
10µg/ml) and lower concentrations (0.001µg, 0.01µg and 0.1µg/ml) failed to show any 
significant inhibition of intracellular M.smegmatis growth. An important observation from 
these experiments was the inability of higher doses of exogenous PAF C-16 to inhibit the 
growth of intracellular M.smegmatis, indicating that PAF C-16 acts in concentration-specific 
manner. These results are in line with some of the previous studies performed with PAF C-16. 
It was shown that human macrophages when treated with higher concentration (10-6 M) of 
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exogenous PAF C-16 showed reduced phagocytic activity as compared to those treated with 
lower concentrations (10-8 and 10-10 M) of PAF C-16 (Borges et al., 2017). Similarly, human 
monocytes showed maximum production of ROIs when stimulated with PAF C-16 at a 
particular concentration (2x10-6M) and increasing the concentration of PAF C-16 (5x10-6M) 
caused a decrease in ROIs production (Pustynnikov et al., 1991). In our study, trypan blue 
staining showed increased cell death in THP-1 cells after treatment with higher concentrations 
of PAF C-16, especially at 10µg/ml PAF C-16. These results indicated a negative effect for 
higher doses of PAF C-16 on the survival of THP-1 cell and can be a possible explanation for 
the lack of growth inhibitory effect of higher doses of PAF C-16. Four independent experiments 
were performed to investigate the effect of PAF C-16 on the growth of intracellular M.bovis 
BCG. However, no consistent trend of growth inhibition was observed during these 
experiments and the results were statistically non-significant. Several previous studies have 
shown that exogenous PAF C-16 can inhibit the growth of intracellular pathogens including 
protozoans such as Leishmania donovani (Lonardoni et al., 2000), Leishmania braziliensis 
(Borges et al., 2017), Trypanosoma cruzi (Aliberti et al., 1999) and fungi such as Candida 
albicans (Kim et al., 2008; Im et al., 1997) both in vivo and in vitro. PAF C-16 induced growth 
inhibition of these intracellular pathogens was shown to be associated with the enhanced 
production of ROIs, RNIs and cytokines such as TNF-α. There is very limited information 
regarding the effect of PAF C-16 on the growth of intracellular mycobacteria. A single previous 
study to investigate the role of endogenous PAF C-16 during M.tb infection in mice showed 
that there was no significant difference in mortality between PAFR deficient (PAFR−/−) and 
wild-type control mice when infected with M.tb and both PAFR−/− and control mice showed 
similar M.tb loads in lungs and liver (Weijer et al., 2003). However, to the best of our 
knowledge, there is currently no information about the effect of exogenous PAF C-16 on the 
growth inhibition of intracellular mycobacteria. 
The biological activity of PAF C-16 in eukaryotic cells can be affected by small modifications 
in its structure (Marathe et al., 2014). In chapter 4, it was shown that small changes in the 
structure of PAF C-16 such as changes in functional groups and increase in carbon chain length 
had no effect on the direct growth inhibition activity of PAF C-16 against mycobacteria. 
Therefore, the effect of small changes in the structure of PAF C-16 was also investigated on 
the growth inhibition of intracellular M.smegmatis using different PAF C-16 structure 
analogues.  
                                                                                                                                                                  Chapter 5 
266 
 
Lyso-PAF is the precursor form of PAF C-16 that contains a hydroxyl group in place of the 
acetyl group at sn-2 position of the glycerol backbone. The enzyme PAF-AH tightly regulates 
the level of active PAF C-16 in the body and converts excess PAF C-16 into Lyso PAF 
(McIntyre et al., 2009). Due to the inability of Lyso PAF to perform most the biological 
functions associated with PAF C-16, this precursor analogue is mostly used as a control in 
experiments performed with PAF C-16 (Montrucchio et al., 2000). In this study, it was 
observed that exogenous Lyso PAF at concentrations 1µg, 5µg and 10µg/ml failed to inhibit 
the growth of intracellular M.smegmatis suggesting that the acetyl group at position sn-2 was 
important for the intracellular growth inhibitory effect of PAF C-16. These results were further 
confirmed by testing another synthetic PAF C-16 analogue, 2-O-methyl PAF for its ability to 
inhibit the growth of intracellular M.smegmatis. It was observed that 2-O-methyl PAF at 
concentrations 1µg, 5µg and 10µg/ml also did not show any inhibitory effect on the growth of 
intracellular M.smegmatis. In 2-O-methyl PAF the acetyl group at position sn-2 is replaced by 
a methyl group. These results further confirmed that the presence of acetyl group at the sn-2 
position was important for the growth inhibition of intracellular M.smegmatis. Structure 
analogues with changes in functional group at sn-2position have previously been shown to lack 
different PAF C-16 associated activities such as aggregation of platelets (McManus et al., 
1981) NO production from endothelial cells (Kikuchi et al., 2008), excitation of synaptic 
transmission in neuronal cells (Clark et al., 1992) and bronchial hyper responsiveness (Cuss et 
al., 1986) etc. 
PAF C-18, a naturally occurring PAF C-16 analogue was also included in the study to 
investigate the effect of increase in the number of carbon atoms in the aliphatic carbon tail on 
the intracellular M.smegmatis growth inhibition. PAF C-18 has two additional carbon atoms in 
the aliphatic carbon tail attached at position sn-1 as compared to PAF C-16. PAF C-18 was 
able to inhibit the growth of intracellular M.smegmatis. PAF C-18 at a concentration of 1µg/ml 
was most potent and on average caused ~50% reduction in the growth of intracellular 
M.smegmatis when compared with the solvent control. Higher concentrations of PAF C-18 
including 5µg/ml and 10µg/ml failed to show any significant inhibitory effect on the growth of 
intracellular M.smegmatis. Previous studies show that PAF C-18 is less potent in activation of 
platelet aggregation but has similar potency to PAF C-16 in activating guinea pig macrophages 
(Stewart and Grigoriadis, 1991). Our results showed that increase in the length of aliphatic 
carbon tail of PAF C-16 did not affect its intracellular growth inhibition potential as PAF C-18 
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showed similar level and pattern of intracellular M.smegmatis growth inhibition when 
compared to PAF C-16. 
Hexanolamino PAF differs from PAF C-16 in the position of the terminal amino group which 
is linked by an additional 4-carbon atoms chain to the phosphate group. Hexanolamino PAF 
was tested for its ability to inhibit the growth of intracellular M.smegmatis and the results 
showed that this structure analogue inhibited the growth of intracellular M.smegmatis at a 
concentration of 5µg/ml. On average, Hexanolamino PAF treatment at 5µg/ml resulted in 
42.6% reduction in the growth of intracellular M.smegmatis, whereas the other two 
concentrations of Hexanolamino PAF (1µg/ml and 10µg/ml) failed to show any significant 
inhibition of intracellular M.smegmatis. Hexanolamino PAF has previously been shown to act 
as both PAF C-16 antagonist and agonist. Hexanolamino PAF inhibited PAF C-16 stimulated 
production of ROS by human macrophage (Rouis et al., 1988) and acted as a partial PAF C-16 
agonist in guinea pig macrophages (Stewart and Grigoriadis, 1991). Our results with 
Hexanolamino PAF showed that changing the position of terminal amino group of PAF C-16, 
reduced the growth inhibition potency due to which an increased concentration was required 
for growth inhibition of intracellular M.smegmatis. 
PAF C-16 performs most of its functions by binding to G-protein coupled receptors, known as 
PAF receptor (PAFR) present on the cell membrane of target cells in mammals (Nakamura et 
al., 1991). To investigate the role of PAF C-16 signalling through PAFR during the intracellular 
growth inhibition of M.smegmatis, PAFR antagonists were used. PAFR antagonists are 
compounds that can bind to PAFR and reduce PAF C-16 activity by blocking PAFR (Singh et 
al., 2012). Treatment of M.smegmatis infected THP-1 cells with highly potent PAFR 
antagonists, ABT-491 or WEB-2086 prior to PAF C-16 treatment, increased the growth of 
intracellular M.smegmatis by 20-24% on average when compared with the M.smegmatis 
infected THP-1 cells treated with 1µg/ml PAF C-16 only, suggesting that PAF C-16 induced 
growth inhibition of intracellular M.smegmatis was due to signalling through its receptor, 
PAFR. PAF receptor antagonist ABT-491 has been shown to be highly effective in suppressing 
PAF C-16 induced platelets degranulation and other PAF C-16 mediated pathological 
conditions such as inflammation, hypotension and lethal effects in rat and guinea pig models 
(Albert et al., 1997). WEB-2086 is also a potent PAF receptor antagonist and has been shown 
to inhibit PAF C-16 induced important activities like platelet aggregation, hypotension and 
vascular permeability in rats (Clavijo et al., 2001).  
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Binding of PAF C-16 to PAFR results in the activation of intracellular signalling components. 
Therefore, we further investigated the role of PAF C-16 intracellular signalling pathway 
components such as PI-PLC, cPLA2 and different second messengers in PAF C-16 induced 
growth inhibition of intracellular M.smegmatis. Binding of PAF C-16 to its receptor on the 
target cell results in the activation of a membrane bound enzyme, Phosphoinositide 
Phospholipase C (PI-PLC) through the associated G-proteins (Shukla, 1992). Treatment of 
M.smegmatis infected THP-1 cells with PLC inhibitor, U-73122 partially mitigated the 
inhibitory effect of PAF C-16 on the growth of intracellular M.smegmatis. On average, U-
73122 treatment at a concentration of 2µM increased the number of intracellular M.smegmatis 
by 25.2 % as compared to M.smegmatis infected THP-1 cells treated with 1µg/ml PAF C-16 
only. During PAF C-16 signalling pathway, the activated PLC causes the hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PIP2) and further leads to the production of second 
messengers Diacylglycerol (DAG) and Inositol triphosphate (IP3) (Ishii and Shimizu, 2000). 
Since these second messengers are produced inside the cell and may come in contact with the 
intracellular M.smegmatis, therefore we investigated one of the second messenger, DAG for its 
direct inhibitory effect on the growth of M.smegmatis. However, DAG did not show any direct 
inhibitory effect on the growth of M.smegmatis in different concentrations (10µg, 25µg, 50µg 
and 100µg/ml). DAG consists of two carbon chains attached to a glycerol backbone via ester 
bonds and was included in the study to check whether compounds with two carbon chains 
attached via ester bond can directly inhibit the growth of mycobacteria. 
PAF C-16 binding to its receptor also causes the activation of cytosolic phospholipase A2 
(cPLA2) due to increased levels of intracellular Ca
+2 (Ishii and Shimizu, 2000). Treatment of 
M.smegmatis infected THP-1 cells with cPLA2 inhibitor, Benzenesulfonamide at 
concentrations of 23nM (IC50) and 56nM (2IC50) partially mitigated the growth inhibitory 
effect of PAF C-16 and increased the survival of intracellular M.smegmatis by 25.5% and 
30.1% respectively when compared to the M.smegmatis infected THP-1 cells treated with 
1µg/ml PAF C-16 only. Activated cPLA2 causes the production of arachidonic acid from 
phospholipids inside the cell (Nakashima et al., 1989). In our study, arachidonic acid at a 
concentration as low as 2.5µg/ml showed direct inhibitory effect on the growth of 
M.smegmatis. These results showed that PAF C-16 signalling via PAFR leads to the production 
of an intermediate intracellular molecule, arachidonic acid, which possess direct growth 
inhibition capacity and might be involved in the growth inhibition of intracellular 
M.smegmatis. 
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Apoptosis is one of the host protective mechanisms against intracellular pathogens that 
involves programmed cell death resulting in the elimination of the pathogen (Behar et al., 
2011). It has been shown that intracellular mycobacteria can be eliminated by macrophages 
through apoptosis (Lee et al., 2006). Flow cytometry was performed to detect PAF C-16 
induced apoptosis in M.smegmatis infected THP-1 cells. However, the results showed that PAF 
C-16 was unable to induce apoptosis in THP-1 cells containing intracellular M.smegmatis and 
that apoptosis had no role in the PAF C-16 induced growth inhibition of intracellular 
M.smegmatis. Previously PAF C-16 has been shown to cause apoptosis in different cells such 
as human epidermal cells (Barber et al., 1998), enterocytes (Lu et al., 2004) and neuronal cells 
(Ryan et al., 2007).  
NO and RNIs such as peroxynitrite have a damaging effect on mycobacteria (Jamaati et al., 
2017; Long et al., 1999). The role of reactive nitrogen species in PAF C-16 induced 
intracellular growth inhibition of M.smegmatis was investigated by using a potent iNOS 
inhibitor, Aminoguanidine hemisulfate (AG). Treatment of M.smegmatis infected THP-1 cells 
with 1mM AG along with 1µg/ml PAF C-16 increased the survival of intracellular 
M.smegmatis by 23.4% on average as compared to 1µg/ml PAF C-16 only treated M.smegmatis 
infected THP-1 cells. PAFC-16 has previously been shown to cause the production of NO and 
RNIs in murine cells including monocytes, macrophages and Kupper cells through activation 
of inducible nitric oxide synthase (iNOS) enzyme (Mustafa et al., 1996; Szabo et al., 1993). It 
was shown that PAF C-16 treatment of T.cruzi infected mouse macrophages resulted in the 
inhibition of intracellular parasite due PAF C-16 induced NO production in these cells (Aliberti 
et al., 1999).  
We also investigated the role of different cytokines (TNF-α, IL-6 and IL-10) in the intracellular 
growth inhibition of M.smegmatis by using neutralizing antibodies against these cytokines. It 
was observed that the addition of 10µg/ml TNF-α neutralizing antibody (mouse anti human-
TNF-α) to M.smegmatis infected THP-1 cells partially mitigated the growth inhibitory effect 
of PAF C-16 on intracellular M.smegmatis as indicated by increase in the number of CFUs 
when compared to 1µg/ml PAF C-16 only treated control. It has been shown that PAF C-16 
can stimulate macrophages to produce TNF-α (Ruis et al., 1991; Dubois et al., 1989). The 
protective role of TNF-α during M.tb infection is well established (Keane et al., 2001; Mohan 
et al., 2001; Bean et al., 1999; Flynn et al., 1995). Several studies have shown that TNF-α helps 
in the induction of NO by activation of iNOS genes in macrophages and causes the elimination 
of intracellular pathogens such as L.major (Fonseca et al., 2003) and T.cruzi (Silva et al., 1995). 
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Additionally, two more cytokines, IL-6 and IL-10 were also investigated for their role in PAF 
C-16 induced intracellular M.smegmatis growth inhibition by using neutralizing antibodies (rat 
anti human IL-6 and anti human IL-10) against these cytokines. However, these neutralizing 
antibodies showed no effect on the PAF C-16 induced growth inhibition of intracellular 
M.smegmatis, suggesting that IL-6 and IL-10 are not involved in the PAF C-16 induced growth 
inhibition of M.smegmatis inside THP-1 cells. PAF C-16 enhances the production of IL-6 in 
mouse macrophages (Thivierge and Rola-Pleszczynski, 1992) and IL-6 has been shown to have 
a protective role during M.tb infection in mice models (Ladel et al., 1997). However, in vitro 
IL-6 was also shown to promote the growth of M.avium by inhibiting the production of IL-1 
and TNF-α (Schindler et al., 1990). IL-10 is an anti-inflammatory cytokine that supresses the 
release of different pro-inflammatory cytokines such as TNF-α, IL-1, IL-6 etc. from activated 
immune cells such as macrophages (Moore et al., 1993). Interestingly, IL-10 has been shown 
to induce the synthesis of PAF C-16 in human monocytes (Bussolati et al, 1997) and 
upregulates the expression of PAFR in monocytes and neutrophils (Thivierge et al., 1999). 
Finally, the effect of exogenous PAF C-16 on the phagocytic activity of THP-1 cells was 
investigated. It was observed that THP-1 cells treated with PAF C-16 in different 
concentrations showed decreased phagocytosis of M.smegmatis when compared with the 
solvent control. On average PAF C-16 treatment at concentrations 0.01µg, 0.1µg, 1µg and 
5µg/ml of THP-1 cells for 2 hours reduced the phagocytosis of M.smegmatis by ≥70% on 
average. These results are contradictory to some of the previous studies where exogenous PAF 
C-16 treatment enhanced the phagocytic activity of immune cell such as macrophages and 
neutrophils (Borges et al., 2017; Muehlmann et al., 2012; Ichinose et al., 1994). 
In conclusion, this study showed that exogenous PAF C-16 was able to inhibit the growth of 
intracellular M.smegmatis in phagocytic THP-1 cells at a specific concentration of 1µg/ml. The 
presence of acetyl group at sn-2 position of the glycerol backbone was shown to be important 
for the growth inhibition of intracellular M.smegmatis. The use of PAF receptor antagonists 
and blocking PAF C-16 intracellular signalling pathway components suggested that the growth 
inhibition of intracellular M.smegmatis was mediated by PAF C-16/PAFR signalling. 
Arachidonic acid a product of the PAF C-16 signalling pathway showed direct inhibitory effect 
on the growth of M.smegmatis. Neutralization of iNOS and TNF-α partially mitigated the 
growth inhibitory effect of PAF C-16, suggesting their involvement in PAF C-16 induced 
growth inhibition of intracellular M.smegmatis. Finally, treatment of THP-1 cells with PAF C-
16 resulted in reduced phagocytosis of M.smegmatis. The data from PAF C-16 and its structure 
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analogs for their inhibitory effect on the growth of intracellular M.smegmatis is summarized in 
table 5.1. 
Table 5.1: Summary for inhibitory effect of PAF C-16 and its analogs on the growth of 
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PAF C-16 + T.cruzi &  
L.donovani 
(Aliberti et al., 
1999; Lonardoni et 
al., 2000) 
Lyso PAF _ Not investigated 
2-O-methyl PAF _ Not investigated 
PAF C-18 + Not investigated 
Hexanolamino 
PAF 
+ Not investigated 
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6.1 Concluding remarks and future perspectives 
In this study, different endogenous host factors (proteins and non-proteins) namely, transferrin, 
lactoferrin, fibrinogen, C-reactive protein (CRP), vitronectin, plasminogen, α-2-macroglobulin 
(α2M), low-density lipoprotein (LDL), high-density lipoprotein (HDL), serotonin, L-alpha 
dipalmitoylphosphatidylcholine (DPPC) and platelet activating factor C-16 (PAF C-16) were 
investigated in vitro for their inhibitory effect on the growth of mycobacteria. Non-pathogenic 
mycobacterial species, M.smegmatis and M.bovis BCG were used as model organisms for M.tb. 
As a result of this screening, a phospholipid compound, PAF C-16, was identified, which 
inhibited the growth of both M.smegmatis and M.bovis BCG in a dose and time-dependent 
manner. The growth inhibitory effect of PAF C-16 seemed to be due to its damaging effect on 
the mycobacterial cell membrane, as indicated by microscopy and flow cytometry. The growth 
inhibitory effect of PAF C-16 was partially mitigated by membrane stabilizing compounds 
such as α-tocopherol, tween-80 and tween-20. The bacterial membrane damaging results 
presented in this thesis can be further validated by performing electron microscopy with PAF 
C-16 treated M.smegmatis and M.bovis BCG in order to physically visualize the mycobacterial 
cell membrane and observe the nature of PAFC-16 induced damage. 
Structurally, PAF C-16 consists of a glycerol backbone with a 16 carbon atoms tail attached at 
position sn-1 via an ether bond, an acetyl group at position sn-2 and a phosphocholine group 
attached to the sn-3 position. In this study, the attachment of carbon tail to the glycerol 
backbone via ether bond was shown to be important for the direct growth inhibitory effect of 
PAF C-16 on mycobacteria, as suggested by the use of compound 1-O-hexadecyl-sn-glycerol. 
Two additional compounds, hexadecyl lactate and miltefosine, having similar carbon tails as 
PAF C-16 but attached via ester bond, were also able to directly inhibit the growth of 
M.smegmatis. To the best of our knowledge, these compounds have previously not been 
investigated for their direct effect on the growth of mycobacteria. Miltefosine is currently used 
for the treatment of Leishmaniasis and has a good safety profile in humans (Jha et al., 1999). 
Similarly, hexadecyl lactate has also been shown to be safe in humans and is used as an additive 
in food, medicines and personal care products (Zhang et al., 2010; Clary et al., 1998). 
Therefore, these compounds need further investigation both for their growth inhibitory effect 
on M.tb directly as well as on the growth of intracellular M.tb and in vivo using animal models. 
The proposed mechanism for the direct M.smegmatis growth inhibition by PAF C-16 is given 
in figure 6.1.




Figure 6.1: Proposed mechanism for direct M.smegmatis growth inhibition by PAF C-16. PAF C-16 interact with the bacterial cell membrane via 
its hydrophobic carbon tail and gets inserted in the lipid membrane. It is hypothesized that the oxygen atom at the sn-2 position produces a kink in 
the carbon tail of PAF C-16. This kink carbon tail of PAF C-16 pushes the phospholipid molecule apart after insertion and disrupts the lipid-lipid 
interaction of the bacterial cell membrane resulting in the formation of pores. This pore formation causes to the efflux of cytoplasmic content and 
changes in osmotic pressure inside the bacteria which ultimately leads to bacterial death.
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Different PAF C-16 structure analogues including Lyso PAF, PAF C-18, Hexanolamino PAF, 
2-O-methyl PAF and Pyrrolidino PAF were also investigated in vitro to ascertain if small 
changes in the structure of PAF C-16 modulated its growth inhibitory potency against 
mycobacteria. Previously, it has been shown that the biological activity of PAF C-16 in 
mammalian systems can be affected to varying degree by small modifications in its structure 
(Marathe et al., 2014; Prescott et al., 2000). However, in the current study, PAF C-16 structure 
analogues including Lyso PAF, PAF C-18, Hexanolamino PAF, 2-O-methyl PAF and 
Pyrrolidino PAF were able to directly inhibit the growth of both M.smegmatis and M.bovis 
BCG in culture at level comparable to PAF C-16. Among the PAF C-16 structure analogues, 
the naturally produced precursor form Lyso PAF is of particular importance since it is 
considered to be biologically inactive and lacks most of the pathological functions associated 
with PAF C-16. Therefore, Lyso PAF can be investigated further for its direct growth inhibitory 
effect against M.tb in culture and in vivo using animal models. However, there could be certain 
limitations associated with testing Lyso PAF as a therapeutic agent for treating mycobacterial 
infections in vivo, as there is a possibility of its conversion into the active form PAF C-16 by 
host enzyme PAF acetyltransferase. Colard et al. showed that mast cells from mice were able 
to convert exogenous Lyso PAF added to the cell culture to active form, PAF C-16 (Colard et 
al., 1993). Similarly, other PAF C-16 structure analogues such as PAF C-18 and Hexanolamino 
PAF also need in vitro and in vivo testing for their growth inhibitory effect on M.tb. 
In our investigation, PAF C-16 was also found to inhibit the growth of intracellular 
M.smegmatis in THP-1 cells at a specific concentration of 1µg/ml. PAF receptor antagonists 
(ABT-491 and WEB-2086) partly mitigated the inhibitory effect of PAF C-16 on the growth 
of intracellular M.smegmatis, suggesting that the growth inhibitory effect of PAF C-16 was due 
to its binding and intracellular signalling via its receptor, PAFR on THP-1 cells. It seemed that 
the acetyl group at the sn-2 position of glycerol backbone of PAF C-16 is important for growth 
inhibition of M.smegmatis inside phagocytic cells. This study showed that changing the acetyl 
functional group at position sn-2 in PAF C-16 could lead to the loss of its ability to inhibit the 
growth of intracellular M.smegmatis. For example, the precursor form Lyso PAF and a 
synthetic PAF C-16 structure analogue, 2-O-methyl PAF lacking the acetyl group at position 
sn-2 were unable to inhibit the growth of intracellular M.smegmatis. These results are in 
agreement with previous studies which show that the presence of acetyl group at position sn-2 
is important for most of the biological activities of PAF C-16 (Kikuchi et al., 2008; Clark et 
al., 1992; Cuss et al., 1986; McManus et al., 1981). 
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Binding of PAF C-16 to its G protein-coupled receptors (PAFR) on the target cells activate 
intracellular signalling pathways (Honda et al., 2002; Ishii et al., 2002). PAF C-16 intracellular 
signalling pathway components, phospholipase C (PLC) and phospholipase A2 (PLA2), were 
shown to be important for the growth inhibition of M.smegmatis inside phagocytic cells in this 
study, as blocking these components resulted in increased survival of the intracellular 
M.smegmatis. Arachidonic acid, a product of the PAF C-16 signalling pathway was shown to 
be able to directly inhibit the growth of M.smegmatis in culture, indicating its potential role in 
the growth inhibition of intracellular M.smegmatis. In addition, inhibition of iNOS enzyme and 
antibody neutralisation of the pro-inflammatory cytokine, TNF-α, suggested that these factors 
were also associated with PAF C-16 induced mycobacterial growth inhibition inside 
phagocytic cells. Both iNOS activation and TNF-α have previously been shown to play an 
important role in the elimination of intracellular mycobacteria (Jamaati et al., 2017; Keane et 
al., 2001; Mohan et al., 2001; Chan et al., 1992). Our results support previous studies where 
exogenous PAF C-16 has been shown to inhibit the growth of different pathogens such as 
Gram-positive bacteria directly in culture (Steel et al., 2002), Leishmania donovani inside 
human macrophages (Lonardoni et al., 2000), and Trypanosoma cruzi (Aliberti et al., 1999) 
and Candida albicans in mice models (Im et al., 1997) indicating the potential protective role 
of PAF C-16 during the host infection with pathogens.  
The proposed mechanism for PAF C-16 induced growth inhibition of intracellular 
M.smegmatis is given in figure 6.2 




Figure 6.2: Proposed mechanism for PAF C-16 induced growth inhibition of intracellular M.smegmatis. Binding of PAF C-16 to its receptor PAFR 
on the target cell activates phosphatidylinositol specific phospholipase C (PI-PLC) enzyme which causes the production of second messengers IP3 
and DAG inside the cell. The second messenger IP3 then causes the mobilization of intracellular Ca
++. DAG along with Ca++ further leads to the 
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activation of phosphokinase C (PKC) enzyme that upregulates the production of reactive nitrogen intermediates and TNF-α, which can inhibit the 
growth of intracellular M.smegmatis. In addition, the elevated level of intracellular Ca++ also causes the activation of cytosolic phospholipase A2 
(cPLA2) enzyme that hydrolyses phospholipids and results in the production of arachidonic acid inside the cell. This arachidonic acid has also the 
potential to inhibit the growth of M.smegmatis. 
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Intestinal epithelial cells were shown in vitro to produce increased quantities of PAF C-16 in 
response to enteric pathogen Salmonella enteritidis as compared to uninfected control cells 
(Egea et al., 2008). Similarly, elevated plasma levels of PAF C-16 were reported in human 
patients during HCV (Caini et al., 2007) and dengue virus infections (Jeewandara et al., 2015). 
We consider that the increased production of PAF C-16 during inflammation and pathogen 
infection might be a part of the host protective immune response to the invading pathogens. 
This argument is supported by a study performed in mice model by Choi et al during which 
endogenous PAF C-16 was shown to be important in conferring protection to the host against 
Candida albicans infection. The protective effect of endogenous PAF C-16 was associated 
with the early activation of NF-κB and upregulation of TNF-α in the infected mice (Choi et al., 
2001). Therefore, it will be interesting to determine levels of PAF C-16 in the blood and at the 
site of infection in animal models infected with M.tb and to compare it with healthy control to 
determine if there are differences in the levels of endogenously produced PAF C-16. In 
humans, it will be interesting to measure PAF C-16 levels at disease sites such as in pleural, 
ascitic and cerebrospinal fluids. Pleural fluid can result due to pleural involvement in different 
disease situations such as infections (tuberculosis and bacterial pneumonia), cancer (lung 
cancer), autoimmune disorders (such as lupus or rheumatoid arthritis) etc. PAF C-16 levels in 
these situations may prove as a diagnostic or prognostic indicator for disease. In TB pleurisy, 
PAF C-16 in pleural fluid may correlate with severity of the disease. 
Granuloma is the hallmark of M.tb infection, where M.tb infection is contained. Granuloma is 
made up of collection macrophages with engulfed bacteria that is surrounded by a collar of 
lymphocytes and is a sign of chronic inflammation (Gonzalez-Juarrero et al., 2001). Immune 
cells such as macrophages (Shindou et al., 2005) and neutrophils (Owen et al., 2005) at the site 
of inflammation have been shown to be produce PAF C-16, which must be interacting with 
surrounding immune cells in autocrine or paracrine fashion. This interaction may be important 
for the integrity of granuloma itself and/or containment of infection within it. Production of 
PAF C-16 can be detected in M.tb infected tissue biopsy by immunohistochemistry using PAF 
C-16 specific antibodies. In vitro granuloma formation technology is now available (Kapoor et 
al., 2013), which will help in understanding the role of PAF C-16 in its formation, modulation 
of its functions such as cytokine production profile and thus help in understanding the 
containment of M.tb infection inside these granuloma.  
The results obtained with PAF C16, PAF C-16 structure analogues and other compounds (1-
O-hexadecyl-sn-glycerol, miltefosine and hexadecyl lactate) need to be validated by repeating 
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the experiments using M.tb. If these compounds are found to be effective in inhibiting the 
growth of M.tb in vitro, then further investigations need to be carried out in animal models for 
their abilities to control M.tb and to monitor their side effects in vivo. Those compounds 
showing potent M.tb inhibition and minimum or no side effects need further investigation for 
finding the optimum dosage in animal models. The commonly used animal models for studying 
M.tb infections include mice, guinea pigs, cattle and macaques. Each of these animal models 
has its advantages and disadvantages. Mice models are good for initial testing because these 
animals are genetically well characterized, cost-effective and due to the availability of a large 
number of reagents for immunologic analysis. On the other hand, the guinea pig is a very 
sensitive model for M.tb, however scarcity of well-characterised immunological reagents is an 
issue. Macaque model of tuberculosis is considered a surrogate model for human tuberculosis, 
but they are expensive to maintain and there are ethical issues in using these animals. 
Once drugs show efficacy and minimum or no side effects in preclinical trials in animal models, 
these can be tested further in humans, initially in phase I, later Phase II, and finally in Phase III 
clinical trials, before they can be awarded license to be used in humans. It is less likely that 
PAF C-16 will pass the stage of preclinical testing, because of its side effects. Increased levels 
of PAF C-16 in humans have been shown to be associated with a number pathological 
conditions such as asthma, increased vascular permeability, thrombocytopenia, tissue injury 
and different inflammatory, gastrointestinal, cardiac and renal disorders (Stafforini et al., 
2003). 
Overall, this study has identified a number of novel compounds such as PAF C-16, Lyso-PAF 
and 1-O-hexadecyl-sn-glycerol, miltefosine and hexadecyl lactate with anti-mycobacterial 
activity. Further investigations are needed to demonstrate their effectiveness both in vitro and 
in animal models to see their effectiveness as anti-TB drugs. Furthermore, this study has thrown 
light on the possible mechanisms of PAF C-16 induced mycobacterial growth inhibition both 
inside and outside phagocytic cells. 
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